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ABSTRACT 
 
 
 Transmissible Spongiform Encephalopathy (TSE) is a set of diseases caused 
by a change in conformation of the cellular prion protein.  This alteration in structural 
formation of the prion protein results in fatal neurodegenerative conditions characterized 
by protein aggregation and massive neuronal death.  The pathogenic mechanisms of 
infectious prion protein and the cellular function of normal prion protein are poorly 
understood.  Prion protein contains metal binding sites, and various divalent metals can 
effectively bind to cellular prion protein.  Therefore, the overarching hypothesis of this 
work was that metal exposure can significantly alter the function of prion protein, which 
might contribute to the pathogenesis of prion disease.  Various cell culture models of 
prion disease were used to test the hypothesis.  First, we examined the effect of 
manganese toxicity and cell death in modified prion protein (3F4) expressing mouse 
neuronal cell (PrPC) and prion knockout mouse neuronal cell (PrPKO) lines.  PrPKO-cells 
were more susceptible to manganese toxicity than PrPC-cells.  PrPKO-cells contained 
lower basal levels of both copper and manganese, and acute exposure to manganese 
resulted in higher susceptibility to manganese toxicity in PrPKO-cells.  Rapid 
internalization of manganese inside the cells was observed, as well as generation of 
reactive oxygen species (ROS) and mitochondrial dysfunction.  Treatment with 
manganese also initiated the apoptotic cascade in both cell lines with sequential 
activation of caspase-9 and -3, followed by cellular apoptosis.  In particular, PrPKO-cells 
treated with manganese retained a higher intracellular manganese content and higher 
ROS generation as compared to PrPC-cells.  This translated into faster onset of 
vi 
mitochondrial dysfunction and higher caspase activity, ensued by increased cell death in 
PrPKO-cells.  Thus, our data indicate that the expression of prion protein was crucial in 
mediating internalization of manganese and protecting the cells against the apoptotic 
cascade induced by manganese.  Interestingly, further examination of the manganese and 
prion protein interaction showed increased prion protein expression in PrPC-cells in a 
time-dependent manner.  We subsequently analyzed the cellular mechanism of 
manganese-induced increases in prion protein levels.  Our data indicate that the increase 
was neither due to increased translational activity nor to decreases in the cellular 
degradative system, including the ubiquitin proteasomal system and the lysosomal system, 
but to decreased protein turnover.  However, the cation cadmium significantly inhibited 
the cellular ubiquitin proteasomal system, leading to formation of oligomers and 
ubiquitinated prion proteins.  Further investigation revealed the decreased protein 
turnover rate of prion proteins induced by manganese treatment was due to increased 
protein stability, as measured by limited proteolysis.  Additional experiments with copper 
also revealed similar findings, suggesting that the divalent metal and prion protein 
interaction could significantly modulate the protein function.  Translating cell culture 
findings to mouse brain slice cultures showed manganese can also increase prion protein 
expression in the slice cultures.  To examine whether the increased prion protein 
expression in mouse brain slice cultures results in altered susceptibility to conversion to 
infectious prion protein (PrPSc), samples corresponding to the greatest increase in prion 
protein expression were collected and subjected to protein misfolding cyclic 
amplification.  The results indicate that manganese treated mouse brain slice cultures 
were not more susceptible to conversion to PrPSc by PMCA.  The findings suggest that 
vii 
the increased PrPC levels are not indicative of higher susceptibility to PrPSc conversion 
under our experimental conditions. 
 Taken together, the interaction of prion protein with manganese can be 
construed as a complex interaction.  However, it is clear that prion protein protects 
against oxidative stress induced by transition metals, thereby ameliorating the neurotoxic 
effect of metals.  Decreased susceptibility to proteolytic digestion following manganese 
treatment suggests increased protein stability of prion protein, but does not promote 
biochemical behavior similar PrPSc under our experimental conditions.  Collectively, our 
data suggest that cellular prion protein is a key metal binding antioxidant protein, and its 
stability can be altered by chronic metal exposure.  This functional interaction of metals 
with prion protein may play a role in the pathogenesis of prion diseases.  
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CHAPTER 1: GENERAL INTRODUCTION 
 
Dissertation Organization 
 
This dissertation is written in an alternative thesis format.  It contains a general 
introduction, five research papers, a general conclusion, and an acknowledgement.  A list of 
references cited is included at the end of each chapter with the exception of the general 
introduction and conclusion, where the references cited is listed after the general conclusion.  
The general introduction (Chapter I) includes a research objective, background information 
concerning metal-induced protein folding neurodegenerative disorders, and a literature 
review of prion disease, prion proteins, and the relationship between metals and prion 
proteins.  Chapter II, “Normal cellular prion protein protects against manganese-induced 
oxidative stress and apoptotic cell death” has been published in Toxicolgical Sciences.  
Chapter III, “Manganese upregulates cellular prion protein and inhibits the rate of proteinase-
K-dependent limited proteolysis in mouse neuronal cells” will be submitted for publication in 
FASEB journal.  Chapter IV, “Copper upregulates and stabilizes the prion protein in mouse 
neuronal cell culture model” will be submitted for publication in Journal of Neurochemistry.  
Chapter V, “Cadmium, not manganese, impairs proteosomal activity in mouse neuronal cells, 
leading to ubiquitination of prion protein” will be submitted for publication in Journal of 
Neurochemistry.  And Chapter VI, “Manganese treatment upregulates prion protein 
expression, but does not facilitate protienase-K-resistant prion protein conversion in mouse 
brain slices” will be submitted for publication in Neuroscience Letters. 
 This dissertation contains the experimental results obtained by the author during his 
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graduate study under the supervision of his major professor, Dr. Anumantha G. Kanthasamy 
in the Department of Biomedical Sciences, affiliated with the Neuroscience and Toxicology 
Interdepartmental Graduate Programs, and the Iowa Center for Advanced Neurotoxicology at 
Iowa State University of Science and Technology. 
 
Research Objective 
 
 Prion disease is a fatal neurodegenerative disorder that affects both humans and 
animals (Prusiner 1984, 1991c; Prusiner and Kingsbury 1985).  Although the prevalence of 
prion disease is relatively low, the possibility of transmission between humans and animals 
raise strong concerns over control of this disease (Collinge et al. 1995; Prusiner 1993a; 
Prusiner et al. 1985).  The etiopathogenesis of prion disease still remains unknown, and thus 
far cures, treatment, or ante-mortem tests are still in infantile stages of development (Priola 
and Vorberg 2004).  Aside from the clinical symptoms for prion disease, studies have shown 
that significant differences in metal content have been observed in diseased human and 
animals (Hesketh et al. 2007; Wong et al. 2001a), suggesting that etiology of the prion 
disease has its basis in metal homeostasis.  Prion protein, an ubiquitiously expressed protein 
primarily in the central nervous system and the immune system, is crucial for prion disease 
(Prusiner 1994; Prusiner et al. 1987; Westaway et al. 1994a).  It is believed that the diseased 
state of an organism occurs when the normal prion protein has converted to a pathogenic 
prion protein (Huang et al. 1995; Jackson et al. 1999; Martins et al. 2001).  It is still unclear 
as to the conversion steps required for the protein to become pathogenic.  However, it is 
widely accepted that the disease cannot progress without the expression of prion protein in 
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the organism.  Although various functions for the protein have been proposed, a clear 
consensus to the exact function remains ambiguous (Borden 1998; Herms et al. 1999; 
Martins et al. 2001; Prusiner 1991b).  So far, many studies indicate the prion protein to be a 
metalloprotein, and having affinity to various cations such as copper, zinc, manganese, and 
nickel (Brown 2004; Di Natale et al. 2005; Hornshaw et al. 1995a).  Interaction of prion 
protein with copper or manganese has been shown to alter the characteristics of the protein to 
behave similarly to the infectious prion protein (Brown 2002; Brown et al. 2000a; Levin et al. 
2005).  Mounting evidence has pointed to the role of metals in the development and 
transmission of the prion disease.  The exact mechanisms of metal involvement in the disease 
are unclear, however, it is possible that imbalances in metal homeostasis could be a risk 
factor.   
The major objectives of this dissertation are: (i) to understand the role of the prion 
protein in cellular function in response to manganese treatment utilizing in vitro cell culture 
models; (ii) to characterize the interaction of prion protein and manganese in cellular models; 
and (iii) to examine whether the studies characterized in in vitro cell culture models translate 
into an explant brain culture model.  Together these studies will enhance our understanding 
of the cellular interaction between prion protein and manganese, and how it modulates the 
cellular metabolism of the prion protein, thereby giving us further insight into the role of 
metals in prion disease. 
 
Background and Literature Review 
 
 This section provides background information related to the studies presented in the 
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dissertation: (1) Metal-induced protein aggregation and neurodegenerative disorders; (2) 
Prion disease: disease and protein function (3) Relationship of copper and prion protein; (4) 
Relationship of manganese and prion protein; (5) Non-protein hypothesis of prion disease; 
(6) Potential therapeutics against prion disease 
 
Background Introduction 
 
 Significant evidence has mounted pointing to the role of redox metals in the 
pathogenesis of various neurodegenerative disorders such as Alzheimer’s disease, 
Parkinson’s disease, and prion disease.  As our aging population increases with advances in 
healthcare and preventive medicine, the prevalence for detrimental neurodegenerative 
disorders has been correspondingly increasing.  In particular, Alzheimer’s disease and 
Parkinson’s disease are among the two most prevalent neurodegenerative disorders that seem 
to correlate positively with increasing age (Gorell et al. 2004; Zawia and Basha 2005).  
Through vigorous research and understanding of the cellular pathways, presence of excessive 
redox metals are seen as one of the major components of various neurodegenerative disorders 
(Campbell et al. 2001; Tritschler et al. 1994).  One pathological hallmark shared by these 
neurodegenerative disorders is the formation of protein aggregates (Andre et al. 2005; Paik et 
al. 1997; Uversky et al. 2002)).   Prion disease is similar to Alzheimer’s and Parkinson’s in 
that it also has protein aggregation as one of the pathological hallmarks of the disease 
(Mattson and Sherman 2003).  However, similarities end there, as the prion disease carries an 
infectious protein component.   
Several studies that suggest the substantive impact of environmental factors on 
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protein aggregation and the resultant neurodegenerative disorders (Andre et al. 2005).  A 
number of studies have revealed numerous changes that accompany aging, especially in the 
brain (Crapper and DeBoni 1978; Maccioni et al. 2001; Tritschler et al. 1994).  One possible 
speculation is that with increasing age, the maintenance of homeostasis could be disturbed 
(Huang et al. 2004b; Mayer 2003; Mocchegiani et al. 2005).  Reduced responses to oxidative 
stress and imbalances in metal content are two of the many other alterations to the aging 
brain that could be considered to be causative agents in the development of 
neurodegenerative disorders (Dexter et al. 1991; Huang et al. 2004b).  Current researchers 
have speculated oxidative stress to be involved in the damage to parts of the brain associated 
with neurodegenerative disorders (Bolin et al. 2006; Huang et al. 2004b; Kachiwala et al. 
2005; Milhavet and Lehmann 2002; Tritschler et al. 1994; Williams et al. 2004; Wong et al. 
2001a; Wong et al. 2000b).  Oxidative stress is normally present in the cellular respiration 
pathways, and cellular systems, including neuronal cellular systems are well equipped to 
handle such stress (Huang et al. 2004b; Toiber and Soreq 2005).  Various cellular antioxidant 
systems such as superoxide dismutase, catalase, and glutathione peroxidase are crucial in 
combating cellular oxidative stress (Tritschler et al. 1994).  When antioxidant systems are 
overwhelmed, cumulative non-reversible damage occurs, resulting in neuronal damage and 
eventually cellular death (Kanthasamy et al. 2003a).   
 Redox metals such as copper, zinc, manganese, and iron are crucial trace element 
metals normally required for physiological processes, and are immaculately regulated by the 
cells (Aust et al. 1985; Sayre et al. 1999).  However, alteration and/or disturbances to the 
concentrations, possibly due to overexposure to these metals, have been known to cause 
severe neurological symptoms (Sayre et al. 2005; Wong et al. 2001a).  Due to the nature of 
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the metals, they participate in pro-oxidative pathways that could be detrimental.  Through the 
Fenton reaction, these metals react with H2O2 to produce OH
· (hydroxyl radical), which in 
turn reacts with various cellular compartments to produce protein carbonylation, lipid 
peroxidation, and more reactive oxygen species (Gutteridge and Bannister 1986; Kitazawa et 
al. 2001).  Such adducts can accumulate in the cells and can be highly damaging, eventually 
causing cell death.  Other metals, such as aluminum and lead are normally not required by 
the body, they can have detrimental affects on human physiological development. It is 
interesting to note that as harmful as both of these metals are, they are accumulated and 
stored in bodies of developing individuals (Carpenter 2001). 
 These metals have been implicated in protein aggregation in the central nervous 
system, and are considered to be the hallmark of neurodegenerative disorders (Holscher 
2005; Kaur and Andersen 2004; Post et al. 2000; Rogers and Lahiri 2004).  In this review, 
the role of metals in the pathogenesis of Alzheimer’s disease, Parkinson’s disease, and prion 
disease will be examined.  Particular emphasis will be placed on the role of metals in protein 
aggregation. 
 
Alzheimer’s Disease and Metal-Iinduced Aggregation of Aβ and τ Protein 
 Alzheimer’s disease (AD) is the leading progressive neurodegenerative disorder in 
the world (Henderson 1993).  Although the exact etiology remains to be solved, a 
combination of genetic and environmental factors have been speculated to have a large 
impact on the development of the disease (Kourie and Henry 2001; Paik et al. 1997; Zatta et 
al. 2003; Zawia and Basha 2005).  AD is characterized by progressive senile dementia early 
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in the disease, followed later by motor and sensory dysfunction (Crapper and DeBoni 1978; 
Maccioni et al. 2001).  Pathologically, AD is most commonly associated with the formation 
of amyloid plaques and neurofibrillary tangles of the neurons (Fasman and Moore 1994; 
Maccioni et al. 2001; Murayama et al. 1999).  Surprisingly, the hallmark sign of amyloid 
plaques found in the diseased individuals are also present to a certain degree in normal 
individuals (Fukumoto et al. 1996).  Amyloid plaques and neurofibrillary tangles (NFT) are 
associated with aggregation of amyloid-β (Aβ) and tau (τ) proteins respectively (Kontush 
2005; Maccioni et al. 2001; Murayama et al. 1999; Ong and Farooqui 2005). Current 
literature have pointed to metals as the possible culprit in aggregation of the proteins, and 
thereby contributing to the initiation/progression of the disease (Clements et al. 1996; 
Garzon-Rodriguez et al. 1999; Huang et al. 2004a; Kuroda and Kawahara 1994; Miura et al. 
2000). 
  The Aβ protein is derived from amyloid precursor protein (APP); a normally 
endogenous transmembrane protein with unclear cellular function (Huang et al. 2000).  A 
few researchers have speculated the role of APP to be involved in neuronal viability, and 
neuronal plasticity associated with memory (Chapman et al. 1999; Dodart et al. 2000; 
Stephan et al. 2002; Storey et al. 1996).  Normally, APP has been observed to be cleaved by 
α-secretase to yield APPs and P3 fragments, both of which have been shown to be soluble 
and non-toxic to neurons (Hooper 2005).  It is believed that through the α-secretase pathway, 
APP is beneficial to cells.  However, APP can also be cleaved by β-secretase and γ-secretase 
to yield APPsβ and Aβ fragments (Galbete et al. 2000; Holscher 2005), and it is believed that 
these fragments are harmful to cells.  The Aβ can exist in three distinct biochemical fractions 
differing in composition between healthy and diseased individuals (Kowalik-Jankowska et al. 
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2002).  Although it is not clear as to the exact pathways of Aβ leading to AD, there has been 
speculation that metals, especially copper, zinc, and iron, may induce aggregation of Aβ 
(FIG 1).  Through the β and γ secretase pathway, APP is believed to be cleaved into Aβ 
fragments  
 
in the extracellular matrix.  These fragments then could interact with heavy metals to alter the  
structure of the protein to have higher β-sheet content.  These β-sheet rich proteins in turn 
Figure 1 Schemtaic of metal induced amyloid formation in Alzheimer’s disease 
Processing of APP and influence of metal on Aβ aggregation (1)Amyloid precursor 
protein (APP) is cleaved by β-secretase from the surface to yield amyloid-β fragment, 
which is mostly α-helical in structure.  (2) This fragment in turn is cleaved by γ-
secretase to yield Aβ40 and Aβ42.  (3)  The cleaved product is soluble with fibril 
forming tendencies.  (4) The Aβ could interact with excessive metals and adopt β-
sheet enriched structure.  (5,6)  The β-sheet rich Aβ in turn are more susceptible to 
forming into aggregations, which later form into fibrils. 
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have the propensity to aggregate together into fibrils.   The structure of Aβ has been observed 
to be mostly α-helical.  Upon metal binding, the structure has been observed to become 
predominantly β-sheet, predisposing the Aβ fragments to aggregate together into neuritic 
plaques (Paik et al. 1997).  It is not clear as to how these plaques in turn are harmful to 
neurons, but researchers have speculated on generation of reactive oxygen species, or 
formation of channels on the surface of neurons causing neuronal damage and eventually 
death (Huang et al. 2004b; Kourie and Henry 2001).  Formation of plaques in turn could be a 
cellular mechanism to sequester harmful proteins.  Certain metals such as lead (Pb) can lead 
to overexpression of APP, where overabundance of APP could predispose greater amount of 
the protein to be cleaved by β and γ-secretase, leading to higher amount of Aβ to be produced 
(Basha et al. 2005).   
 
 Progression of AD is not only plagued with neuritic plaques, but also formation of 
NFT in neurons (Ma et al. 2005; Maccioni et al. 2001).  Hyperphosphorylated τ protein is 
one of the main constituents present in NFT of AD, and other neurodegenerative disorders 
(Gomez-Ramos et al. 2006; Li et al. 1998; Sanchez and Cohen 1994).  The τ protein is a 
microtubule associated protein found in the central nervous system and functions to assemble 
and disassemble tublins for neuronal cytoskeletal structure (Maccioni et al. 2001; Sanchez 
and Cohen 1994).  In cases of AD, τ proteins can polymerize and form fibrils called paired 
helical filaments formed with hyperphosphorylated τ, disrupting the normal function of these 
proteins (Maccioni et al. 2001).  These filaments of protein aggregates become the basis for  
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NFT, leading further protein aggregation.  Recently, extensive research has pointed to the 
possibility of redox metals to participate in aggregation of hyperphosphorylated τ (FIG 2).  
 
Figure 2 Model depiction of hyperphosphorylated τ protein aggregation induced 
by metals Role of metals in aggregation of τ protein (1) Normally the τ protein is 
involved in assembly and disassembly of microtubules, and it is crucial for 
cytostructure.  (2) In case of Alzheimer’s disease, the τ protein becomes 
hyperphosphorylated and is not able carry out is normal function.  (3)  In presence of 
excessive metal, the hyperphosphorylated τ proteins can aggregate in neurofibrillary 
tangles. 
 
 
 
  
 
 
 
Normal form of τ protein has been found to be part of microtubules as a structural element.  
Upon hyperphosphorylation, τ proteins are not able to take part in formation of microtubules. 
Although not clear, this could be the step in which hyperphosphorylated τ protein could 
interact with heavy metals, predisposing the proteins to aggregate together.  Supporting this 
possibility, when the metal composition of NFT were carefully analyzed, high amounts of 
aluminum and iron were found in NFT protein aggregates from AD patients (Shin et al. 
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2003).  More interestingly, both metals were also found to promote aggregation of 
hyperphosphorylated τ proteins in vitro (Shin et al. 2003).  Such findings suggest that 
presence of excessive redox metals could speed up aggregation of hyperphosphorylated τ 
proteins in cases of AD patients and increase the formation of NFT in neurons. 
 
Parkinson’s Disease and Metal-Induced Aggregation of α-Synuclein 
 Parkinson’s disease (PD) is the second most common form of neuronal degeneration 
affecting the elderly population of United States today.  The exact causes of PD are 
ambiguous, but studies have indicated strongly to environmental factors as one of the key 
components to the etiology of the disease (Kanthasamy et al. 2003b; Powers et al. 2003).  
Some of the environmental toxicants believed to be involved in etiology of PD are redox 
metals and pesticides (Zatta et al. 2003).  Large number of researchers have shown 
correlation of increased concentration of iron with prevalence of PD cases (Gerlach et al. 
1994; Marder et al. 1998).  However, presences of excessive metals are not the only factors 
that contribute to the cause of PD.  Studies have pointed to number of factors including 
oxidative stress, formations of free radicals proteomic stress, neuromelanin iron interaction, 
mitochondrial dysfunction to name few of the factors (Kanthasamy et al. 2005; Kanthasamy 
et al. 2003b; Sun et al. 2005).  In epidemiological studies, excessive manganese exposure has 
been observed among miners, metal workers, industrial welders, and farmers using 
manganese based pesticides Maneb and Mancozeb (Marsh and Gula 2006; Racette et al. 
2001).  Excessive exposure to manganese and manganese containing compounds are 
especially known to produce PD-like symptoms in humans and in primates (Carpenter 2001; 
Kitazawa et al. 2002).  The neuronal degeneration found in PD is more specific for the 
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dopaminergic cells of the substantia nigra, affecting the motor system (Dexter et al. 1991; 
Fored et al. 2006; Gorell et al. 1999b; Kanthasamy et al. 2005; Racette et al. 2001).  
Affected individuals diagnosed with PD show resting tremor, bradykinesia (slowness of 
movement), stiffness, and accompanied by gait or balance problems (Fored et al. 2006; 
Racette et al. 2001).  Pathologically, the dopaminergic neurons of the substantia nigra 
undergoes large number of neuronal degeneration, and what is more interesting is that these 
neurons exhibited increase in cytosolic filamentous inclusions called Lewy bodies, 
predominantly composed of misfolded α-synuclein proteins (Munch et al. 2000; Uversky et 
al. 2001).   
The α-synuclein proteins are short natively unfolded proteins that are normally 
abundant in the central nervous system; however, a clear consensus as to the specific 
function of this protein remains to be determined (Ostrerova-Golts et al. 2000).  So far, there 
have been two mutations that have been identified with the α-synuclein protein: A30P and 
A53T (Ostrerova-Golts et al. 2000).  These two mutations results in abnormal folding of the 
α-synuclein protein leading to ubiquitination, and aggregate into fibrils which are gathered in  
Lewy bodies (Ostrerova-Golts et al. 2000).  There are two differing thoughts on how metals 
cause aggregation of α-synuclein and formation of Lewy bodies.  One possible pathway is an 
indirect involvement of metal by inducing oxidative stress, while another pathway adopts a 
direct interaction leading to abnormal protein folding mechanism (FIG 3).  In the oxidative  
stress pathways, it is believed that excessive concentrations of iron and other metals in the 
extracellular matrix enter dopaminergic neuronal cells of the substantia nigra, and reacts with 
dopamine to produce reactive oxygen species (Anantharam et al. 2002; Berg et al. 2001).  
These reactive oxygen species in turn cause advanced glycation endproducts (AGE) to  
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Figure 3 Schematic of indirect metal induced α-synuclein protein aggregates in Lewy 
body Indirect effect of metals on α-synuclein protein aggregation (1) With high 
concentration of metals outside the cells, the metals could enter a dopaminergic cells of the 
substantia nigra.  (2)  Once inside the metals can undergo Fenton reaction with dopamine, 
and cause oxidative stress.  The oxidative stress in turn could cause formation of advance 
glycation endproducts (AGE) on α-synucleins.  (3) Once α-synucleins have AGE, they have 
a greater tendency to aggregate together.  (4) Aggregated α-synucleins are ubiquitinated for 
degradation.  (4b) Significant amount of aggregated α-synuclein in turn clog the proteasomal 
system, effectively imparing the degradative process.  (5) Ubiquitinated aggregates of AGE 
α-synucleins are localized to Lewy bodies. 
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form,which in turn crosslinks α-synucleins together (Munch et al. 2000).  Crosslinked α-
synucleins in turn are targeted for degradation and ubiquitinated, but unprocessed and  
aggregated into Lewy bodies (Munch et al. 2000).  In abnormally folded protein induced 
aggregation pathway, the metal binding capacity of α-synuclein is involved (Andre et al. 
2005; Rasia et al. 2005) (FIG 4).  The C-terminus of α-synuclein contains charged amino 
acid motifs that have the potential to bind to metals (Rasia et al. 2005).  Studies have 
suggested that binding of metals to this site has the potential to alter the conformation of α-
synuclein (Andre et al. 2005; Rasia et al. 2005).  This describes a protein precursor model in 
where the abnormal folding of the protein mediates an intermediate precursor protein 
conformation, which predisposes the abnormal conformation of the protein for fibril 
formation found in Lewy bodies.  Findings from other studies support this hypothesis by 
showing that in these aggregated proteins metal ions are incorporated into the fibrils 
(Uversky et al. 2001).  Additionally, studies examining fibril formation induced by metals 
with or without pesticides and PD related toxicants found that in vitro incubation of α-
synuclein with metals alone resulted in acceleration of fibril formation (Uversky et al. 2002).   
The same study showed that pesticides such as rotenone and dieldrin were found to 
accelerate fibril formation even without metals.  More interestingly, combination of 
pesticides with metals resulted in synergistic effect, where the rate of fibril formation was far 
greater than the combined rate of toxicant and metals alone.  Together current research 
strongly implicates environmental factors, especially redox metals in the etiology of PD.  
 
Prion Disease 
 Prion diseases are a rarer form of neurodegenerative disorder that also involves  
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Figure 4 Schematic of direct interaction of metal induced α-synuclein protein 
aggregation  Direct effect of metals on aggregation of α-synuclein (1) The normally 
unfolded form α-synuclein interacts with heavy metals.  (2) The interaction causes the 
structure of α-synuclein to adopt an alternative conformation.  (3) The alternative 
structures are predisposed for fibril formation. 
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protein aggregation.  More often known as spongiform encephalopathy due to formation of 
large vacuoles in the brain, this fatal neurodegenerative disorder can afflict humans, 
ruminants, feline and feline-species, mink, and experimentally transmitted mice and hamster 
(Collinge and Palmer 1992; Fisher et al. 1998).  There are a number of variations in the prion 
disease due to the differences in pathology, as well as modes of pathogenesis (Collinge et al. 
1996; Jackson and Collinge 2001).  Interestingly enough, the cause of disease are multi-fold 
in dimension with possibility of iatragenic routes from infected surgical materials, human 
grafts, and even blood transfusions; or hereditary in nature as some cases of familial cases of 
Gerstmann-Straussler-Scheinker (GSS), familial Creuzfeldt-Jakob Disease (fCJD), and 
familia Fatal Insomnia (fFI); or even sporadic cases such as variant CJD, sFI (Collinge 2001). 
In humans, the prion disease first came to light with findings of Kuru cases by Gadjucek in 
the indigenous tribal population of the Fore people in Papua New Guinea where they 
practiced ritualistic cannibalism (Prusiner 1984).  Those afflicted with Kuru came down with 
severe motor function accompanied by degeneration of the cerebellum, dementia, prion 
‘plaques’ in the white matter, and dementia (Brown and Gajdusek 1991).  More recently 
publicized forms of prion disease were the new variant CJD, where people came down with 
the disease due to consumption of contaminated beef (Scott et al. 1999).  Pathology of CJD 
usually consists of dementia, spongiform vacuoles without prion plaque formation, with the 
exception of nvCJD, where florid prion plaques are present (Budka et al. 1995).  GSS are 
usually hereditary in nature with florid plaques, late onset dementia, and motor dysfunction 
(Goldgaber et al. 1989).  And lastly, the fatal insomnia is characterized by insomnia as the 
name suggest, followed by eventual death (Goldfarb et al. 1992).  The latent phase of the 
disease could be as short as few months in cases of nvCJD to decades as in cases of Kuru.  
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Thus far, there are no pre-mortem tests to verify for the disease, and as of date, no cures or 
immunization are available.   
The commonality between all prion diseases is an abnormal form of an endogenous 
surface expressed protein called the prion protein (Prusiner et al. 1980a).  This protein is 
ubiquitously expressed in most parts of the body, but more robustly expressed in the central 
nervous system as well as the in the lymph system (Bueler et al. 1992).  The protein has 
octapeptide repeats along the N-terminus that has a strong affinity to divalent cations, and 
number of studies point to copper as the main substrate for the protein (Brown et al. 1997b; 
Hornshaw et al. 1995a).  Although the exact role of the protein remains to be solved, various 
functions have been proposed from the protein acting as a cell adhesion molecule, an anti-
oxidant, or even a metal chelator (Brown et al. 1997c; Choi et al. 2006; Schmitt-Ulms et al. 
2001).  Whatever the normal function of the prion may be, it is clear that the protein is the 
culprit in the pathogenesis of the disease (Prusiner et al. 1993).  While the normal form of 
prion protein (PrPC) contains a predominant α-helical structure, the infectious form (PrPSc) 
has high β-sheet content (Choi et al. 2006; Hogan et al. 1981; Huang et al. 1995; Wille and 
Prusiner 1999).  Once in the infectious PrPSc state, not only is the protein infectious, but it 
also becomes highly resistant to normal forms of inactivation that would modify nucleic 
acids (Chatigny and Prusiner 1980).  The normal forms are believed to bind to copper while 
in the abnormal form has been purported to bind to other divalent cations besides copper 
(Hornshaw et al. 1995b; Miura et al. 1996).  Brown and colleagues have shown that PrPC 
upon binding to manganese becomes less susceptible to proteinase-K digestion (Brown et al. 
2000a; Nishina et al. 2004; Quaglio et al. 2001).  Others have speculated that PrPC binding 
with manganese or non-copper cations could alter the structural conformation of the protein, 
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thereby predisposing the protein to a β-sheet prone conformation (Bocharova et al. 2005; 
Levin et al. 2005; Wong et al. 2004).  Such protein conformational change could lead to 
aggregation of the protein, and eventually into fibrils (Ding et al. 2005; Levin et al. 2005; 
Ross and Poirier 2004).  Normal PrP exists on the cellular surface bound to GPI anchor with 
affinity to bind with heavy metal, which can potentially alter the conformation of PrP from α-
helix rich to β-sheet rich conformation (Fig 5).  Changes to the structural content predispose 
the β-sheet rich PrP to aggregate together.  Alternatively, upon conformational change, PrP 
could be internalized into endosomes for degradative pathway.  The altered conformation 
resists degradation, and more β-sheet rich PrP aggregates into the endosome.  A more 
detailed review of the prion protein will be discussed in the prion protein literature review. 
More recently, using Protein Misfolding Cyclic Amplification (PMCA) technique it 
was shown that in presence of certain divalent cations, the formation of PK resistant prion 
protein was seen at an earlier cycle as compared to the treatment without metals (Soto et al. 
2005; Soto et al. 2002).  This further validates the possibility that metals that interact with 
prion protein can induce misfolding of the protein.   
 
Conclusion of Background Information 
 Environmental factors such as metals have been correlated to neurodegenerative 
disorders such as AD, PD, and prion disease (Campbell et al. 2001; Zatta et al. 2003; Zawia 
and Basha 2005).  One common hallmark shared by these three neurodegenerative disorders 
is the formation of protein aggregation (Mattson and Sherman 2003).  Strong evidence exists 
to show the crucial role of metals interacting with the proteins to favor protein aggregation 
(Gaeta and Hider 2005).  Although metals could be an important component, by no means 
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are they the only causative factor in development of neurodegenerative disorders discussed 
here.  Most likely, the developments of these disorders are due to orchestral composition of 
various environmental, genetic, and even sporadic conditions.  Some positive speculations of 
using chelators to entrap excessive metals have been proposed, with supportive data 
(Cuajungco et al. 2005; Gaeta and Hider 2005; Shin et al. 2003; Sigurdsson et al. 2003).  
However, approaching cures to these neurodegenerative disorders require multifaceted 
strategies to effectively combat progression and even development of these ailments. 
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Figure 5 Schematic of metal induced altered processing of PrP 
Effect of metal on prion protein aggregation (1) Normal PrP exists on the cellular surface 
bound to GPI anchor.  (2) PrP has the affinity to bind with heavy metal, which can 
potentially alter the conformation of PrP from α-helix rich to β-sheet rich conformation. (3) 
Changes to the structural content predispose the β-sheet rich PrP to aggregate together. (4) 
Alternatively, upon conformational change, PrP could be internalized into endosomes for 
degradative pathway.  (5) The altered conformation resists degradation, and more β-sheet 
rich PrP aggregates into the endosome. 
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Prion protein literature review 
 
 Prion diseases refer to a class of fatal transmissible spongiform encephalopathy (TSE) 
that affects the central nervous system (CNS) of both humans and animals.  The well-known 
prion diseases include bovine spongiform encephalopathy (BSE) in cows, chronic wasting 
disease (CWD) in deer, scrapie in sheep, and Creutzfeldt-Jakob Disease (CJD) in humans 
(Collinge and Palmer 1992).  Once thought to be caused by a virulent particle, the cause of 
the disease was later proven to be due to an abnormal conformation of a host protein 
(Chatigny and Prusiner 1980).  Studies have shown that the propagation of the infectious 
prion protein cannot occur in the absence of host prion proteins (Prusiner et al. 1993), 
indicating the causal role of prion proteins in the pathogenesis of the disease. Prion diseases 
cause severe neuronal damage mainly in the brain regions that coordinate motor function, 
including the basal ganglia, cerebral cortex, thalamus, and cerebellum (Baringer et al. 1983; 
Gibbs et al. 1985; Hainfellner et al. 1997)  The major neurological symptoms are 
extrapyramidal motor signs, cerebellar ataxia, pyramidal signs, and myoclonus (Brown and 
Gajdusek 1991; Haltia et al. 1991). The neuronal damage is characterized pathologically as 
massive neuronal degeneration associated with accumulation of the abnormal prion protein 
PrPSc (scrapie isoform) derived from the normal prion protein PrPC (cellular isoform) through 
unknown cellular mechanisms (Collinge 2001; Ma et al. 2002).  The neuropathological 
changes include vacuolation of neurophils, neuronal loss, and gliosis in the brain of diseased 
animals and humans (Collinge and Palmer 1992; Owen et al. 1989; Palmer and Collinge 
1992).  Incubation time of the disease can range anywhere from a few months to decades, 
and pre-mortem biopsy is not available for diagnosis (Hill et al. 1999; Serban et al. 1990).   
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Figure 6. Homology of PrPC between different species  
PrPC homology was obtained from NCBI Entrez protein database. 
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With recent evidence pointing to possible trans-species infection via ingestion, possible 
contamination of human food supplies has increased concerns over food safety.  This review 
summarizes recent findings on the role of metals in physiological functions of PrPC proteins, 
as well as in the pathophysiology of prion diseases.  A special emphasis has been focused on 
the role of transition metals such as copper and manganese in the disease process. 
 
Characterization of Prion Disease 
PrPC sequence is very well conserved throughout mammalian species, which may explain its 
capacity for possible interspecies transmission (Hill et al. 2000; Horiuchi et al. 2000).  The 
close homology (> 90%) between different species is presented in Figure 6.  Homology of 
PrPC was obtained from NCBI Entrez protein database.  Yellow corresponds to highly 
conserved regions in the species listed, while blue corresponds to moderately conserved 
regions, and white corresponds to less conserved regions. 
Nevertheless, some significant differences do exist between species in certain regions 
of PrPC, such as the number of octapeptide repeats.  Deletional studies have shown that the 
whole protein may not be necessary for the infection and propagation of the disease 
(Supattapone et al. 1999).  It is believed that there is a region that has a direct physical 
interaction between the PrPC and PrPSc, allowing for the PrPSc to act as a template for the 
conformational change of PrPC into PrPSc, and this region is believed to be crucial in the 
formation of PrPSc from PrPC (Telling et al. 1996).   
 
Human Prion Diseases 
Table 1 briefly lists the various types of human prion diseases and the possible 
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mechanism of pathogenesis.  The heritable, transmittable, and sporadic nature of human 
prion disease is quite interesting.  About 20 mutations have been reported in the PrP gene 
that is linked to the inherited human prion disease (Collinge et al. 1989; Goldgaber et al. 
1989; Hsiao et al. 1989).  Each of the human forms of the prion disease has very distinct 
pathologies and symptoms.  Whether inherited, transmitted, or sporadic in nature, PrPSc from 
the brain of diseased individuals is infectious, and can be transmitted horizontally (Flechsig 
et al. 2001; Hogan et al. 1999; Ricketts and Brown 2003; Zobeley et al. 1999) 
 
 
Table 1: Human form of prion disease 
Types Mechanism of Pathogenesis 
Sporadic  
    sCJD 
    sFI 
 
Spontaneous conversion of PrPC to PrPSc? (exact causes unknown) 
Familial 
    fCJD 
    GSS 
    fFI 
 
Genetically linked mutations in the human Prnp gene 
Infectious 
    vCJD 
    iCJD 
    Kuru 
vCJD: possibly from contaminated cow products; iCJD: through 
HGH, dura mater grafts, and surgical tools contaminated with 
infectious prion protein from symptomatic patients; Kuru: from 
ritualistic cannabalism 
 
sporadic Creutzfeldt-Jakob disease (sCJD); iatrogenic Creutzfeldt-Jakob disease (iCJD); 
familial Creutzfeldt-Jakob disease (fCJD); variant Creutzfeldt-Jakob disease (vCJD); 
Gerstmann-Sträussler-Scheinker syndrome (GSS); sporadic Fatal Insomnia (sFI); familial 
Fatal Insomnia (fFI); Human Growth Hormone (HGH).  
 
 
Creutzfeldt-Jakob Disease  
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 Creutzfeldt-Jakob disease is the most prevalent type of human transmissible 
spongiform encephalopathy accounting for 90-95% of all human cases of TSE (Belay 1999; 
Holman et al. 1996).  Occurring at incidences of 1 case per 1 million in the general 
population, it is primarily seen in older populations (Holman et al. 1996).  CJD has been 
known to occur sporadically, through iatrogenic transmission, or have a familial component 
(Collinge 2001).  Symptoms of CJD include dementia, memory loss, personality changes, 
hallucinations, speech impairment, jerky movements, balance and coordination problems, 
awkward gait, and seizures (Zeidler et al. 1997).  Once prominent, these symptoms 
deteriorate rapidly, leading to inevitable death.  The pathological signs of CJD are highly 
variable between cases, but commonly include spongiform degeneration in the cerebral 
cortex, hippocampus, putamen, caudate nucleus, thalamus, and the molecular layer of the 
cerebellar cortex (DeArmond and Prusiner 1995b; Lantos et al. 1992; Manuelidis 1994).  In 
these brain regions, neuronal loss, reactive astrocytosis, and in very few cases amyloid 
plaque formation (5-10%), are found (Lantos et al. 1992; Parchi et al. 1999).  Sporadic cases 
of CJD, which account for the majority of CJD cases, are usually found in older patients with 
average onset age of 60 years (Parchi et al. 1999).  A majority (90%) of the sporadic CJD 
patients are homozygous for methionine or valine at codon 129 (Hill et al. 2003; Palmer and 
Collinge 1993; Palmer et al. 1991; Windl et al. 1996).  Although exact causes have not been 
defined, two possible hypotheses have been proposed.  One is the possibility of random 
mutation that could occur in the PrP gene with older patients, and the other could be due to 
sporadic conformational change from PrPC to PrPSc (Hill et al. 2003; McKintosh et al. 2003; 
Prusiner 1998a).  
 Familial CJD is the next most prevalent type accounting for about 5-15% of all CJD 
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patients (Goldfarb et al. 1991; Goldgaber et al. 1989).  It is commonly associated with a 
mutation at codon 200, as well as minor occurrences with a mutation at codon 178 (Brown et 
al. 1992; Gabizon et al. 1994; Lee et al. 1999; McKintosh et al. 2003; Meiner et al. 1997; 
Rosenmann et al. 1998).  Iatrogenic CJD is much rarer and is believed to be caused by 
person to person transmission.  Transmission has been documented from human growth 
hormone injections, dura mater grafts, and even from properly sterilized surgical tools (el 
Hachimi et al. 1997; Hogan et al. 1999; Keeler et al. 2006; Mitrova and Belay 1999).  Lastly, 
the more publicly known form of CJD is the variant type, believed to be caused by 
consumption of contaminated beef products (Bruce et al. 1997; McLean et al. 1998; Zeidler 
et al. 1997).  In addition to the neuropathology described for CJD patients, variant CJD 
patients also display prominent plaques in both the occipital lobe and the cerebellum (Brown 
et al. 2003).  Although the genetic predisposition for people susceptible to variant CJD 
remains to be fully solved, it is interesting to note that as of date, all variant CJD patients 
were homozygous for methionine at codon 129 (Parchi et al. 1999; Windl et al. 1996).  Most 
recently in cases of CJD, increased protein 14-3-3 levels in the cerebralspinal fluid have been 
discovered (Baxter et al. 2002; Richard et al. 2003); although it is too early in the 
development, it may become a future biomarker for those infected with the human prion 
disease. 
 
Kuru 
 Transmissible spongiform encephalopathy affecting the Fore tribe in Papua New 
Guinea has been shown to be caused by the practice of cannibalistic rituals (Gajdusek 1972; 
Gajdusek and Alpers 1975).  Although cannibalistic consumption of deceased family 
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members is believed to be the primary mode of infection, entry of the infection through open 
wounds is not out of the possibility.  In the native word Kuru refers to ‘trembling with cold 
and fever’ is also commonly known as the laughing sickness.  Gajdusek originally described 
the progression of the disease to have three stages: first the ambulant stage, where the 
patients have unstable stance and gait, tremors, shivering, and deteriorated speech (Gajdusek 
and Gibbs 1968; Gibbs and Gajdusek 1971).  This stage is followed by the sedentary stage, 
where the affected individuals are no longer able to walk, have severe tremors and ataxia, 
and uncontrollable laughter.  The final terminal stage is marked by severe ataxia, muscle 
degeneration and death.  The neuropathology of Kuru is characterized by severe atrophy of 
the vermis and the flocculonodular lobe of the cerebellum with amyloid plaques in the 
granule cell layer and the molecular layer (Gibbs and Gajdusek 1971; Lampert et al. 1972; 
Prusiner and DeArmond 1991).  As compared to the amount of neurodegeneration in the 
cerebellum, the cerebral cortex has slight spongiform degeneration (Budka et al. 1995; 
Guiroy et al. 1994). 
 
Fatal Insomnia 
 The majority of fatal insomnia cases are familial in nature with a mutation found at 
codon 178, where aspartic acid is replaced with asparagine (Chen et al. 1997; McLean et al. 
1997; Reder et al. 1995; Tateishi et al. 1995).  Only a small fraction of fatal insomnia cases 
have been discovered to be sporadic.  Although not clear, studies have suggested 
polymorphism at codon 129 to play a role in the development of the disease (Petersen et al. 
1994; Reder et al. 1995).  Fatal insomnia has been characterized in 4 progressive stages 
starting with increasing insomnia, and panic attacks (Goldfarb et al. 1994; Prusiner 1993b; 
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Reder et al. 1995).  Hallucinations shortly follow, with complete inability to sleep.  The last 
stage is marked by dementia and death.  The neuropathological symptoms are similar to 
those found the CJD patients, but also have plaque formation in the thalamus (McLean et al. 
1997; Reder et al. 1995). 
 
Gerstmann-Sträussler-Scheinker  
GSS occurs at a prevalence of 1-10 cases per 10 million people, and is completely 
hereditary in nature (Hsiao and Prusiner 1991; Prusiner 1991a).  Multiple mutations in the 
PrP gene have been linked to GSS cases (Table 2).  GSS is pathologically different from the 
other human prion disease in its multi-centric PrP-positive amyloid plaques in the basal 
ganglia and the cerebellar and cerebral cortex.  Other differences include the highly truncated 
forms of PrP and later onset of dementia; additionally, some GSS has protease-sensitive 
PrPSc, (Barcikowska et al. 1993; Giaccone et al. 1992; Hsiao et al. 1992; Hsiao and Prusiner 
1991).  The mutations F198S and Q217R are also characterized by formation of 
neurofibrillary tangles in the cerebral cortex (Zaidi et al. 2005).  Mutation Y145Stop results 
in 10-20 µm spherical PrP amyloid deposits in the brain parenchyma and the leptomeninges 
(Hachiya et al. 2005; Kundu et al. 2003).  Similar to CJD, an isoform of 14-3-3 protein has 
been detected in the cerebralspinal fluid of GSS patients (Di Fede et al. 2007).  
 
Table 2: GSS mutations 
Normal codon Codon site Mutation 
Proline 102 Leucine 
Proline 105 Leucine 
Alanine 117 Valine 
Tyrosine 145 Stop 
Phenylalanine 198 Serine 
Glutamine 217 Arginine 
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Animal Prion Diseases 
The prion diseases affecting animals, i.e., scrapie, bovine spongiform encephalopathy 
(BSE), chronic wasting disease (CWD), and transmissible mink encephalopathy (TME), 
share some of the common characteristic pathologies that have been described for CJD in 
humans (Collinge 2001; Hill and Collinge 2003; Westaway et al. 1995).  Table 3 outlines the 
animal prion diseases and possible mechanisms of pathogenesis.  With most of these animals 
being used for human consumption, the threat of animal to human transmission has the 
potential to steer people away from consuming meat products from these animals, which 
could result in severe economical repercussions.   
 
Table 3: Animal form of prion disease 
Types Mechanism of pathogenesis 
Sporadic  
    Scrapie in sheep and goat 
    CWD in wild  
    BSE, BASE 
Spontaneous conversion of PrPC to PrPSc? 
(exact causes unknown) 
  
Infectious  
    Scrapie in sheep and goat 
    CWD in wild 
    Transmissible mink encephalopathy 
    Feline spongiform encephalopathy 
 Experimental transmission in mice,      
hamsters 
Possible horizontal and vertical transmission; 
contaminated MBM feed; experimental 
infections; exact causes unknown 
 
Chronic wasting disease (CWD); bovine spongiform encephalopathy (BSE); bovine 
amyloidotic spongiform encephalopathy (BASE) 
 
 
Bovine Spongiform Encephalopathy 
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Prevalent cases of bovine spongiform encephalopathy have significantly risen in 
various parts of Europe, and the U.S.  Although not clear as to the reason for BSE outbreaks, 
one possible instance is the rendering practices of cattle and other species infected with 
transmissible encephalopathy (Prusiner 1997).  In light of the recent outbreak of BSE in UK, 
the majority of the countries with beef production have stopped rendering practices.  As in 
cases of new variant CJD, it is suggested that the infection was due to consumption of 
contaminated beef products (Scott et al. 1999). Reports from researchers have suggested that 
there may be two separate ‘strains’ of BSE (Baron et al. 2006; Buschmann et al. 2004; 
Buschmann et al. 2006; McGill and Wells 1993; Yamakawa et al. 2003).  Typical cases of 
BSE display behavior abnormalities, hyper-reactivity, gait abnormalities, weakness, loss of 
body control, and recumbency (Chesebro 1998; Collinge 2001; Prusiner 1997).  Vacuolations 
of the neurons, especially the cell bodies, as well as the neuropils of the grey matter, are 
significantly affected in various parts of the brain (Brown et al. 2003; Prusiner et al. 1991).  
In typical BSE cases, these vacuolations are the greatest in the brainstem, and to a certain 
extent the cerebral cortex (Brown et al. 2003; Manuelidis et al. 1997; Wadsworth et al. 
1999b).  Although rare, atypical cases of BSE have been discovered in various parts of the 
world (Buschmann et al. 2004; Buschmann et al. 2006).  In atypical cases of BSE, otherwise 
known as bovine amyloidotic spongiform encephalopathy (BASE), amyloid plaques are 
found in the white matter (Biacabe et al. 2004; Yamakawa et al. 2003).  Also, the 
accumulation pattern of PrPSc in BASE has been found to be significantly different than 
typical BSE.  Even the protein glycosylated forms show different electrophoretic profiles 
(Biacabe et al. 2004; Gretzschel et al. 2005; Vidal et al. 2006).  
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Scrapie in Sheep and Goat 
Naturally occurring cases of scrapie affecting sheep and goat have been identified in 
Europe for the last 200 years (Brotherston et al. 1968; Renwick and Zlotnik 1965).  Typical 
symptoms include ataxia, weakness, wasting, and abnormal behaviors such as scraping 
against fences and walls, hence the name scrapie (Gibbs and Gajdusek 1971; Prusiner 1982; 
Prusiner et al. 1982).  Vacuolation, neuronal loss, and reactive astrocytosis have been shown, 
and are localized to the cerebellum (Prusiner 1992; Prusiner and DeArmond 1991).  Studies 
strongly correlate the occurrence of scrapie with polymorphism of the PrP gene (Carlson et al. 
1986; Race et al. 1990; Westaway et al. 1994c).  They have been proposed at codon 136 (A 
or V), 153 (R or H), and at 171 (Q, R, or H).  Epidemiological studies have suggested that 
genotype VRQ for the previously mentioned codons have been found to be the most 
susceptible to scrapie, while genotype AHQ offered mild resistance, and genotype ARR had 
the highest resistance to scrapie infection (Andreoletti et al. 2000; Ersdal et al. 2005; Wong 
et al. 2004). 
 
Chronic Wasting Disease 
Naturally occurring cases of transmissible spongiform encephalopathy primarily 
affecting the elk, whitetailed deer, and mule deer populations have been found in North 
America (Guiroy et al. 1993; Williams and Young 1992).  Typical symptoms include weight 
loss, excessive salivation, and unusual behavior (Williams and Young 1992).  Similar to 
other transmissible spongiforms, vacuolations of the neuropil and neurons are seen, as well 
as astrocytic hypertrophy, formation of amyloid fibrils, and plaques (Guiroy et al. 1993; 
Sigurdson et al. 1999; Spraker et al. 2004).  Although not clear as to the exact etiology 
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behind CWD, a few have speculated to the possible role of metal imbalance in the animal’s 
diet (Purdey 2000, 2004). 
 
Transmissible Spongiform Encephalopathy of Other Animals 
Transmissible spongiform encephalopathy of mink, feline species, and exotic 
ungulates has also been documented (Collinge 2001; DeArmond and Prusiner 1995a; 
Prusiner 1993b, 1998b).  Feline species, especially those housed in zoos have been affected 
(Ryder et al. 2001; Sigurdson and Miller 2003).  Behavioral changes, and gait abnormalities 
were the primary symptoms observed, and vacuolation of neuropils and neurons were found 
mostly in the basal ganglia, cerebral cortex and the thalamus (Ryder et al. 2001).  Similarly, 
cases of transmissible spongiform encephalopathy in exotic ungulates (greater kudu, nyala, 
and antelopes) have been observed (Brun et al. 2000).  And lastly, outbreaks transmissible 
mink encephalopathy has been documented in mink farms (Robinson et al. 1994; Sigurdson 
and Miller 2003).  These infected animals show signs of hyper-excitation, severe problems 
with coordination, difficulty walking, and jerkiness of limbs (Bartz et al. 2002; Prusiner 
1991a).  Pathological features were very similar to those found in scrapie (Bartz et al. 2002; 
Marsh and Hadlow 1992; Sigurdson and Miller 2003; Wells 1993).  Although the exact 
causes of transmissible spongiform encephalopathy in these animals could not be explained, 
speculations point to infected cattle used as feed (Marsh and Bessen 1993; Marsh and 
Hadlow 1992). 
 
 
Cross-species Transmission 
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Although the exact mechanism of infection is not clear, experimental infections can 
occur between various species.  Although each species has a distinct form of prion disease, 
infection can be transmitted from one species to another (Priola and Lawson 2001).  Current 
research has suggested that species barrier does exist between species.  In experimental 
models of cross-species transmission, increased incubation period from infection to onset of 
clinical symptoms have been observed (Lowenstein et al. 1990; Prusiner 1991a).  Studies 
have suggested that this prolonged incubation period of the disease may be due to efficiency 
of infection, pathogenesis, and strain efficacy.  It is further suggested that the increased 
incubation periods are due to the compatibility of prion protein from one species to the other, 
and the strain used (Kocisko et al. 1995; Lowenstein et al. 1990; Telling et al. 1994).  These 
strains are differentiated by the differences in the glycosylation profiling, the intensity of 
bands, location of detection, and molecular weights.  Studies have shown that in human prion 
diseases, the existence of various strains is more apparent with differences in symptoms, and 
protein profiling (Collinge et al. 1996; el Hachimi et al. 1997; Manuelidis 1994; Manuelidis 
and Fritch 1996; Prusiner 1993b; Telling et al. 1996).  In small animal models of prion 
disease, strain differences are observed depending upon the source of the infectious prion 
protein (Liberski et al. 1991; Lowenstein et al. 1990; Race et al. 2002).  It is interesting to 
note that even athough initial cross-species transmission requires an extended incubation 
period, subsequent passage into the same species resulted in decreasing incubation period to 
clinical diseased state (Hill and Collinge 2001, 2004; Scott et al. 1997).  These studies clearly 
indicate to the possibility of cross-species transmission of the prion disease, and the 
importance of understanding the disease. 
Possible Routes of Infection 
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Although it is unclear as to the origin of PrPSc, the hypothesis of spontaneous 
conversion from PrPC to PrPSc has not been dismissed.  In cases of familial forms of prion 
disease in human, the genetic component to the disease is most likely the main factor in 
development of prion disease.  In cases of iatrogenic cases of human prion disease, sources 
vary from human grafts with dura mater, injection of human growth hormones, blood 
transfusions, and even surgical tools that have been sterilized properly.  With most prion 
disease occurring in animals, the source of infection is believed to be through contaminated 
feed, and in cases of nvCJD patients, it is believed to be from consumption of contaminated 
beef products.  These findings would suggest that the mechanism of infection from ingestion 
to the diseased state is a crucial step in understanding the pathogenesis of disease.  Although 
most of the ingested materials would be digested, PrPSc could persist in the digestive tract 
due to the protease-resistance of the infectious protein (Maignien et al. 1999).  Ingestion 
studies have suggested intestinal mucosa to be the most important area of potential infection 
(Bons et al. 1999; Fournier et al. 1998).  Although entry of PrPSc through open wounds in the 
mouth is not unlikely, as evidenced by hamsters infected through the dental route, stronger 
evidence lies with the role of Peyer’s patch and follicular dendritic cells (FDC) (Brown et al. 
1999b; Ingrosso et al. 1999; Jeffrey et al. 2000b; Manuelidis et al. 2000; Muramoto et al. 
1992, 1993).  It is not clear as to how the infectious PrPSc crosses the intestinal mucosa and 
into the Peyer’s patches, but studies with Caco2 cells (intestinal epithelial cells) show that 
PrP could be found concentrated in the apical side (De Keukeleire et al. 2007).  From there, 
infection could occur and PrPSc could be shed, infecting surrounding cells and cells in the 
Peyer’s patch.  Studies with mice have revealed that PrPSc accumulates in the follicular 
dendrocyte cells (FDC) in the lymphoid tissues before detection in the central nervous 
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system (Brown et al. 1999b; Jeffrey et al. 2000b).  Support for the role of FDCs come from 
studies with mice lacking functional FDCs; these studies showed impairment in the 
progression of the disease in these mice, strongly implicating FDCs in the entry of prion 
disease into the body (Jeffrey et al. 2000a; Montrasio et al. 2000; Muramoto et al. 1992; 
Oldstone et al. 2002).  From infected FDCs, other lymphoid tissue could become infected, 
and it is possible that the sympathetic nervous system innervating the lympoid organs could 
in turn become infected, as well as the tissues in the periphery (Brown et al. 2000b; Prinz et 
al. 2003).  This could lead to PrPSc being introduced to the central nervous system. 
Structure of PrPC
 
Figure 7. Structure of mouse prion protein  
PrPC molecule is 254 amino acids in length, with N-terminal and C-terminal sequences 
that are cleaved shortly after translation.  GPI anchor is attached to the C-terminus post-
cleavage of the signal sequence, and addition of two N-linked glycosylations occurs at 
Asn 181 and 197.  Three α-helices are present at 144-157 (α1), 172-193 (α2), and 200-227 
(α3).  A disulfide bridge is formed between α2 and α3 at Cys 179 and 214, respectively.  
Two small β-sheets are also present at 129-131 (β1) and 161-163 (β2).  Toward the N-
terminus is the octapeptide repeat region (PHGGGWGQ) which has His residues 
suggested to play a role in metal binding.  Additional metal binding sites His 96 and 111 
are also present.   
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PrPC is a highly conserved protein among the mammalian species (Martins and Brentani 
2002).  It is a surface protein, predominantly found in the CNS and several other cell types, 
linked via a glycosyl-phosphoinositol (GPI) anchor, with two N-linked glycosylations 
(McKinley and Prusiner 1986).  PrP gene is found on chromosome 20 in humans and 
encodes for 254 amino acid sequences before processing (Figure 7).  In the PrP structure, 
three α-helices are present at 144-157 (α1), 172-193 (α2), and 200-227 (α3).  A disulfide  
 
 
 
 
 
 
 
 
Figure 8. Representation of three glycosylated forms of prion protein 
 
bridge is formed between α2 and α3 at Cys 179 and 214, respectively.  Two small β-sheets  
are also present at 129-131 (β1) and 161-163 (β2).  Toward the N-terminus is the octapeptide  
repeat region (PHGGGWGQ), which has His residues suggested to play a role in metal 
binding.  Additional metal binding sites His 96 and 111 are also present.  The first 22 amino 
acid residues of the N-terminus are cleaved shortly after translation, and in the endoplasmic 
reticulum, two N-linked glycosylation sites are further processed and modified (Barry and 
Prusiner 1986; Prusiner et al. 1987; Prusiner et al. 1980b).  A GPI anchor is attached to the 
C-terminus post-cleavage of the signal sequence, and addition of two N-linked glycosylations 
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occurs at Asn 181 and 197. 
 Glycosylation of PrPC can be variable and could have either diglycosylation, 
monoglycosylation, or left as unglycosylated, as shown in three glycosylation patterns 
commonly observed with Western blots (Korth et al. 2000; Parchi et al. 1997; Taraboulos et 
al. 1992) (FIG 8).  This was demonstrated by cleaving the N-lniked glycosylation with 
treatment of N-glycosidase F (PNGase F) (Haraguchi et al. 1989).  This treatment results in 
only single band being observed at the lowest unglycosylated state.  It is not clear as to the 
exact role of the glycosylation, but researchers have speculated to the role of glycosylation in 
detection of diseased state and altered susceptibility to infection (Endo et al. 1989; Haraguchi 
et al. 1989; Lehmann and Harris 1997; Parchi et al. 1997; Rudd et al. 1999; Somerville and 
Ritchie 1990; Taraboulos et al. 1990).  Changes in the glycan profiles between PrPC and 
PrPSc have been speculated, but this remains to be solved (Barret et al. 2005; Caughey et al. 
1989; Priola et al. 1994).   Abnormal processing of glycosylation in experiments with 
tunicamycin prevented glycosylation of PrP, but did not inhibit formation of PrPSc (Caughey 
et al. 1989; Taraboulos et al. 1990).  However, studies that examined altered glycosylation of 
PrP suggests that cellular distribution of PrPC as a result of changing glycosylation could 
affect the formation and the susceptibility to infection (DeArmond et al. 1997; Korth et al. 
2000).  Interestingly, in one study examining the expression of PrP in aging mice found that 
there was a significant difference in the glycan profile of PrP between young and aged mice 
(Goh et al. 2007).  Studies have pointed to the possibility of glycosylation influencing PrPSc 
conversion (Priola and Lawson 2001; Rudd et al. 2002; Russelakis-Carneiro et al. 2002; 
Wong et al. 2000c).  Additionally, another study examining PrP from normal human brain 
samples concluded that there are insoluble aggregates and PK-resistant PrP (Yuan et al. 
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2006).  This finding supports the hypothesis of abnormal conformation of PrPSc that could 
exist in normal brain in equilibrium with PrPC.  These studies might suggest that there may 
be a correlation of age with disease development or onset of prion disease. 
 PrPC contains several octapeptide repeat sequences (PHGGSWGQ) toward the N-
terminus, which have binding affinity for divalent metals such as copper, zinc, nickel and 
manganese, with preferential binding for copper (Hornshaw et al. 1995b; Viles et al. 1999).  
Although it is not clear as to whether any divalent cation could bind to this site, it is strongly 
speculated that this site is crucial for prion activity and important in the etiology of the prion 
disease.  The number of octapeptide repeats differs from species to species, and a higher 
number (>24) of repeats have been associated with the human form of the prion disease 
known as Gerstmann-Sträussler Sheinker (GSS) syndrome (Palmer et al. 1993).  More 
recently, higher affinity sites have been identified at His 96 and 111 (Jackson et al. 2001; 
Jones et al. 2004), but the exact role of these higher affinity metal binding sites remains 
elusive.  Other model studies have suggested that most of the N-terminus is rather 
unstructured, while the C-terminus is highly structured, with two α-helices linked via 
disulfide bond, a shorter α-helix, and two short strands of β-sheet structures (Di Natale et al. 
2005; Jones et al. 2005a; Renner et al. 2004; Viles et al. 2001).  Binding of the divalent 
cation to the octapeptide repeats has been speculated to facilitate the folding of the largely 
unstructured N-terminus, thereby stabilizing the protein conformation (Cereghetti et al. 2003). 
 Normal PrPC is synthesized in the endoplasmic reticulum, transitted through the Golgi 
network and eventually to the cell surface.  In cells, ER is the major area where proteins are 
translated and folded with help of chaperone proteins.  One study has shown that when 
normal processing PrP was prevented with ER stress, these PrP became better substrates for 
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PrPSc conversion with PMCA technique (Hetz et al. 2007).  Properly folded prion protein is 
present on lipid membrane rafts, and is believed to be internalized via clathrin-mediated 
endocytosis with a half-life of about 6 hrs (Peters et al. 2003; Prado et al. 2004).  Internalized 
PrPC and abnormally folded protein is rapidly degraded via the ubiquitin proteasomal system 
(Ciechanover and Brundin 2003; Kang et al. 2004; Laszlo et al. 1992).  In addition to the 
full-length protein that is expressed on the cell surface, studies have indicated that various 
transmembrane forms of the protein could exist as well (Giese and Kretzschmar 2001; Hegde 
et al. 1998).  Two distinct transmembrane forms, N-terminus attached to the membrane 
(NtmPrP) and C-terminus attached to the membrane (CtmPrP), have been shown to exist in 
both animal and cell culture models of prion disease (Hegde et al. 1998; Mishra et al. 2002; 
Walmsley et al. 2001).  Although the role of these transmembrane forms of PrP in the 
etiology of disease is not clear, researchers have shown that CtmPrP transgenic mice 
developed neurodegeneration similar to prion disease, but without the PK-resistant core 
(Hegde et al. 1998; Kim and Hegde 2002; Kim et al. 2001).  Another group of researchers 
has found similar CtmPrP forms in GSS patients with P102L mutations (Mishra et al. 2002);  
they speculated that these alternative transmembrane forms of PrP could be an optimal 
substrate for PrPC – PrPSc conversion. 
Since the change from PrPC to PrPSc is not accompanied by any alteration to the 
sequences, it is important to distinguish one form from another (Prusiner 1989).  By 
proteinase-K digestion, the majority of the N-terminus is cleaved, leaving only the protease-
resistant core to be detected (McKinley et al. 1983; Prusiner et al. 1984; Prusiner et al. 
1980c), and as such, various antibodies have been developed for detection of PrP in both 
non-infectious and infectious forms, as well as differences in host-types (Figure 9).   
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Figure 9. Map of anti-PrP detection loci and their species 
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Conformational Changes in PrPC  
Changes in conformation into the infectious prion protein (PrPSc) from PrPC result 
from dramatic change in the secondary structure, with increased β-sheet content, and 
decreased α-helix content (Gasset et al. 1993; Huang et al. 1996).  These altered 
conformations tend to aggregate into insoluble fibrils and are resistant to proteinase-K 
digestion (Martins and Brentani 2002; Turk et al. 1988; Yakovleva et al. 2004).  There are 
two different models for the prion conversion from PrPC to PrPSc (Figure 10).  Both 
schematic representations of conversion of PrPC to PrPSc can be used to explain the length of 
incubation period prior to onset of clinical disease (Prusiner 1998b).   
There has been some speculation about an additional chaperone protein requirement  
of protein X for propagation, while others have maintained that imbalance of metal binding 
may be the key factor in the formation and propagation (DeArmond and Prusiner 1995b; 
Telling et al. 1995).  Originally, the synthetic form of the prion protein, even in its abnormal 
conformational folding, failed to induce prion disease in animals (Kaneko et al. 1997; 
Nguyen et al. 1995).  However, more recent studies by Prusiner’s group have shown that 
they were able to induce neurological disease in transgenic mice, and not in wild-type mice, 
with synthetic prion proteins (Legname et al. 2005).  The brain lysates obtained from the 
diseased animals were able to propagate the disease out to further passages into uninfected 
mice. 
 
Physiological functions of PrPC
Although PrPC is highly expressed in the central nervous system, the biological role is not 
well established.  The prion protein has been speculated to function as an antioxidant, a 
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Figure 10. Schematic representations of conversion of PrPC to PrPSc 
In the nucleation-polymerization model, there is a static presence of both PrPC and PrPSc, 
converting back and forth.  The conversion of PrPC to PrPSc tends to propagate at a slower 
rate than the conversion rate of PrPSc to PrPC.  However, the PrPSc aggregate together to form 
a nucleus in which addition of PrPC quickly converts PrPC into PrPSc.  This nucleation-
polymerization of PrPC into PrPSc aggregates is a fast reaction, leading to further 
accumulation of PrPSc.  In the template assistance model, the PrP exists in the normal (PrPC) 
state in an equilibrium with partially abnormal (PrP*) state.  From the PrP* state, the 
conversion into PrPSc is a slow conversion rate.  However, once PrPSc is formed, it can act as 
a template which can convert PrP* into PrPSc at a fast rate, thereby increasing the amount of 
PrPSc formation.  These two hypothetical models depict why the initial incubation periods 
occur, and the rapid progression into the diseased state, once detected. (figure modified from 
Cohen and Pruisner 1998). 
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metal transporter, a cell adhesion molecule, and a signal transducer (Deignan et al. 2004;  
 
Lasmezas 2003; Martins and Brentani 2002; Martins et al. 2001; Wechselberger et al. 2002).  
A number of studies performed with prion-knockout cells and mice have shown that the 
PrPC-lacking phenotypes were more sensitive to oxidative stress (Brown et al. 2002; Brown 
et al. 1997d; Sakudo et al. 2004).  While these knockout mice developed normally and did 
not have any physical abnormalities, some researchers have reported several changes that 
accompanied the prion knockout mice (Lledo et al. 1996; Mallucci et al. 2002; Prusiner et al. 
1993).  Weakened GABA-A receptor-mediated fast inhibition and impaired long-term 
potentiation, sleep disturbances and altered circadian rhythms, increased susceptibility to 
epileptic seizures, and late onset fatal ataxia with severe cerebellar degeneration were 
observed.  However, consistent with the prion protein theory, mice devoid of prion protein 
were not susceptible to prion infection.  In cell culture models, perturbations to various 
intracellular antioxidant systems such as glutathione levels, glutathione reductase activity, 
glutathione peroxidase activity, and superoxide dismutase (SOD) activity have been observed 
(Brown et al. 1997d).  Similarly, infection with PrPSc has also been associated with increased 
susceptibility to oxidative stress (Wong et al. 2001a), suggesting that infection ablates the 
normal physiological role of PrPC. 
Others have speculated that the prion protein functions as a metal transporter (Opazo 
et al. 2003; Whittal et al. 2000).  Comparison of various metal levels in the brain of prion 
protein knock-out versus wild-type mice has shown significant differences in the amount of 
metals present in the brain (Brown 2003; Thackray et al. 2002; Wong et al. 2001a).  
Similarly, those mice infected with scrapie have altered brain metal content (Fernaeus et al. 
2005a; Thackray et al. 2002; Wong et al. 2001a). Differences in iron, copper, and manganese 
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levels were also observed. 
A number of study results have implicated the associative role of the PrPC with 
various cellular adhesion molecules that are important in the role of cell proliferation and 
survival.  PrPC has been reported to interact with surface cell adhesion molecules such as 
neural cell adhesion molecule (NCAM) and laminin (Santuccione et al. 2005; Zanata et al. 
2002).  Additionally, since PrPC is localized to lipid rafts, a role in signal transduction has 
been hypothesized (Mouillet-Richard et al. 2000; Reilly 2000).  Recent studies have shown 
that PrPC has a role in neurite outgrowth and survival of neurons as well (Chen et al. 2003; 
Santuccione et al. 2005).  More recently, cytoplasmic polyadenylation element binding 
protein (CPEB), a protein involved in synaptic plasticity and long-term memory, has been 
found to self-replicate in a prion protein-like manner (Darnell 2003; Si et al. 2003).  
Although a clear consensus as to the role of prion protein in memory has not been reached, 
there has been an increased interest in the investigation of the role of prion proteins in 
memory function (Bailey et al. 2004; Papassotiropoulos et al. 2005; Shorter and Lindquist 
2005).   
In cellular aspects, the prion protein is thought to have a protective role.  However, 
there are differing opinions; one researcher has shown that cytosolic accumulation of PrPC is 
not toxic, but rather protects human neuronal cells against Bax-induced cell death (Roucou et 
al. 2003), while another group has shown that cytosolic accumulation of PrPC was highly 
toxic, and distinctly different than PrPSc (Ma et al. 2002).  A recent study has shown that 
cytosolic PrPC is not toxic to N2a mouse neuroblastoma cells and primary neurons 
expressing the pathogenic form of PrP mutants (Fioriti et al. 2005).  Alternatively, PrPC has 
been proposed to function in various neuroprotective signaling pathways (Chiarini et al. 
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2002).  In one study, cells lacking the prion protein were more susceptible to serum 
deprivation, and were protected against disruption of cellular homeostasis (Kim et al. 2004; 
Vassallo et al. 2005).  We have recently shown that PrPC can protect against oxidative 
damage in cell culture models; not only was expression of prion protein protective against 
manganese-induced neurotoxicity, but the expression also protected against hydrogen 
peroxide toxicity.  Although a clear consensus has not been reached with regard to the exact 
function of prion proteins, understanding the normal function will help elucidate the 
pathogenesis of prion disease. 
To examine the effect of PrPSc, a smaller fragment (PrP 106-126) has commonly been 
used by researchers (Brown et al. 1997a; Brown et al. 1998a; Herms et al. 1997; 
Kretzschmar et al. 1997).  The PrP 106-126 fragment encompasses the protease-resistant 
core found in PrPSc, and also has fibrillogenic properties with propensity to aggregate 
together (Brown et al. 1996b; Florio et al. 1996; McHattie et al. 1999).  Studies have found 
that the PrP 106-126 fragment is taken up into neuronal cells, and sequestered (McHattie et 
al. 1999).  Researchers have shown that this fragment could elicit cellular death through 
apoptosis (Brown et al. 1997a; Burkle et al. 1999; Kretzschmar et al. 1997).  It is interesting 
to note that cells lacking prion protein expression were significantly less susceptible to 
cellular apoptosis induced by the PrP 106-126 fragment (Brown et al. 1994; Brown et al. 
1998c); as shown with human neuroblastoma cell line (SHSY-5Y) cells, the fragments 
caused p38 activation, followed by activation of effector caspase-3, leading to cell death 
(Corsaro et al. 2003; Hope et al. 1996; Singh et al. 2002; Thellung et al. 2002).  One group 
of researchers found that the fragment causes apoptotic cell death via mitochondrial 
disruption and activation of the apoptotic cascade (O'Donovan et al. 2001).  Other 
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researchers suggest that these fragments cause cellular death by aggregating together to form 
a transmembrane channel (Florio et al. 1996; Kourie and Culverson 2000; Kourie et al. 2001; 
Thellung et al. 2000).  Although the fact that this fragment could cause cellular death in prion 
protein expressing cells is novel, a more interesting study examined the response of microglia 
cells to PrP 106-126 fragment treatment (Brown et al. 1996a, 1997c, 1998d; Garcao et al. 
2006; Hafiz and Brown 2000; Peyrin et al. 1999); upon treatment, the microglia cells were 
observed to be activated and caused neuronal cell death (Garcao et al. 2006; Giese and 
Kretzschmar 2001).   
 Although numerous roles for PrP have been hypothesized, a clear consensus is yet to 
be reached on the exact physiological role.  With high homology of the gene between 
mammalian species, we can assume that it is required; otherwise, why would it be conserved 
in the mammalian genome?  This and number of other questions remain, however, we know 
through current research, that PrP is crucial in the development and progression of prion 
disease.  Thus, understanding the physiological role of PrP is an important step in battling 
prion disease. 
   
Copper 
Copper is an essential trace element that is crucial for development and survival of 
organisms (Burch and Hahn 1979; Elbowicz-Waniewska 1968; Wysokinska 1964).  In nature 
copper can exist in two oxidation states (+1 and +2), and due to its redox states, copper can 
effectively function as a catalyst for several enzymes (Agarwal et al. 1989; O'Dell 1976; 
Solomons 1985), including cytochrome C oxidase, ferroxidase, monoamine oxidase, copper 
zinc superoxide dismutase, dopamine β-monoxygenase, and as well as in the biological 
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electron transport system (Agarwal et al. 1989; Camakaris et al. 1999; Solomons 1985).  
Copper is also crucial in hemoglobin formation, drug metabolism, carbohydrate metabolism, 
catecholamine synthesis, and in cross-linking collagen, elastin, and hair keratin (Agarwal et 
al. 1989; Camakaris et al. 1999).  In normal adults intake of copper via ingestion is 
calculated to be about 1-3 mg per day (Registry 2004).  Recommended dietary allowance has 
been established to be approximately 0.9 mg per day for adults, 0.34 mg for 1-3 year old, 
0.44 mg for 4-8 year olds, and 0.7 mg for 9-13 year olds (Araya et al. 2005; Barceloux 1999; 
Failla 1999; Grajeta et al. 2003; Rodriguez Rodriguez et al. 2000).  Although ingestion of 
copper by food and water is the primary source of copper, with increasing atmospheric 
pollution, inhalation has become another source of copper intake (Harrison 1973; Tsuji 1971; 
Vasconcelos and Tavares 1998).  The Agency for Toxic Substance and Disease Registry has 
estimated the atmospheric content of copper in the United States to be between 5 and 200 
ng/m3 (Registry 2004).   
Normally, free copper is rare in biological systems since the reactive nature of copper 
makes it prone to undergo toxic reactions via Fenton and Haber-Weiss reaction (Aust et al. 
1985).  Ingested copper is usually bound to metal transport proteins such as copper 
transporter, glutathione, cerulopasmin, albumin, azurin, and plastocyanin, and absorbed 
through the small intestines and the stomach (Camakaris et al. 1999; Evans 1973; Krizek et 
al. 1997; Pizarro et al. 1999; Zietz et al. 2003).  Protein-bound copper is readily transported 
into the cells, and gets distributed to enzymes and proteins requiring copper (Camakaris et al. 
1999; Evans 1973; Solomons 1985).  Remaining copper ends up in the liver, and excess is 
excreted into the bile and later into the feces (Araya et al. 2005; Barceloux 1999).   
Due to its importance in the human system, problems with copper metabolism can 
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lead to copper-related disorders, such as Menke’s disease, and Wilson’s disease (Goka et al. 
1976; Herron 1976; Hunt 1980; Madsen and Gitlin 2007).  Menke’s disease is caused by an 
X-linked recessive disorder in which P-type ATPase pump (ATP7A) does not function 
properly (Enjolras et al. 1978; Goka et al. 1976; Holtzman 1976; Tumer et al. 1999).  This 
protein is mainly found in the placenta, the blood-brain barrier, and the gastrointestinal tract 
(Richardson and Suryo Rahmanto 2007; Voskoboinik and Camakaris 2002); it is located on 
the trans-Golgi network and functions to pump copper across the Golgi to copper-requiring 
proteins and enzymes (La Fontaine et al. 1998a; Suzuki and Gitlin 1999; Voskoboinik and 
Camakaris 2002).    This disorder is marked by the inability of the pump to effectively uptake 
and distribute copper, resulting in severe copper deficiency.  Those patients with this disorder 
display symptoms of hypopigmented hair, connective tissue abnormalities, aortic aneurisms, 
kinky hair syndrome, and severe neurodegeneration (Harris 1993; Holtzman 1976; Leone et 
al. 1985; Mercer 1998). 
In the opposite spectrum is Wilson’s disease, in which there is an impairment of 
biliary copper excretion from the body (Ala et al. 2007; Ferenci 2005; Gunther et al. 2007; 
Herron 1976; Huster et al. 2005; Yarze et al. 1992).  Wilson’s disease is an autosomal 
recessive disorder caused by a similar P-type ATPase pump (ATP7B) found primarily in the 
liver (Bowcock et al. 1994; Cuthbert 1995; Kovacevic and Zekan 2003; Scheffer et al. 1992).  
Inability of the pump to function properly results in excessive accumulation of copper in the 
body, causing cirrhosis and neurodegeneration (Harada et al. 2000; La Fontaine et al. 1998b; 
Langner and Denk 2004; Suzuki and Ogura 2000).  Excessive copper also tends to 
accumulate in the basal ganglia of the brain, causing gliosis and neuronal loss similar to 
Parkinson’s disease (Ferenci 2004; Palladini et al. 1977; Tumer and Horn 1996; Yuzbasiyan-
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Gurkan et al. 1991).   
 
Copper and PrPC
 It is well established that PrPC binds with copper, and PrPC can be isolated with 
copper affinity columns (Muller et al. 2005; Todorova-Balvay et al. 2005).  A number of 
studies have used recombinant prion protein to measure the binding affinity of different 
amino acid sequences of prion protein to copper (Table 4).  Although the proposed binding 
affinities differ, most researchers would agree that copper binds specifically to the 
octapeptide region toward the N-terminus of the prion protein (Aronoff-Spencer et al. 2000; 
Hornshaw et al. 1995b).  In general, binding of metals to the octapeptide region reduces 
copper in a pH-dependent manner (Miura et al. 2005).  As aforementioned, additional copper 
binding sites with higher binding affinities have been identified above the octapeptide region 
(Jones et al. 2004).   
Table 4: Prion protein copper binding affinity studies 
Kd for copper (II) Sequences examined Authors 
6.7 µM 60-91 (Hornshaw et al. 1995b) 
5.9 µM 23-98 (Brown et al. 1997b) 
14 µM 23-231 (Stockel et al. 1998) 
10 pM and 4 pM 52-98 and 91-231 (Jackson et al. 2001) 
 
 The octapeptide region is crucial to metal ion induced endocytosis of the prion 
protein (Brown and Harris 2003; Perera and Hooper 2001).  Also, the high conservation of 
the metal binding regions among various mammalian species indicates a correlative role 
between copper and the prion protein.  Interestingly, brain from prion protein knock-out mice 
appears to contain significantly less copper as compared to brain from wild-type mice 
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(Brown et al. 1998b; Brown et al. 1997d).  Likewise, studies with PrPSc-infected mice have 
shown significantly lower levels of copper compared to brains of wild-type mice (Thackray 
et al. 2002; Wong et al. 2001a).  This evidence suggests a role of the prion protein as a 
possible copper transporter in the central nervous system.  Additional studies have shown 
that over-expression of PrPC resulted in higher binding of copper in the membrane fraction, 
which further supports the possible notion that PrPC is a copper transporter (Herms et al. 
1999; Stuermer and Plattner 2005).  PrPC may be concentrated in the synapse of neurons, 
suggesting that prion protein may regulate copper levels at the synaptic junction, possibly by 
acting as a metal sink (Nishimura et al. 2004).  Although it is a distinct possibility that 
disturbance of the copper regulating function of PrPC at the neuronal synapse could result in 
neuronal susceptibility to oxidative damage as a result of excessive free copper, a more 
recent study indicated that PrPC may not be responsible for copper uptake in the 
synaptosomes (Giese et al., 2005). Table 5 outlines the major findings of studies examining 
the role of copper in PrP function. Together these findings would strongly suggest that 
copper-PrPC interactions may be more complex than originally perceived. 
Table 5: Effect of copper on PrP 
 
Effect References 
Induction of PrP gene (Pauly and Harris 1998; Toni et al. 2005; Varela-Nallar et al. 2005, 2006) 
  
PrP metabolism (Haigh et al. 2005; Pauly and Harris 1998; Toni et al. 2005) 
  
Promote aggregation of PrP (Jobling et al. 2001; Tsiroulnikov et al. 2006a) 
  
Oxidize PrP, leading to aggregation (Requena et al. 2001) 
  
Inhibit infectious conversion (Cox et al. 2006) 
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Table 5 continued 
  
Formation of PK resistant PrP (Qin et al. 2000; Quaglio et al. 2001; Treiber et al. 2006) 
  
SOD-like activity (Brown and Besinger 1998; Brown et al. 1999a; Wong et al. 2000a) 
  
Inhibit PrPres amplification (Orem et al. 2006; Sarafoff et al. 2005) 
  
Delays onset of disease (Hijazi et al. 2003) 
  
Conformational change to N-
terminus 
(Brown et al. 2004; Donne et al. 1997; Leclerc 
et al. 2006; Whittal et al. 2000) 
  
Inhibit fibril formation (Bocharova et al. 2005; Giese et al. 2004) 
  
Stabilize PrP 
(Bocharova et al. 2005; Kuczius et al. 2004; 
Sigurdsson et al. 2003; Tsenkova et al. 
2004)sigur(Cereghetti et al. 2003) 
  
Shedding of PrP (Parkin et al. 2004) 
 
Prion protein (PrP); proteinase-K (PK); superoxide dismutase (SOD); proteinase-K resistant 
PrP (PrPres) 
 
Effect of Copper on PrPC Expression 
 Additional evidence supports the role of copper in the physiological control of PrPC 
expression.  Recent results showed that copper could modulate PrPC expression by reducing 
PrPC mRNA, as well as total PrPC found in cell lysates (Toni et al. 2005).  Along with these 
changes in PrPC expression, the amount of PrPC shed into the extracellular media was greatly 
increased.  This effect on PrPC by copper was abolished by co-treatment with the copper 
chelator cuprizone, indicating that these events required extracellular copper.  Another study 
has shown that treatment with copper dramatically increased PrPC levels in neuronal cells 
(Varela-Nallar et al. 2005).  Likewise, co-treatment with the copper chelating compound 
bathocuprionedisulfate (BCS) returned PrPC levels to normal.  The increased prion protein 
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expression was shown to be specific for copper and cadmium, and not for any other metals.  
The capability of copper to modulate the expression levels of PrPC would indicate a 
functional role of copper in the physiological function of PrPC.   
 
Role of Copper in Physiological Function of PrPC as an Antioxidant 
 The role of the prion protein in the brain is not as well defined as other synaptic 
proteins.  Not only does the PrPC seem to act as a copper transporter, but studies have also 
shown PrPC has superoxide dismutase (SOD)-like activity, enabling its effective functioning 
as an antioxidant in the central nervous system (Brown et al. 1997b).  Studies with 
recombinant prion protein showed proper protein folding in the presence of copper, 
endowing PrPC with antioxidant capacities. Further, two atoms of copper bound to PrPC were 
sufficient for SOD-like activity (Stockel et al. 1998).  However, this SOD-like function of 
PrPC was demonstrated in in vitro simulations, and studies have refuted the possibility that 
prion protein functions as an SOD-like protein in vivo (Hutter et al. 2003).  Studies with PrP 
knock-out mice have shown decreased SOD activity, not to mention increased susceptibility 
to oxidative stress (Brown and Besinger 1998; Brown et al. 1997d).  These observations 
strongly indicate PrPC functions to increase antioxidant levels indirectly or directly.  One 
theoretical view is that the low binding affinity of PrPC to copper would preclude its ability to 
functions as metal-associated enzymes (Jones et al. 2005b).  Other groups have shown that 
the prion protein does not have SOD-like activity in vivo or in vitro (Hutter et al. 2003; Jones 
et al. 2005b).  Although the role of the PrPC as a direct-acting SOD or as an indirect 
oxidative stress-reducer is not yet definitive, PrPC clearly has some protective role in the 
central nervous system.   
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Role of Copper in Pathogenesis of Prion Disease 
Copper has been shown to have the capacity to convert PrP into protease-resistant and 
detergent-insoluble forms in certain in vitro conditions (Quaglio et al. 2001) and to inhibit 
formation of fibrils from recombinant PrP (Bocharova et al. 2005).  Although some of these 
biochemical changes are commonly associated with initial stages of PrPSc formation, 
additional studies have shown that copper-induced biochemical changes were distinct and 
reversible.  A study with yeast PrP have shown that yeast grown in copper supplemented 
media contained PK-resistant PrP (Treiber et al. 2006).  This suggests that copper treatment 
could induce formation of PK-resistant PrP.  However, although PK resistance is one of the 
hallmarks of prion disease, their conclusion is hasty.  Since PrP is a copper binding protein, 
the presence of copper could merely modulate the proteolytic susceptibility of the protein.    
Similarly, another study has shown that copper could modulate the protease resistance of 
PrPSc molecules (Nishina et al. 2004).  The study showed that PrPSc formed in the absence of 
copper was 20 times more susceptible to proteinase–K digestion, whereas addition of copper 
reinstated the normal protease resistance.  Additionally, a study with protein misfolding 
cyclic amplification (PMCA) showed that PrPSc with copper could propagate and form more 
PrPSc from PrPC in the presence of deoxycholic acid (Kim et al. 2005).  Additional support 
for the role of copper in the pathogenesis of prion disease is that chelating copper delays the 
onset of the disease (Sigurdsson et al. 2003).  Earlier studies have shown that chelating 
copper (using cuprizone) resulted in spongiform-like degeneration in the animal brain 
(Blakemore 1972; Kimberlin and Millson 1976).  Of note, homeostatic balance of copper in 
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the central nervous system is crucial for normal function, and these studies clearly support 
the role of copper with PrPC in the pathogenesis of prion disease.  However, a number of 
questions still need to be answered: Is copper needed in the normal functioning of the PrPC?  
What are the cellular mechanisms underlying copper-induced conversion of PrPC to PrPSc? 
Furthermore, is copper required for increased susceptibility to infection?   
 
Manganese  
Manganese (Mn) gets its name from the Latin root magnes, which means magnet.  It 
is one of the most abundant metals on earth, and it has been widely used in industrial settings 
from welding to steel production, and in the production of pesticides and fertilizers.  In 
nature it exists in 11 oxidation states ranging from -3 to +7, and in biological systems, +2 and 
+3 are the most prevalent oxidation states.  Since manganese can exist in multiple oxidation 
states, it is able to participate in various cellular and enzymatic reactions.  In the human body, 
manganese is an essential trace element required for survival.  It is crucial in blood clotting, 
ATP production, normal functioning of cartilage, bone, and other connective tissues (Keen et 
al. 1999).  It is also a key component in various enzymes such as pyruvate carboxylase for 
carbohydrate metabolism, arginase for protein metabolism, and manganese superoxide 
dismutase for removal of reactive oxygen species from the mitochondria (Aschner and 
Aschner 2005).  Dietary deficiencies in manganese are rare; however, studies have shown 
that diets low in manganese can lead to dermatitis, hypercholesterolemia, and elevation of 
serum calcium and phosphorus (Hurley et al. 1983).  On the other hand, exposure to high 
levels of manganese can cause deleterious health problems commonly known as manganism 
(Aschner and Aschner 1991; Yu et al. 2003).  Prolonged exposure to high levels of 
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manganese has caused an irreversible Parkinson-like condition called manganism (Beuter et 
al. 1999; Gibbs et al. 1999; Myers et al. 2003).  The pathological symptoms associated with 
manganism are often described as Parkinson-like symptoms, however, there are specific 
hallmarks of manganism that are not found in Parkinson’s patients (Dobson et al. 2004).  
Early signs of manganism are associated with psychiatric disturbances, while later signs of 
manganism are similar to symptoms found with Parkinson’s disease and are associated with 
rigidity, bradykinesia, dystonia and ineffectiveness of levo-dopa therapy (Beuter et al. 1999; 
Erikson et al. 2004; McMillan 1999).   
The required amount of manganese can be obtained through normal diet in grains, 
vegetables, fruits, nuts, and tea.  Dietary reference intakes for manganese have been 
established to be approximately 2 mg per day for adults, about 0.6 mg per day for children, 
and 0.3 mg per day for infants (Aschner and Aschner 2005; Finley and Davis 1999; Hurley et 
al. 1983; Keen et al. 1999).  Although, the actual dietary intake of manganese in adults has 
been estimated to be 3-9 mg per day, well above the dietary reference intake amount, studies 
have shown that only 5% of ingested manganese is retained in the body (Finley et al. 1997).   
Free states of manganese are rarely found in the human body as they are immaculately 
regulated in the body.  Most of the manganese in the bloodstream has been found as a protein 
complex with various proteins such as transferrin, albumin, and β-globulin (Harris and Chen 
1994; Rabin et al. 1993).  One of the critical areas that manganese is transported to is the 
brain; studies have indicated that various transporting mechanisms are involved in uptake of 
manganese into the brain through the blood-brain-barrier (Aschner and Gannon 1994; 
Aschner et al. 1999; Crossgrove et al. 2003; Crossgrove and Yokel 2004; Yokel et al. 2003).  
Facilitated diffusion, active transport, divalent metal transporter-1 (DMT-1/ metal transporter 
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protein-1), and transferrin have been implicated in the transport of manganese into the brain.  
Although transferrin normally binds to iron, manganese in the trivalent state can bind to 
transferrin, suggesting a possible iron-manganese competition for transferrin (Aschner and 
Aschner 1990; Roth and Garrick 2003).  Supporting this possibility, studies have shown that 
animals with low iron diets exhibited higher manganese content in the brain (Zheng et al. 
1999).   
Manganese can be absorbed into the body through several routes, most importantly 
through inhalation of airborne manganese; inhalation toxicity has become an important issue 
lately.  The exposure amount to manganese has been studied by the Agency for Toxic 
Substance and Disease Registry at 33 and 5 ng manganese/m3 for urban and nonurban areas, 
respectively (Registry 2000).  Moreover, the airborne exposure to manganese has been found 
to be higher in occupation-related population (Gorell et al. 1999a; Keen et al. 1999; Myers et 
al. 2003). Some studies have suggested that there is a gender-dependent, as well as age-
dependent accumulation of manganese in the body, more specifically in the brain (Erikson et 
al. 2004; Finley 2004; Mergler et al. 1999).  Inhalation of manganese from air pollution can 
be a possibility of exposure to the normal population, but this is still being debated (Davis 
1999).  Within the population, it seems that older adults and females are more susceptible to 
manganese accumulation post exposure (Erikson et al. 2004; Mergler et al. 1999).  An 
additional study examined increase in absorption of manganese in rats with higher body fat 
content (Finley and Davis 2001).  Interestingly, not all manganese-derived compounds are 
absorbed equally, with MnCl2 having the highest absorption rate and MnPO4 having the 
lowest absorption rate; which correlates absorption to be dependent on compound species 
and solubility (Aschner et al. 1999; Normandin et al. 2004).   
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Once inside the brain, radioactive manganese (54Mn) has been observed to be 
localized to the dentate gyrus and the hippocampus of rats, and given time, spreads 
throughout the brain (Takeda et al. 1994).  Magnetic resonance imaging has shown that 
accumulation is more specific in the globus pallidus region of the basal ganglia (Lucchini et 
al. 2000).  However, with prolonged exposure to manganese, increased metal content was 
observed in the cerebellum, all parts of the basal gangalia, and temporal and frontal cortex in 
rats (Yu et al. 2003).  Based on the locale of the manganese accumulation site, numerous 
neurobehavioral, as well as neuropsychiatric tests have been conducted on individuals with 
higher risk of manganese exposure (Bowler et al. 1999; Gibbs et al. 1999; Lucchini et al. 
1999; McMillan 1999).  A neuropsychiatric study reported increase in anxiety, nervousness, 
irritability, emotional disturbance, and aggression in individuals with manganese exposure 
(Bowler et al. 1999; Lucchini et al. 1999).  While subclinical movement disorders showing 
rigidity, reduction in complex reaction time, and slowed hand-eye coordination reactions 
were commonly seen (Gibbs et al. 1999; Lucchini et al. 1999).  Animal models have been a 
great tool for researchers examining manganese toxicity, and have given great insight as to 
the pathology of over-exposure to manganese.  Prior studies of Sloot and colleagues have 
shown that manganese injected into the striatum has a selective capacity to accumulate in the 
basal ganglia (Sloot and Gramsbergen 1994; Sloot et al. 1996; Sloot et al. 1994).  
Accordantly, a functional study examining the specific transport of manganese across the 
blood-brain barrier, and distribution through the rat brain revealed that other distribution may 
be mediated through transferrin and more than one carrier-mediated transport including 
divalent metal transporter-1 (DMT-1) (Crossgrove et al. 2003; Sloot and Gramsbergen 1994; 
Sotogaku et al. 2000).  In neonatal rats given oral doses of manganese, decreased dopamine 
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levels in the brain were detected and high toxicity was found in early stages of development 
(Tran et al. 2002a; Tran et al. 2002b).  Animal model based studies of synaptic transmission 
have also given a better insight as to the mechanism of manganese toxicity after uptake.  
Several studies have examined the effect of manganese on GABA release (Gwiazda et al. 
2002; Takeda et al. 2003; Takeda et al. 2002b).  The release of manganese into the synapse 
seems to have a modulatory function on neurotransmission (Takeda et al. 2002a, 2003), 
while treatment with a low concentration of manganese preferentially effects striatal GABA 
levels before dopamine (Gwiazda et al. 2002).  The striatal nigra region has been observed to 
clear manganese at a very slow rate and this iscorrelated to damage with concentration of 
manganese reaching toxic thresholds (Ponzoni et al. 2002; Tomas-Camardiel et al. 2002).  
Many researchers speculate that the oxidative damage due to excessive manganese is the 
culprit behind the neurodegeneration (Gavin et al. 1999).  However, a study by Weber and 
coworkers examined manganese’s effect on neonatal rat brain development and showed that 
there was an increase in cerebrocortial glutathione in treated rats (Weber et al. 2002).  
Aside from the pathology that is induced by excessive manganese, there have been 
numerous studies examining the cellular aspect of manganese toxicity.  Studies have shown 
that regardless of cell origin, they effectively take up exogenous manganese (Aschner et al. 
2002). Although the specific mode of entry into the cells is still being debated, it is most 
likely that either DMT-1 or transferrin are the common pathways for manganese uptake 
(Crossgrove et al. 2003; Roth et al. 2002; Sloot and Gramsbergen 1994; Sotogaku et al. 
2000).  Once inside the cell, excessive manganese causes destruction throughout the cell, 
primarily affecting the mitochondria (Malecki 2001; Malthankar et al. 2004).  However, there 
seems to be a preference for manganese to be more toxic to dopaminergic cells (Higashi et al. 
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2004).  Some may speculate that the increased susceptibility to manganese is due to 
dopamine content, but rather it could be due to the cell having the capacity for dopamine 
producing pathway (Stredrick et al. 2004).  Dopamine is known to be highly unstable, thus 
the pathway in producing dopamine could easily be a highly unstable one, making it a prime 
target for manganese toxicity.   
 
Manganese and PrPC
Studies have shown that manganese, like copper, can bind to PrPC and can also be 
used for formation of PrPSc from PrPC via the PMCA technique (Kim et al. 2005).  In another 
study, yeast incubated with manganese-supplemented media produced PK-resistant PrP, 
suggesting that this could be a causative factor in generation of prion disease (Treiber et al. 
2006).  Similarly, rat astrocytes treated with manganese for prolonged periods of time also 
induced a PK-resistant form of PrP (Brown et al. 2000a).  Although studies have suggested 
that manganese does have a binding affinity to the octapeptide repeat region of PrP, a study 
Garnett and Viles suggested that manganese does not bind to PrP (Garnett and Viles 2003).  
Recombinant PrPC has been shown to bind to manganese in vitro, and when refolded in the 
presence of manganese, proteinase-K resistant forms of PrPC were found (Brown et al. 
2000a).  These forms were not pathogenic, yet interestingly, PrPC binding with a different 
metal could potentially alter the secondary structure of a protein.  These PrPC, refolded in the 
presence of manganese, retained some SOD-like activity similar to copper-bound PrPC, but to 
a lesser capacity.  It appears that manganese interaction with PrP facilitates alteration to the 
protein property.  Studies with recombinant PrP showed that with presence of manganese, the 
aggregation of the recombinant PrP increased dramatically (Giese et al. 2004; Levin et al. 
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2005).  Another study highlighted the effect of manganese on fibril formation of PrP 
(Tsenkova et al. 2004).  The effect of manganese in PrP function has been outlined in Table 
6. 
Interestingly, mice infected with PrPSc have dramatic differences in blood, muscle, 
and brain metal content as compared to the non-infected mice (Thackray et al. 2002).  These 
infected mice showed increased manganese and decreased copper content, suggesting that 
during the course of disease infection, altered metal content could be an initial sign of 
infection, or the altered metal content could be due to the infection itself.  Further supporting 
the higher metal content in infected animals, a recent study has shown similar trends with 
increased manganese content in scrapie-infected sheep (Hesketh et al. 2007).  What was 
more interesting was that the elevated manganese was consistently found in blood, and this 
elevation was readily detected prior to the onset of disease symptoms. 
 
Table 6: Effect of manganese on PrP 
 
Effect References 
  
Formation of PK resistant PrP (Brown et al. 2000a; Deloncle et al. 2006; Treiber et al. 2006) 
  
Promote aggregation of PrP (Giese et al. 2004; Levin et al. 2005) 
  
Formation of PrPres (Kim et al. 2005; Sarafoff et al. 2005) 
  
Promote fibril formation (Tsenkova et al. 2004) 
 
Prion protein (PrP); proteinase-K (PK); proteinase-K resistant prion protein (PrPres) 
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Iron and PrPC
 Iron is one of the most important metals required for survival.  It is highly regulated 
in physiological systems to maintain homeostatic balance.  Free iron does not exist in 
physiological systems, and is always found bound to various iron transporting proteins, and 
iron bound enzymes.  More recently, Fernaeus and colleagues demonstrated that iron 
regulation is disturbed in scrapie-infected mouse neuroblatoma cells (Fernaeus et al. 2005a; 
Fernaeus and Land 2005; Fernaeus et al. 2005b).  Apparently, normal processing of iron by 
these cells was interrupted by infection, resulting in decreased intracellular iron levels.  The 
presence of additional iron resulted in increased reactive oxygen species formation and cell 
death.  These findings suggest that scrapie infection alters iron metabolism, and decreases the 
cell’s capacity to deal with excessive iron.  Also, these findings suggest that cells have a very 
small tolerance of iron disturbance, since the scrapie infection consists of only a small 
percentage of cells.  A recent study demonstrates that the iron-binding protein ferritin forms a 
complex with a fragment PrPSc to enhance the transport of PrPSc in an intestinal endothelial 
cell model (Mishra et al. 2004), suggesting a role for ferritin in transport of infected prion 
protein across the intestine.  
 
Role of Other Metals in the Physiological Function and Pathogenesis of the Prion 
Protein 
Divalent cations such as manganese, iron, zinc, nickel, and many others, may have 
the potential to interact with PrP.  Table 7 shows the effect of different metals on PrPC 
function.  While binding studies have shown that only manganese, zinc, and nickel have 
higher binding affinities, other metals could have a role in physiological function, or in 
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alteration of the normal function of PrP (Gaggelli et al. 2005).  Nickel (II) has been used in 
metal affinity columns to isolate PrP (Yin et al. 2003).  More importantly, metal imbalance in 
the brain has been hypothesized to cause prion disease (Thackray et al. 2002; Wong et al. 
2000b).  Metal imbalance could occur through aging, environmental sources or even from 
nutritional deficiencies.  To investigate the influence of environmental factors on sporadic 
forms of prion disease, evaluation of the correlation between increased prion disease and soil 
mineral levels has been proposed (Chihota et al. 2004; Purdey 2000, 2004).  PrPC may be 
specific for copper, but similarities in ionic strength, hydration size, and valence may allow 
other metals to bind to PrPC if present in sufficient concentrations.  
 
Table 7: Effect of other metals on PrP 
 
Metal Effect References 
Inhibit fibril formation of PrP (Bocharova et al. 2005) 
  
Formation of aggregates of PrP (Jobling et al. 2001; 
Tsiroulnikov et al. 2006b) 
  
Formation of PrPres (Kim et al. 2005) 
  
Alter PrP metabolism (Brown and Harris 2003) 
  
Inhibit formation of PrP106-126 channel (Hirakura et al. 2000) 
  
Zinc 
Alter structural conformation of PrP (Wadsworth et al. 1999a) 
   
Iron Formation of PrPres (Kim et al. 2005) 
 
Prion protein (PrP); proteinase-K (PK); proteinase-K resistant prion protein (PrPres) 
 
Non-protein Hypothesis of Prion Disease. 
Although substantial evidence has been presented by various researchers to note that 
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the infectious component of the prion disease is the prion protein, there are others that find 
the protein-only hypothesis unlikely (Brown 1987; Manuelidis 2004, 2007).  However, this 
skepticism is not without reason as there are missing “pieces” to the completion of the 
protein-only hypothesis.  One evidence points to the lack of information about the structure 
of the infectious prion protein, as crystallized structure of the infectious form has not been 
resolved to date (Bazan et al. 1987; Huang et al. 1995, 1996; Manuelidis et al. 2007).  
Although the normal form of prion protein has been resolved, the lack of structure of the 
infectious form leads to doubt whether the actual infectious structure of the prion protein 
exists.  Another form of support comes from the fact that none of the synthesized proteins are 
infectious (Ball et al. 2001; Legname et al. 2004).  This lack of infectivity in the synthesized 
form strongly suggests that the proteins may not carry an infectious component.  Recently, 
researchers have shown that a synthesized form has been able to cause neurodegeneration in 
specially bred transgenic mice (Legname et al. 2005).  One of the most persuasive results 
that non-prion particles may be involved in prion disease dates back to a 1971 study by 
Bignami and colleagues, in which they showed that 25 nm virus-like particles were also 
found in scrapie-infected brain (Bignami and Parry 1971); this work was carried on and more 
recently, a different group also isolated a similar particle in humans as well (Liberski and 
Jeffrey 2004).  Manuelidis and coworkers have hypothesized that the actual factor of 
transmissible spongiform encephalopathy is due to a virion and is independent of 
pathological prion protein (Manuelidis 2007).  Their studies highlighted the fact that 
treatment with phorbol myristate acetate (PMA) dramatically increased PrPres after PK 
digestion.  Also, they have suggested that since a 25 nm-sized virus-like particle copurifies 
with prion protein, the virion like particle has always been present in animal inoculations.  
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The increase in PrPres following PMA treatment has attributed to the possibility of host prion 
protein acting as a cellular facilitator for the 25 nm virus-like particle to infect the host with 
transmissible spongiform encephalopathy.  A different speculation on the alternative to 
protein-only hypothesis was presented by Ng and colleagues, where with mathematical 
epidemiological computations, they have speculated that it was not possible for proteins to be 
the sole factor in the spread of the disease, but rather a microbial vector as the major 
component to the spread of the prion disease (Ng et al. 2007).  Despite the possibilities of the 
prion disease being caused by virus-like particles, current research has stacked the odds in 
the favor of the protein-only hypothesis. 
 
Potential Therapy against Prion Disease 
 Thus far, neither effective treatment nor prevention methods have been discovered for 
prion disease (Begic et al. 2002; Brown et al. 2000b; Collinge et al. 1991; Gavier-Widen et 
al. 2005; Serban et al. 1990).  Most of the confirmed cases have been identified through post-
mortem tests, and development of ante-mortem tests are required for effective detection 
(Begic et al. 2002; Gofflot et al. 2004).  There are different methods of dealing with prion 
disease (Caramelli et al. 2006; Gilch and Schatzl 2003; Nunziante et al. 2003; Trevitt and 
Collinge 2006); since total eradication of the disease has not been possible, reducing the 
infectivity or reducing the substrate or vaccinations has been attempted.  Similar with other 
neurodegenerative disorders, significant immune responses are absent due to PrPSc having the 
same amino acid sequences as the endogenous PrPC (Kalinke et al. 2006; Roberts 2002; 
Westaway and Carlson 2002).  Most recently, vaccination attempts have been tested by 
having the prion peptide displaying papilloma virus-like particles (Ebringer et al. 2007; 
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Handisurya et al. 2007; Vana et al. 2007).  This resulted in antibodies that were produced 
against PrPC, effectively decreasing the concentration of PrPC in the host.  Studies to curb 
infection with various compounds have been experimented with limited results (Table 8).  In 
vitro cell cultures studies have been commonly used to test the efficacy of the compound, and 
positive candidates were used in in vivo studies (Chabry et al. 1998; Poli et al. 2003; Priola 
et al. 2000; Yung et al. 2004).  None of the compounds have been able to cure prion disease 
in vivo, but have shown to be effective in delaying the onset of disease.  One of the 
compounds that have been tested is the polyanionic compounds glycosaminoglycans (GAGs) 
(Gonzalez-Iglesias et al. 2002; Snow et al. 1989; Snow et al. 1990).  These compounds are  
 
Table 8: Therapeutic approaches to prion disease 
 
 
Anti-prion agent Result References 
   
Dextran sulfate 
Decrease in PrPSc and PrPC in 
cell culture, delays onset of 
disease in mice 
(Adjou et al. 2003; 
Beringue et al. 2000; 
Shyng et al. 1995) 
   
Pentosan polysulfate Decrease PrP
Sc in cell culture, 
delays onset of disease in mice 
(Dealler and Rainov 2003; 
Larramendy-Gozalo et al. 
2007) 
   
Heparan sulfate Decrease accumulation of PrP
Sc 
in cell culture 
(Adjou et al. 2003; 
Larramendy-Gozalo et al. 
2007; Supattapone 2004; 
Vana et al. 2007) 
   
Congo red 
Cure infection in cell culture, 
prevent accumulation of PrPSc 
in cell culture, delays onset of 
disease in hamsters 
(Demaimay et al. 2000; 
Frid et al. 2007; Poli et al. 
2003; Sellarajah et al. 
2004) 
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Table 8. (continued)   
Anti-prion agent Result References 
   
Suramin 
Downregulation of surface PrP, 
interferes with protein 
oligomerization, decrease PrPSc 
in cells 
(Gilch et al. 2001; 
Ladogana et al. 1992; 
Nunziante et al. 2005) 
   
Methotrexate and 
amphotericin B 
Prolong disease incubation 
time in mice, hamsters, and 
green monkeys 
(Adjou and Seman 2002; 
Demaimay et al. 1999; 
Hartsel and Bolard 1996; 
Hartsel and Weiland 2003; 
Seman and Adjou 1999) 
   
Quinacrine, chloroquin, 
and quinacrine 
derivatives 
Inhibits PrPSc propagation in 
cell cultures, delays onset of 
disease in mice, moderate 
effects delaying human prion 
disease 
(Barret et al. 2003; Benito-
Leon 2004; Dollinger et al. 
2006; Furukawa et al. 
2002; Kobayashi et al. 
2003; Korth et al. 2001; 
May et al. 2003; 
Murakami-Kubo et al. 
2004; Ryou et al. 2003; 
Yung et al. 2004) 
   
Prion specific 
antibodies 
Prevents PrPSc formation in cell 
cultures 
(Poli et al. 2003) 
   
RNAi Reduces PrP
Sc and PrPC in cell 
culture, reduced PrPC animals 
(Golding et al. 2006; 
Pfeifer et al. 2006; Tilly et 
al. 2003) 
   
RNA aptamers Reduces PrP
Sc production in 
cell culture 
(Proske et al. 2002) 
   
   
 
polysaccharide sidechains of proteoglycans and are usually involved in cell adhesion, 
migration, and proliferation.  Related compounds congo red and its derivatives have also 
been used to inhibit infection by decreasing the amount of PrPC available (Frid et al. 2007; 
Sellarajah et al. 2004; Smid et al. 2006).  Other compounds such as methotrexate and 
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amphotericin B originally used for antibiotic purposes, have been tested for their efficacy in 
inhibiting prion infection as well (Adjou and Seman 2002; Hartsel and Bolard 1996; Hartsel 
and Weiland 2003; Seman and Adjou 1999).  Surprisingly, anti-malarial compounds 
quinacrine, chloroquine and their derivatives has shown positive results and are extensively 
studied for their anti-prion activity (Barret et al. 2003; Caramelli et al. 2006; Doh-ura 2004; 
Ryou et al. 2003; Yung et al. 2004).  Aside from chemical compounds, prion specific 
antibodies, RNAi technology, and RNA aptamers have been effectively targeted for use 
(Beringue et al. 2004; Kanyo et al. 1999; Kong 2006; Proske et al. 2002; Tremolizzo et al. 
2004).  While most of these methods have been used to directly target PrPC, thereby reducing 
the substrate level, statins such as lovastatin and squalestatin have been used to alter PrPC 
location (Kocisko et al. 2003).  
 The etiology of prion disease and the normal physiological functions of the PrPC 
remain to be answered.  Mounting evidence points to the role of copper in the antioxidant 
role of PrPC and metal imbalance in prion disease.  Although most of these trace element 
metals are needed in maintenance of normal physiological conditions, perturbations of these 
metal levels in the brain could have detrimental effects.  A hypothetical model depicting the 
role of metals in the conversion of PrPC to PrPSc is shown in Fig. 11.  In the schematic model 
of metal-induced changes in the structure and function of PrPC, PrPC and PrPSc could exist 
normally in equilibrium, with the possibility that PrPSc is normally degraded to undetectable 
levels.  Various metals such as cadmium and zinc could potentially inhibit proteasomal 
activity, thereby increasing the amount of detectable PrPSc.  Alternatively, displacement of 
copper with manganese binding to PrPC could potentially alter the structure into an 
intermediate form having higher β-sheet content.  With replacement of copper, these would 
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revert back to PrPC forms.  There also would have to be another event where partially β-
sheet-rich PrPC could turn into PrPSc forms.  In turn, the formation of PrPSc could lead to 
aggregation in presence of excessive manganese, thereby contributing to the development of 
the prion disease.  Environmental exposure to excessive manganese and other metals may 
induce structural and functional changes in prion protein.  Therefore, it is imperative to 
investigate the interactions of metals with cellular prion proteins in order to better understand 
not only the normal function of the PrPC in the nervous system, but also the pathogenic 
mechanisms associated with conversion of PrPC to PrPSc.  A detailed understanding of the 
role of metals in prion diseases will ultimately enable development of a successful treatment 
strategy for this currently untreatable neurodegenerative condition.  
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Figure 11. Hypothetical model of metal induced changes in the structure and function 
of PrPC .   Schematic model of metal-induced changes in the structure and function of PrPC. 
Normal prion protein (PrPC) and an abnormal form (PrPSc) could exist normally in 
equilibrium, with the possibility that PrPSc is normally degraded to undetectable levels.  
Various metals such as cadmium and zinc could potentially inhibit proteasomal activity, 
thereby increasing the amount of PrPSc to a detectable level.  Alternatively, displacement of 
copper with manganese could potentially alter the structure into an intermediate form having 
higher β-sheet content.  With replacement of copper, these would revert back to PrPC forms.  
There also would have to be another event where partially β-sheet-rich PrPC could turn into 
PrPSc forms.  In turn, the formation of PrPSc would lead to aggregation in the presence of 
excessive manganese, thereby becoming toxic to neuronal cells. 
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CHAPTER II: NORMAL CELLULAR PRION PROTEIN PROTECTS AGAINST 
MANGANESE-INDUCED OXIDATIVE STRESS AND APOPTOTIC CELL DEATH 
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Abstract 
The normal prion protein is abundantly expressed in the CNS, but its biological 
function remains unclear.  The prion protein has octapeptide repeat regions that bind to 
several divalent metals, suggesting that the prion proteins may alter the toxic effect of 
environmental neurotoxic metals.  In the present study, we systematically examined whether 
prion protein modifies the neurotoxicity of manganese (Mn) by comparing the effect of Mn 
on mouse neural cells expressing prion protein (PrPC-cells) and prion-knockout (PrPKO-cells).  
Exposure to Mn (10 µM-10 mM) for 24 hr produced a dose-dependent cytotoxic response in 
both PrPC-cells and PrPKO-cells.  Interestingly, PrPC-cells (EC50 117.6µM) were more 
resistant to Mn-induced cytotoxicity, as compared to PrPKO-cells (EC50 59.9µM), suggesting 
a protective role for PrPC against Mn neurotoxicity.  Analysis of intracellular Mn levels 
showed less Mn accumulation in PrPC-cells as compared to PrPKO-cells, but no significant 
changes in the expression of the metal transporter proteins transferrin and DMT-1.  
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Furthermore, Mn-induced mitochondrial depolarization and ROS generation were 
significantly attenuated in PrPC-cells as compared to PrPKO-cells.  Measurement of 
antioxidant status revealed similar basal levels of glutathione (GSH) in PrPC-cells and PrPKO-
cells; however, Mn treatment caused greater depletion of GSH in PrPKO-cells.  Mn-induced 
mitochondrial depolarization and ROS production were followed by time- and dose-
dependent activation of the apoptotic cell death cascade involving caspase-9 and -3.  
Notably, DNA fragmentation induced by both Mn treatment and the oxidative stress inducer 
hydrogen peroxide (100µM) was significantly suppressed in PrPC -cells as compared to 
PrPKO-cells. Together, these results demonstrate that prion protein interferes with divalent 
metal Mn uptake and protects against Mn-induced oxidative stress and apoptotic cell death.  
 
Introduction 
Prion-related diseases are a family of neurodegenerative disorders that affect various 
mammalian species including animals and humans (Collinge 2001; Collinge and Palmer 
1992; Prusiner 1998).  Prion-related encephalopathies include conditions such as scrapie in 
sheep, bovine spongiform encephalopathy (BSE) in cattle, and Creutzfeldt-Jacob disease 
(CJD) and Gerstmann-Straussler-Scheinker syndrome (GSS), among others, in humans 
(Bendheim et al. 1985; Prusiner 1989; Prusiner et al. 1985).  Prion diseases cause severe 
neuronal damage mainly in the brain regions that control motor function, but can affect other 
areas, including the basal ganglia, cerebral cortex, thalamus, and cerebellum (Chiesa and 
Harris 2001; Collinge 2001; Mastrangelo and Westaway 2001; Porter et al. 2000; Schreuder 
1994).  The characteristic feature of prion diseases is conversion of normal cellular prion 
(PrPC) to the abnormal pathogenic scrapie isoform (PrPSc) through a still undefined 
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mechanism, which eventually results in the extracellular accumulation of PrPsc aggregates 
(Brandner et al. 2000; Collinge and Palmer 1993; Kretzschmar 1999; Prusiner and Kingsbury 
1985).  The infectious PrPSc is thought to act as a template and promote the conversion of 
more PrPC to PrPSc, resulting in the amplification of the infectious and toxic species.  Thus, 
the normal cellular PrPc protein is required for the pathogenesis of spongiform 
encephalopathies (Cohen and Prusiner 1998; Kretzschmar 1999; Prusiner et al. 1988).  
PrPC is a cell surface glycoprotein expressed predominantly in neurons and glia 
(Bazan et al. 1987; Hafiz and Brown 2000; Rudd et al. 2001).  Studies have shown PrPC 
possesses intrinsic superoxide dismutase (SOD)-like activity, conferring antioxidant 
properties which may aid in cellular resistance to oxidative stress (Brown et al. 1997c; 
Brown et al. 1999).  Although the exact mechanism by which PrPC acts as an antioxidant is 
unclear, there is evidence that PrPC contributes to the cellular SOD activity and to the 
maintenance of GSH levels inside the cell (Brown and Besinger 1998; Brown et al. 1999; 
Choi et al. 1998; White et al. 1999).  PrPC has been established as a copper (Cu2+) binding 
protein, which is essential for its normal function (Thackray et al. 2002).  The octapeptide 
repeat regions of PrPC bind to Cu2+, Zn2+, and Mn2+ with varying affinities (Brown et al. 
1997b; Choi et al. 2006; Hornshaw et al. 1995a).  These findings are further supported by 
implications of altered metal binding and oxidative stress metabolism in the pathogenesis of 
prion disease (Wong et al. 2000).  Prion protein-deficient mice exhibit decreased SOD 
activity, glutathione reductase activity, and altered metal content compared to naive mice 
(Brown et al. 1997c; Klamt et al. 2001).  Additionally, copper and manganese content levels 
are significantly altered in prion protein-deficient mice, suggesting that the normal activity of 
PrPC may regulate cellular metal homeostasis (Brown 2003; Brown and Harris 2003; Watt 
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and Hooper 2003).  Recent studies have shown over-expression of PrPC results in a 
phenotype that is more resistant to oxidative stress, and the lack of expression results in a 
phenotype that is more sensitive to oxidative stress (Brown et al. 1997c; Sakudo et al. 2004).  
Alterations in metal binding capacity of PrPC have recently been implicated in propagation of 
prion diseases (Wong et al. 2001).  Prolonged exposure to Mn has been suggested to lead to 
substitution of Cu in PrPC, resulting in the loss of antioxidant activity; this may also aid in the 
conversion of PrPC to PrPSc in vitro (Brown et al. 2001).  
Oxidative stress and programmed cell death have recently been implicated in a 
number of neurodegenerative disorders including prion disease (Choi et al. 2006; 
Kanthasamy et al. 2003; Tritschler et al. 1994).  The neurotoxic peptide fragment of human 
PrPC (PrP 106-126) has been shown to induce ROS production, mitochondrial dysfunction, 
MAP kinase activation, caspase-3 activation, and apoptosis in multiple cell types (Brown 
2000; Brown et al. 1997a; Burkle et al. 1999; Florio et al. 1996).  We and others have 
recently shown that oxidative stress and caspases mediate Mn-induced apoptotic cell death in 
neuronal cells (Aschner 1999; Kitazawa et al. 2005; Latchoumycandane et al. 2005; Roth 
and Garrick 2003; Roth et al. 2002; Weber et al. 2002; Worley et al. 2002).  In the current 
study, we characterized whether PrPC alters Mn-induced oxidative stress and apoptosis in 
neuronal cells and report that PrPC protects against Mn-induced GSH depletion, ROS 
generation, caspase-3 activation, and DNA fragmentation, possibly by interfering with Mn 
uptake. 
 
Materials and Methods 
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Chemicals.  Hydrogen peroxide (H2O2), MTT, Trolox®, and manganese chloride (MnCl2) 
were purchased from Sigma (St. Louis, MO); ApoAlert® Glutathione Detection Kit was 
purchased from Clontech (Palo Alto, CA); Sytox® Green nucleic dye,  Dihydroethidium, 
DIOC , and Hoechst 333426  nucleic dye were purchased from Molecular Probes (Eugene, 
OR).  Ac-DEVD-AFC (Acetyl-Asp-Glu-Val-Asp-7-amido-4-trifluoromethylcoumarin), Ac-
LEHD-AFC (Acetyl-Leu-Glu-His-Asp-7-amido-4-trifluoromethylcoumarin), Z-VAD-FMK 
(Z-Val-Ala-Asp-fluoromethyl ketone), and Z-DEVD-FMK (Z-Asp-Glu-Val-Asp-
fluoromethyl ketone) were purchased from MP Biomedicals (Aurora, OH).  Cell Death 
Detection ELISAplus Assay Kit was purchased from Roche Molecular Biochemicals 
(Indianapolis, IN).  Bradford protein assay kit was purchased from Bio-Rad Laboratories 
(Hercules, CA).  DMEM, fetal bovine serum, L-glutamine, penicillin, and streptomycin were 
purchased from Invitrogen (Gaithersburg, MD).  Nitric acid was purchased from Fisher 
Scientific (Pittsburgh, PA). 
 
Cell culture.  The mouse PrP cDNA and vector alone were engineered into a mouse neural 
cell line (CF10) derived from PrP knockout mice as described previously (Kocisko et al. 
1994; Priola et al. 1994; Takemura et al. 2006).  cDNAs encoding mouse PrP cDNA with a 
hamster epitope were first cloned into the retroviral vector pSFF in order to establish a stable 
cell line.  The substitution of lysine and valine residues at position 108 and 111 with 
methionine residues allows the mouse prion protein to be recognized by the 3F4 monoclonal 
antibody.  Stable cell lines that constitutively expressed mouse wild-type PrPC (PrPC-cells) 
were selected with G418.  CF10 cells stably expressing the pSFF vector alone were also 
established and designated as PrPKO-cells.  These cell lines were kindly provided by Dr. 
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Susan Priola (Rocky Mountain Laboratory, NIAIDS, Mt) PrPC- and PrPKO-cells were grown 
in DMEM with 5% fetal bovine serum supplemented with 2 mM L-glutamine, 50 units of 
penicillin, and 50 µg/ml streptomycin in a humidified atmosphere of 5% CO2 at 37ºC. 
 
Immunocytochemistry. Cells were plated onto coverslips coated with 0.1 mg/ml poly-L-
lysine. After 24 to 48 hr, the cells were fixed with 4% formaldehyde and permeabilized with 
0.2% Triton X-100. The cells were then incubated with antibodies directed against the 3F4 
epitope in the prion protein (1:500; Signet Labs, Berekely, CA) overnight at 4°C, followed by 
incubation with the appropriate Alexa-488 secondary antibody (1:1000; Molecular 
Probes,Eugene, OR) for 90 min at room temperature. The cells were then mounted on slides, 
viewed, and imaged under a Nikon 2000U microscope. For confocal microscopy, a Nikon C1 
microscopy system was employed. All images were processed in MetaMorph 5.7 from 
Universal Imaging (Downingtown, PA).   
 
Western blotting.  PrPC- and PrPKO-cells were lysed, homogenized, sonicated, and 
centrifuged as described previously (Kaul et al. 2003; Kitazawa et al. 2002).  The 
supernatants were collected as cell lysates, and protein concentrations were determined and 
used for SDS-gel electrophoresis.   Cytoplasmic fractions containing equal amounts of 
protein were loaded in each lane and separated on a 10-12% SDS-PAGE gel as described 
previously (Kaul et al. 2003; Kitazawa et al. 2002).  Proteins were then transferred to 
nitrocellulose membrane, and non-specific binding sites were blocked by treating with 5% 
non-fat dry milk powder.  The membranes were then treated with primary antibody directed 
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against the 3F4-epitope present in the prion protein (1:500 dilution), followed by treatment 
with secondary HRP-conjugated anti-mouse antibody.  Secondary antibody-bound proteins 
were detected using Amersham’s ECL chemiluminescence kit (Piscataway, NJ).  For 
determination of differences in divalent metal transporter-1 (DMT-1) and transferrin between 
PrPC-cells and PrPKO-cells, blots were probed with anti-mouse DMT-1 (1µg/ml) and anti-
mouse transferrin (1µg/ml) (Alpha Diagnostic International, San Antonio, TX).  Following 
incubation with primary antibodies, the blots were incubated with secondary HRP conjugated 
anti-mouse antibody and processed for ECL detection.  To confirm equal protein loading, 
blots were reprobed with a β-actin antibody (1:5000 dilution).  All Western blot images were 
captured with a Kodak 2000 MM imaging system. 
 
Cytotoxicity assays.  To examine cell death, cells were plated and grown on 6-well plates at 
density of 5x105 and treated with MnCl2 in a range of concentrations from 10 µM to 10 mM 
for 24 hr.  Cell death was determined by the Trypan blue exclusion method with an Improved 
Nebauer-type Hemacytometer as described previously (Anantharam et al. 2002).  The cell 
viability was normalized as percent of control.  Cell death was also measured using the Sytox 
Green cell death assay as described previously (Latchoumycandane et al. 2005).  Briefly, the 
cells were exposed to 100 µM manganese and 1 µM Sytox for 24 hr.  Sytox green is a cell-
impermeable nucleic acid dye that enters dead cells and intercalates with DNA to produce 
green fluorescence.  After treatment, the Sytox-positive cells were imaged using a Nikon 
TE2000 microscope and SPOT digital camera (Diagnostic Instruments, Sterling Heights, 
MI).  Cells undergoing apoptosis exhibit a strong green fluorescence because the dye 
permeates through the cells and intercalates with DNA in the nuclei. 
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Determination of intracellular manganese concentration.  Inductively coupled plasma mass 
spectrometry (ICP-MS) was used to determine intracellular manganese concentration.  The 
ICP-MS device was a high-resolution double focusing instrument operated in medium 
resolution (m/∆m = 4,000) in order to resolve 55Mn+ from any potential interferences (Shum 
et al. 1992).  The cells were treated with either 30 or 100 µM Mn for 6 hr.  For measurements 
with antioxidants, cells were pretreated with 2mM Trolox® (vitamin E analog), and then 
exposed to 100µM Mn for 6 hr.  After washing twice with phosphate buffered solution 
(PBS), the number of cells was counted.  Samples containing an equal number of cells were 
resuspended in 1% nitric acid and spiked with gallium.  69Ga+ was chosen as an internal 
standard because its m/z ratio is similar to that of the element of interest, and it has no major 
spectroscopic interferences.    A 10 µl aliquot of a 10 ppm Ga standard was added to each of 
the samples.  A multi-element standard was prepared using 10 µl aliquots of 10 ppm standard 
solutions of Mn, Cu, and Ga in 1 ml 1% nitric acid.  All solutions were prepared with Milli-Q 
18.2 MΩ water. The nitric acid blank, the three-element standard, and each of the samples 
were introduced into the ICP-MS via a 100 µl/min self-aspirating PFA nebulizer (Elemental 
Scientific, Inc., Omaha, NE).  Between samples, the nitric acid blank was used to rinse the 
nebulizer.   The results for each sample are calculated using the integrated average 
background-subtracted peak intensities from 20 consecutive scans.  In order to correct for 
differences in elemental sensitivity in the ICP, the three-element standard was used to derive 
a normalization factor for each element.  Using this normalization factor and the isotopic 
abundances of each element, the concentrations of manganese and copper were calculated for 
each sample.   
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Determination of mitochondrial depolarization by manganese.  Depolarization of 
mitochondrial membrane potential (∆Ψm) was assessed by flow cytometry using DIOC6 as 
previously described (Kitazawa et al. 2001).  Prior to analysis, cells were collected and 
incubated with 40nM of DIOC6 for 15 min.  At the end of the incubation period, cells were 
washed once, resuspended in PBS, and analyzed using the Becton Dickenson FACScan™ 
flow cytometer (Becton Dickenson, San Francisco, CA) with excitation at 484nm and 
emission at 501nm. 
 
3-(4,5-dimethylthiazol-3-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay.  This assay is 
widely used to assess cell viability by measuring the activity of mitochondrial dehydrogenase 
enzymes that cleave the tetrazolium ring to produce formazan (Brown et al. 1994; Kitazawa 
et al. 2001).  After Mn treatment, cells were washed once and further incubated in serum-free 
DMEM containing 0.25mg/ml MTT for 1 hr at 37ºC.  Supernatant was removed, and MTT 
crystals were solubilized in 200 µl dimethyl sulfoxide.  The mitochondrial activity was 
measured with the SpectraMax spectrophotometer (Molecular Devices Corporation, San 
Diego, CA) at 570nm with the reference wavelength at 630nm. 
 
Determination of ROS production by manganese.  Flow cytometry analysis was performed 
with a Becton Dickenson FACScan™ flow cytometer (Becton Dickenson, San Francisco, 
CA).  Dihydroethidium, a sodium borohydride-reduced derivative of ethidium bromide, was 
used to detect ROS.  When hydroethidium is loaded into the cells, it binds to cellular 
macromolecules.  ROS are generated, which reduce hydroethidium to ethidium bromide, thus 
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increasing the fluorescence signal (620 nm).  This ROS assay was performed as per the 
method described previously (Kitazawa et al. 2002).  Cells were re-suspended in PBS with 2 
mM calcium at a density of approximately 1x106 cells and incubated with 10 µM 
dihydroethidium for 15 min at 37ºC in the dark to allow the dye to load into the cells.  
Following addition of Mn, ROS generation was measured at 60 min.  The flow cytometric 
data were analyzed with Cellquest™ data analysis software (Becton Dickenson, San 
Francisco, CA). 
 
Visualization of ROS production induced by manganese.  PrPC- and PrPKO-cells were plated 
at a density of 5x105 cells in 6-well plates and grown overnight.  Cells were then incubated 
with 100 µM Mn and 5 µM dihydroethidium at 37ºC for 5 min in the dark. After treatment, 
cells were washed once with PBS, and the fluorescence positive cells were viewed 
microscopically using 620 emission filter.  Pictures were taken at 15 min intervals over 60 
min using a Nikon TE2000 microscope and SPOT digital camera (Diagnostic Instruments, 
Sterling Heights, MI).   
 
Glutathione assay.  Methods adapted from ApoAlert® Glutathione Detection Kit (Clontech, 
Palo Alto, CA) were used to measure intracellular glutathione (GSH).  After manganese 
treatment, the cell lysates were prepared according to the manufacturer’s protocol.  The cell 
lysates were centrifuged at 132,000xg for 10 min.  The resulting supernatant was collected 
and incubated with 1 mM monochlorobimane (glutathione binding dye) for 20 minutes at 
37ºC.  Binding of the monochlorobimane dye with glutathione was measured using a 
fluorescence plate reader (excitation 395 nm, emission 480 nm, Molecular Devices 
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Corporation, Gemini XS Plate Reader).  Results were calculated by normalizing the 
fluorescence signals from the samples to the amount of protein.  Protein concentration was 
measured using the Bradford protein assay as described previously. 
 
Superoxide dismutase assay.  Methods were adapted from the Superoxide Dismutase Assay 
Kit (Cayman Chemical, Ann Arbor, MI).  Both PrPC-cells and PrPKO-cells were grown to 
confluency, and collected for assay of both total superoxide dismutase (SOD) and Mn-SOD 
activity.  Cells were homogenized in cell homogenization buffer (20 mM HEPES, 1 mM 
EGTA, 210 mM mannitol, and 70 mM sucrose, pH 7.2).  Cytosolic lysates were prepared by 
centrifugation at 10,000Xg for 15 min at 4ºC, and the resulting supernatant was used for 
measurement of total SOD activity.  The pellet was resuspended in the cell homogenization 
buffer with 3 mM KCN to measure Mn-SOD activity.  SOD standard was prepared from 
SOD standards provided by the kit.  All the samples were incubated with diluted radical 
detector (hypoxanthine) and xanthine oxidase, and placed on the orbital shaker for 20 min at 
room temperature.  After the incubation, absorbance was measured at 450 nm using a plate 
reader.  Activity of SOD in the samples was calculated with the standard curve obtained from 
the SOD standard, and normalized to protein concentration.  One unit of SOD was defined as 
the amount of enzyme required to exhibit 50% dismutation of the superoxide radical. 
 
Enzymatic assay for caspases.  Caspase-3 and caspase-9 activities were measured as 
described in our previous publications (Anantharam et al. 2002; Kaul et al. 2003; Kitazawa 
et al. 2003; Kitazawa et al. 2002).  After exposure to manganese, the cells were washed with 
PBS, resuspended in lysis buffer containing 50 mM Tris/HCl (pH 7.4), 1 mM EDTA, 10 mM 
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EGTA, and 10 µM digitonin, and incubated at 37ºC for 20 min.  Lysates were centrifuged at 
132,000xg, and the cell-free supernatants were incubated with 50 µM Ac-DEVD-AFC 
(fluorometric caspase-3 substrate) or 50 µM Ac-LEHD-AFC (fluorometric caspase-9 
substrate) at 37ºC for 1 hr.  Formation of 7-amido-4-trifluoromethylcoumarin (AFC), 
resulting from caspase cleavage, was measured using a fluorescence plate reader (excitation 
400 nm, emission 505 nm).  All the fluorescence signals from the samples were normalized 
to protein concentration, as determined with the Bradford protein assay. 
 
In situ labeling of apoptosis.  Hoechst 33342 nucleic dye was used to visualize nuclear 
condensation, which was one of the distinct morphological changes observed (Kitazawa et al. 
2003).  The cells were grown on coverslips coated with poly-lysine (0.1 mg/ml) for 1 day at 
37 ºC with 5% CO2.  Attached cells were treated with 100 µM Mn for 24 hr.  After exposure, 
cells were washed once with PBS and treated with 10 µg/ml Hoechst 33342 for 10 min in the 
dark.  Cells were washed once with PBS and fixed in 10% buffered formalin for 30 min at 
room temperature in the dark.  After fixing, the cells were washed three times with PBS for 5 
min each to remove the formalin, followed by one wash with H2O.  Then the coverslips were 
mounted on slides and observed with a Nikon TE2000 microscope and SPOT digital camera 
(Diagnostic Instruments, Sterling Heights, MI). 
 
DNA fragmentation assay.  DNA fragmentation assays were performed using a recently 
developed Cell Death Detection ELISAplus Assay Kit.  This is a fast, highly sensitive and 
reliable assay for detection of early changes in cells undergoing apoptotic cell death 
(Anantharam et al. 2002; Kaul et al. 2003; Kitazawa et al. 2002).  DNA fragmentation was 
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measured in PrPKO and PrPC cells exposed to manganese at time points correlating to the 
maximum caspase-3 activation. For H2O2 study, both PrPC and PrPKO cells were incubated 
with 100µM H2O2 for 24 hr. In inhibitor studies, Z-DEVD-FMK (50 µM) or Z-VAD-FMK 
(100 µM) was co-treated with 100 µM Mn for 18 hr.  After treatment, 20 µl of cell lysate was 
prepared according to the manufacturer’s protocol.  The assay solution consisted of a mixture 
of anti-histone biotin and anti-DNA-horseradish peroxidase directed against various histones 
and antibodies to both single-stranded DNA and double-stranded DNA, which are the major 
constituents of nucleosomes.  After 2 hr of incubation, unbound components were removed 
by washing three times with the incubation buffer provided with the kit.  The nucleosomes 
retained by anti-DNA-horseradish peroxidase in the immunocomplex were quantified 
spectrophotometrically with ABTS [2,2'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid)] 
as horseradish peroxidase substrate (supplied by the kit).  Measurements were made at 405 
nm against an ABTS solution as a blank (reference wavelength 490 nm).  All sample 
concentrations were normalized to protein concentration using the Bradford protein assay. 
Statistical analysis 
Data were analyzed with Prism 3.0 software (GraphPad Software, San Diego, CA).  
Bonferroni’s and Dunnett’s multiple comparison testing were used to delineate significant 
differences between PrPC-cells, Mn treated PrPC-cells, PrPKO-cells, and Mn treated PrPKO-
cells.  For the cell viability assay, a nonlinear regression curve was fit onto the data, and EC50 
concentrations were extrapolated.  For comparison between two samples, Student’s T-test 
was performed to examine the differences.  Differences with p<0.05, p<0.01, and p<0.001 
were considered to be significant and are indicated by asterisks.  Non-significant differences 
were noted as ns.  The sample size was calculated based on a statistical power analysis of our 
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preliminary data. It was determined that n=6 was large enough (95% confidence intervals) to 
distinguish significant differences among the treatment groups as well as the cell types.  
 
Results 
 
Generation of stable prion protein expressing cell lines 
To understand the physiological role of prion protein, we used the mouse PrPC and PrPKO 
neural cells.  Constitutive and stable expression of prion protein was verified using 
immunoblot and immunohistochemical analyses.  Figure 1A shows stable expression of a di-
glycosylated (32 kDa), mono-glyocosylated, and unglycosylated prion protein band in PrPC-
cell lysates, but not in PrPKO-cell lysates, as determined by Western blot analysis using a 
monoclonal antibody directed against the 3F4 epitope in mouse prion protein.  Stable 
expression of mouse prion protein was further confirmed by immunocytochemical analysis 
(Fig. 1B).  The bright green immunofluorescence-staining pattern in the PrPC-cells revealed 
that the prion protein was distributed on the surface of the cells, whereas no 
immunoreactivity was detected in the PrPKO-cells.  Blue staining represents nuclear staining 
with Hoechst 33342. 
 
Prion protein expression protects against manganese-induced cytotoxic cell death 
PrPKO- and PrPC-cells were exposed to Mn concentrations ranging from 0.01 to 1 mM 
for 24 hr, and the extent of cell death was determined by the Trypan blue exclusion method.  
Fig. 2A shows a dose-dependent increase in cytotoxic cell death with Mn treatment.  Data 
analysis yielded an EC50 for Mn-induced cytotoxic cell death of approximately 59.9 µM and 
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117.6 µM for PrPKO- and PrPC-cells, respectively.  These results suggest that the PrPC-cells 
were more resistant to cell death induced by manganese.   
In addition, cytotoxicity was also monitored qualitatively with the Sytox fluorescence 
assay.  Microscopic analysis clearly displayed the protective effect of prion protein, as 
evident by the reduced number of Sytox-positive green cells in Mn-treated PrPC-cells when 
compared to Mn-treated PrPKO-cells (Fig. 2B).  Changes in cellular morphology due to the 
Mn treatment can be seen in the phase-contrast images. 
 
Intracellular manganese is significantly attenuated in prion protein expressing cells 
To verify whether cellular prion protein alters the intracellular Mn accumulation, the 
Mn concentration was measured by ICP-MS in PrPC- and PrPKO-cells.  Table 1 shows the 
intracellular Mn levels in Mn-treated PrPKO- and PrPC-cells.  ICP-MS revealed a significant 
difference in intracellular Mn levels in untreated PrPC- and PrPKO-cells.  The basal 
intracellular Mn levels were determined to be 2.38 ± 0.6 ng/mg protein and 0.245 ± 0.034 
ng/mg protein, respectively.  PrPC-cells had a 9-fold higher basal level of Mn compared to 
PrPKO-cells, suggesting that the PrPC-cells were able to retain Mn more effectively than 
PrPKO-cells.  Exposure to 30 µM and 100 µM Mn resulted in a dose-dependent increase in 
intracellular Mn levels in both PrPC- and PrPKO-cells (Table 1).  Intracellular Mn 
accumulation was increased by 840- and 2200-fold in 30 and 100 µM Mn-treated PrPKO-
cells, respectively, whereas intracellular Mn levels increased by only 48- and 180-fold, 
respectively, in PrPC-cells.  These results suggest significantly reduced Mn uptake in PrPC-
cells.  Since PrPC has been implicated in copper binding, copper levels for both PrPC-cells 
and PrPKO-cells were examined.  Similar to Mn values, PrPC-cells exhibited higher basal 
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copper levels as compared to PrPKO-cells.  Following Mn treatment, no significant alterations 
in copper levels were noted in PrPC-cells, but a slight decrease was observed in PrPKO-cells.  
This suggests that PrPC may be involved in metal homeostasis, and the lack of the protein 
may result in lower than normal basal metal levels.  Conversely, exposure to high 
concentrations of metals may result in reduced capability to prevent excessive metals from 
accumulating inside the cells.  We also examined whether Mn exposure alters the levels of 
DMT-1 and transferrin in PrPC-cells and PrPKO-cells.  As shown in Fig. 3, Western blot 
analysis showed no significant differences in DMT-1 and transferrin between PrPC-cells and 
PrPKO-cells following 100µM Mn treatment, suggesting that the levels of these metal binding 
proteins do not account for the difference in Mn uptake in PrPC-cells and PrPKO-cells.  Also, 
basal levels of DMT-1 and transferrin were not altered in PrPC-cells and PrPKO-cells.  Mouse 
liver lysates and/or mouse brain lysates were used for a positive control.   
 
Prion protein attenuates manganese-induced mitochondrial dysfunction 
One of the main cellular targets of Mn has been reported to be mitochondria, and as 
Mn accumulates in the mitochondria it inhibits the mitochondrial complex I activity (Gavin 
et al. 1992, 1999; Gunter et al. 2006; Gunter et al. 2004).  Accumulation of Mn in the 
mitochondria leads to mitochondrial impairment and increased ROS generation (Gunter et al. 
2004).  In the present study, we examined whether Mn treatment alters mitochondrial 
dysfunction in both PrPC- and PrPKO-cells.  Cells were plated out onto 96 well plates and at 1, 
3, 6, 9, 15, 18, and 24 hr post Mn-treatment, mitochondrial activity was measured by MTT 
assay at each time point.  As shown in Fig. 4A, PrPKO-cells exhibited greater loss of 
mitochondrial activity as compared to PrPC-cells following Mn treatment.  The time course 
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data of PrPKO-cells showed a leftward shift, indicating increased sensitivity of PrPKO-cells to 
Mn.  Next, we measured the mitochondrial membrane protential (∆Ψm) in Mn-treated PrPC- 
and PrPKO-cells by flow cytometry with a DIOC6 fluorescent probe to further determine the 
role of prion protein in Mn-induced mitochondrial dysfunction.  After incubation with 
DIOC6, cells were treated with manganese and at 6hr, ∆Ψm was measured.  PrPC-cells did 
not exhibit any loss of ∆Ψm at 6hr, whereas PrPKO-cells showed a significant loss of ∆Ψm 
(Fig. 4B).   
 
Manganese treatment induces ROS generation 
Recent studies from our lab and others have shown that oxidative stress mediates Mn-
induced apoptotic cell death in dopaminergic cells (Gunter et al. 2006; Kitazawa et al. 2005; 
Latchoumycandane et al. 2005; Stokes et al. 2000; Weber et al. 2002).  Therefore, we 
attempted to determine whether Mn exposure induces ROS generation in PrPC- and PrPKO-
cells.  Flow cytometric analysis using the ROS-sensitive fluorescence probe hydroethidine 
revealed that treatment with 100 µM Mn induces ROS generation.  Fig. 5A depicts a 
representative flow cytometric histogram of ROS generation in untreated and Mn-treated 
PrPC- and PrPKO-cells.  Exposure to 100 µM Mn for 60 min resulted in a 128% and 194% 
increase in ROS generation in PrPC- and PrPKO-cells compared to untreated control cells, 
respectively (Fig. 5B).   
For further confirmation of the flow cytometric data, we measured dihydroethidium 
fluorescence in Mn-treated cells.  Increases in dihydroethidium fluorescence, an indicator of 
ROS levels, were monitored in PrPKO- and PrPC-cells every 15 min for up to an hour in 100 
µM Mn-treated cells. As shown in Fig. 6, Mn treatment induced a time-dependent increase in 
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the number of cells positive for dihydroethidium fluorescence in both PrPC- and PrPKO-cells.  
However, the number of dihydroethidium-positive cells was significantly less in Mn-treated 
PrPC-cells as compared to PrPKO-cells.  Together, these data suggest that normal prion 
protein expressing cells are more resistant to Mn-induced oxidative insult.  
To verify that the increased uptake of Mn by PrPKO-cells was not due to increased 
ROS generation, both PrPC-cells and PrPKO-cells were pretreated and co-treated with 2mM 
Trolox®, which is a potent antioxidant that protects against ROS.  As seen in Table 2, co-
treatment with Trolox did not prevent Mn internalization into the cells, and no significant 
difference was observed between Mn treatment and Mn + Trolox co-treatment in both PrPC- 
and PrPKO-cells. 
 
Prion protein expression protects against manganese-induced decreases in GSH levels 
To determine whether increases in ROS production are also accompanied by 
decreases in antioxidant GSH levels, we measured initial GSH levels in untreated PrPKO- and 
PrPC-cells. Fig. 7A shows that there is no significant difference in baseline GSH levels 
between these two cell lines, suggesting that prion protein expression does not affect the 
basal intracellular GSH levels.  We also investigated whether GSH metabolism is altered in 
prion protein expressing cells.  For this study, we exposed both PrPC-cells and PrPKO-cells to 
bulthionine sulfoximide (BSO), an inhibitor of GSH synthesis, and determined the 
intracellular GSH levels.  Fig. 7B shows that exposure to 100 µM BSO for 6 hr resulted in 
decreased intracellular GSH levels in both these cell types.  There was no significant 
difference between PrPC and PrPKO-cells.   We then investigated whether Mn treatment alters 
GSH levels in PrPKO- and PrPC-cells.  Exposure to 100 µM Mn for 24 hr decreased 
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intracellular GSH levels in both PrPC- and PrPKO-cells (Fig. 7C).  However, the decrease in 
GSH levels was more pronounced in PrPKO-cells than in PrPC-cells.  We also measured total 
cellular SOD as well as mitochondrial SOD (MnSOD) in PrPC-cells and PrPKO-cells to 
determine any difference in the basal activity of this important antioxidant enzyme.  Our 
results show that neither total SOD nor MnSOD activity was altered in PrPC-cells and PrPKO-
cells (Fig. 7D). Taken together with cellular GSH (Fig 7A), these results indicate no significant 
difference in antioxidant status between PrP - and PrP -cells.  C KO
 
Manganese-induced caspase-9 and -3 activation is significantly suppressed in PrPC- cells 
ROS production in cells is known to activate many proapoptotic factors, including 
cytochrome C, which subsequently triggers activation of the caspase cascade (Cassarino et al. 
1999; Tan et al. 1998).  Sequential activation of the apoptotic factor caspase-9 followed by 
caspase-3 is important in mediating oxidative stress-induced cellular death.   
We examined whether Mn-induced differences in cytotoxic cell death between PrPC- 
and PrPKO-cells are due to differences in the activation of the caspase cascade in these cell 
lines.  Exposure to Mn resulted in time-and dose-dependent increases in caspase-9 enzyme 
activity.  Fig. 8 shows the activation of caspase-9 in PrPC- and PrPKO-cells treated with 30 
µM Mn (Fig. 8A) and 100 µM Mn (Fig. 8C).  The activation of caspase-9 started at 18 hr, 
peaked at 24 hr, and then started to decrease at 30 hr in cells treated with 30 µM Mn.  
Increasing the concentration of Mn to 100 µM resulted in the earlier activation of caspase-9 
activation, starting at 6 hr, peaking at 18 hr, and then decreasing at 24 hr.  Exposure to 30 µM 
Mn resulted in an increase in caspase-9 enzyme activity by 610% in PrPKO-cells and by 
470% in PrPC-cells at 24 hr, respectively.  Similarly, exposure to 100 µM Mn resulted in an 
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increase in caspase-9 enzyme activity by 690% by 18 hr in PrPKO-cells and by 549% in PrPC-
cells.  Data analysis revealed that the Mn-induced increase in caspase-9 activation was 
significantly reduced in PrPC-cells, suggesting that prion protein may protect cells against 
Mn-induced activation of early initiator apoptotic protease caspase-9.  
Manganese exposure also induced a time- and dose-dependent increase of effector 
caspase (caspase-3) activation in PrPC- and PrPKO-cells.  Fig. 8 also shows the activation of 
caspase-3 in PrPC- and PrPKO-cells treated with 30 µM Mn (Fig. 8B) and 100 µM Mn (Fig. 
8D).  The activation of caspase-3 started to appear after 12 hr, peaked at 24 hr, and then 
started to decrease at 30 hr in 30 µM Mn-treated cells.  Increasing the Mn concentration to 
100 µM resulted in earlier activation of caspase-3, starting at 6 hr, peaking at 18 hr, and then 
decreasing at 24 hr.  Exposure to 30 µM Mn resulted in an increase in caspase-3 enzyme 
activity by 760% at 24 hr in PrPKO-cells and by 400% in PrPC-cells, respectively.  Similarly, 
exposure to 100 µM Mn increased caspase-3 enzyme activity by 646% at 18 min in PrPKO-
cells and by 579% in PrPC-cells, respectively.  Comparative analysis of caspase-3 data 
revealed that the Mn-induced increases in caspase-3 activation were significantly different 
between PrPC-cells and PrPKO-cells following 30 µM Mn-treatment.  However, the extent of 
caspase-3 activation was similar, and not significantly different, between these two cell lines 
in 100 µM Mn-treated cells. Together, these data suggest that cellular prion protein may 
protect against Mn-induced increase in caspase-3 activation.   
 
In situ fluorometric detection of manganese-induced apoptosis 
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To understand the functional consequence of the activation of caspases, we examined 
whether Mn induces apoptosis.  Chromosomal breakdown and DNA condensation are 
hallmarks of cells undergoing apoptosis.  To identify whether Mn induces apoptotic cell 
death, we used in situ fluorometric analysis to detect chromatin condensation using Hoechst 
33342 dye.  After treatment with Mn, PrPKO- and PrPC-cells were fixed and stained with 
Hoechst 33342 dye. Exposure to 100 µM Mn for 24 hr induced chromatin condensation in 
both PrPC- and PrPKO-cells, as observed by the tightly bound dye to the highly condensed 
DNA (Fig. 9).  Image analysis revealed that a significant number of Mn-treated PrPKO-cells 
showed nuclear condensation, whereas only a small percentage of cells exhibited chromatin 
condensation in Mn-treated PrPC-cells. The Hoechst 33342 staining of untreated control cells 
was weak and diffuse, indicating no significant nuclear condensation in these cells (Fig. 9B, 
far left).  These results suggest that prion protein expressing cells are less susceptible to Mn-
induced apoptotic cell death.  
 
Prion protein expression protects against manganese-induced DNA fragmentation 
To further confirm that Mn induces apoptotic cell death, we used DNA ELISA 
sandwich assay to quantify the extent of DNA fragmentation in PrPKO- and PrPC-cells.  Mn 
treatment induced a dose-dependent increase in DNA fragmentation in both PrPKO- and PrPC-
cells (Fig. 10).  Exposure to 30 µM Mn for 24 hr resulted in 137% and 291% increases in 
DNA fragmentation in PrPC- and PrPKO-cells, respectively (Fig. 10A). Similarly, exposure to 
100 µM Mn for 18 hr resulted in 540% and 809% increases in DNA fragmentation in PrPC- 
and PrPKO-cells, respectively (Fig. 10B).  Together, these results further confirm that PrPc-
cells are less susceptible to Mn-induced apoptotic cell death.    
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Next, we determined whether caspases mediate Mn-induced apoptotic cell death.  Fig. 
10C shows that co-treatment with Z-VAD-FMK (a pan caspase inhibitor) significantly 
attenuated Mn-induced apoptotic cell death in PrPKO- and PrPC-cells.  Co-treatment with 100 
µM Z-VAD-FMK blocked Mn-induced DNA fragmentation by 267% and 226% in PrPC- and 
PrPKO-cells, compared to Mn treatment alone.  Treatment with Z-VAD-FMK alone did not 
have any effect on DNA fragmentation, (i.e., the cells appeared similar to untreated cells).  
Since Z-VAD-FMK did not completely block DNA fragmentation in both cells, caspase-
independent apoptotic cell death may also contribute to Mn-induced apoptotic cell death.   
To determine whether cellular prion protein protects against apoptotic cell death 
during oxidative insult, we measured DNA fragmentation in H2O2 treated PrPC- and PrPKO-
cells.  DNA fragmentation was only slightly increased in PrPC-cells following treatment with 
100µM H2O2 for 24hr, whereas a two-fold increase in DNA fragmentation was observed in 
PrPKO-cells (Fig. 10D), indicating cellular prion can attenuate oxidative stress-induced 
apoptotic cell death.  
 
Discussion  
In the present study, we show that expression of prion protein rescues PrPKO-cells 
from Mn-induced apoptotic cell death by attenuating ROS production, caspase-3 activation, 
and DNA fragmentation.  Our studies also demonstrate that expression of prion protein 
reduces intracellular accumulation of manganese during the metal exposure.  To our 
knowledge, this is the first study demonstrating the protective role of prion protein in Mn-
induced neurotoxicity.  Furthermore, the excellent response of PrPC-cells and PrPKO-cells to 
the toxic effect of manganese is similar to the response observed in other neuronal cell 
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models used in previous studies, indicating that PrPC-cells and PrPKO-cells are very useful in 
vitro models for studying the role of prion protein in metal neurotoxicity. 
 
 Prion protein is a cell surface glycosylated protein, predominantly expressed in the 
CNS of most mammalian species (Martins and Brentani 2002; McKinley et al. 1987; 
Prusiner 1984).  It is a 254 amino acid peptide with several octapeptide repeat sequences 
(PHGGSWGQ) toward the N-terminus, which have variable binding affinity for divalent 
metals such as copper, zinc, and manganese, with preferential binding for copper (Hornshaw 
et al. 1995b; Viles et al. 1999).  The number of octapeptide repeats differs from species to 
species, ranging from 4-8 repeats (Goldfarb et al. 1991; Hornshaw et al. 1995b). Although 
the role of the octapeptide repeats is yet to be characterized, binding of the divalent cation to 
the octapeptide repeats may stabilize protein conformation by facilitating the folding of the 
largely unstructured N-terminus of the protein (Cereghetti et al. 2003).  Previous studies have 
shown the prion protein to be a Cu-binding protein, and binding of Cu seems to be essential 
for its normal function (Garnett and Viles 2003; Hornshaw et al. 1995b).  Copper binding 
also enhances the antioxidant activity of the prion protein (Brown et al. 2001).  Loss of Cu 
binding and decreased concentrations of Cu and other metals in the brain have been observed 
in Prion diseases including CJD and BSE (Lehmann 2002; Rossi et al. 2004; Thackray et al. 
2002).  A growing body of evidence indicates that Mn can also interact with the prion protein 
(Brown et al. 1997c; Giese et al. 2004; Tsenkova et al. 2004) to possibly alter its function.  
Recent studies have shown that PrPC can be stimulated from the cells to be shed into the 
media (Parkin et al. 2004).  This was first described by Parkin et al., who demonstrated that 
PrPC can be cleaved from the surface of the cells through proteolytic cleavage at the site of 
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the GPI-anchor.  Similarly, Toni et al. also described shedding of PrPC from cells induced 
through treatment with copper (Toni et al. 2005).  Both these papers speculated that this 
mechanism could protect cells against scrapie infection, suggesting that this could be a 
normal pathway for PrPC.  We hypothesize that the shedding mechanism could be a way for 
cells to excrete excessive amounts of metals (i.e., copper, manganese, zinc) through a 
protein-metal complex.  This could be a reason why the PrPKO-cells treated with manganese 
exhibited higher manganese content, and increased cellular death. Our future studies will 
focus on this issue of metal-induced shedding of prion proteins to determine possible 
mechanisms underlying the protective effect of cellular PrPC against metal neurotoxicity.  
 
Manganese is an essential element in development and survival, but also has been 
classified as an environmental neurotoxin (HaMai and Bondy 2004; Mergler et al. 1999; 
Pamphlett et al. 2001).  Excess manganese accumulates in the mitochondria and inhibits both 
mitochondrial complex I & II, which leads to disruption of the mitochondrial electron 
transport system (Galvani et al. 1995; Gunter et al. 2006). Disruption of mitochondrial 
respiration results in increased levels of oxygen in the cytosol, which can generate ROS.  
Oxidative stress resulting from manganese has been shown to induce apoptotic cell death in 
many different cell types (Castilho et al. 1999; Hirata 2002; Kitazawa et al. 2005; 
Latchoumycandane et al. 2005; Stredrick et al. 2004).  In the present study, Mn-induced 
cytotoxicity was significantly attenuated in a dose-dependent manner in cells that over-
express prion protein compared to prion protein knockouts.  The EC50s were determined to be 
117.6 µM and 59.9 µM for PrPC- and PrPKO-cells, respectively.  Our results agree with 
previous studies which show prion protein can protect against cytotoxic cell death in multiple 
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cell types in response to various stimuli (Roucou et al. 2003), and loss of prion protein results 
in enhanced sensitivity to stress (Brown et al. 1998; Brown et al. 1997c; White et al. 1999).  
However, the molecular and cellular mechanisms underlying the neuroprotective role of 
prion protein are poorly understood.  In this study we also show that PrPC-expressing cells 
have higher levels of basal intracellular accumulated Mn compared to PrPKO-cells.  The 
elevated basal Mn in PrPC-cells may be due to internalization of Mn-bound prion proteins.  
The intracellular Mn accumulation is dramatically suppressed in Mn-treated PrPC-cells 
compared to PrPKO-cells, and may explain the partial resistance of PrPC-cells to Mn-induced 
cytotoxicity.  Furthermore, our data showing lower copper and manganese levels in cells 
lacking PrPC indicate that PrPC can function to regulate cellular metal content. 
 
We and others recently showed that Mn induces ROS production, mitochondrial 
dysfunction, cytochrome C release, activation of multiple caspases and apoptotic cell death in 
neuronal and non-neuronal cell types (Hirata 2002; Kitazawa et al. 2005; Latchoumycandane 
et al. 2005; Malthankar et al. 2004; Roth et al. 2002).  In this study we examined ROS 
production in PrPC- and PrPKO-cells following Mn treatment.  Mn-induced ROS generation 
was significantly suppressed in a dose- and time-dependent manner in PrPC-cells compared 
to PrPKO-cells.  The antioxidant activity of prion protein may in part contribute to the reduced 
ROS generation observed in PrPC-cells.  Recently, Rachidi et al. showed that expression of 
prion protein increases copper binding and antioxidant enzyme activities in the rat kidney 
RK13 cell line (Rachidi et al. 2003).  In the present study, we found that Mn exposure 
reduced GSH levels to a greater extent in PrPKO-cells than in PrPC-cells.  However, we found 
no significant differences in the baseline levels of GSH antioxidant levels between the PrPC- 
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and PrPKO-cells.  Furthermore, the ability of BSO (inhibitor of γ-glutamylcysteine synthase) 
to suppress baseline GSH production was identical in both PrPC- and PrPKO-cells, suggesting 
that the basal antioxidant system is not impaired or altered in PrPC-cells.  Our results are also 
in agreement with those of Senator et al. who showed that paraquat-induced decreases in 
GSH levels were significantly lower in prion protein over-expressing A74 kidney cells 
(Senator et al. 2004).   
 
Recent studies from our lab and others have shown that Mn-induced mitochondrial 
dysfunction and oxidative stress cause a sequential activation of caspase-9 and caspase-3, 
and induce DNA fragmentation (Anantharam et al. 2002; Kaul et al. 2003; Kitazawa et al. 
2003; Kitazawa et al. 2002).  In this study, PrPC over-expression significantly reduced Mn-
induced caspase-9 and caspase-3 activation compared to PrPKO-cells, suggesting that prion 
protein expression suppresses activation of caspases via ROS or mitochondrial mechanisms.  
However, our results are not in agreement with those of Paitel et al. who showed that prion 
protein over-expression potentiated stuarosporine-stimulated increases in caspase-3 
activation in HEK293 cells (Paitel et al. 2004).  This may be due to the type of stimulus 
and/or type of cell model used in their study. 
 
The biochemical consequences of caspase-3 activation culminate in apoptotic cell 
death. DNA fragmentation and chromatin condensation are considered biochemical 
hallmarks of apoptosis and are terminal events in the apoptotic cell death process.  Recent 
studies demonstrate that apoptosis plays a role in the pathology of prion diseases (Daniels et 
al. 2001; Massimino et al. 2002; Schatzl et al. 1997; Zanata et al. 2002).  In particular, the 
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small fragment of prion protein encompassing 106-126 residues has been shown to be 
neurotoxic to neurons through the apoptotic pathway (Brown 1998; Brown et al. 1994; 
Chiarini et al. 2002; Thellung et al. 2000; Zanata et al. 2002).  In the present study, in situ 
fluorometric experiments using Hoechst 33324 revealed that Mn exposure induces chromatin 
condensation in both PrPKO- and PrPC-cells; however, PrPC-cells exhibited fewer apoptotic 
nuclei.  Quantification of DNA fragmentation by the ELISA method further confirmed the 
effect of manganese on neuronal apoptosis.  Manganese-induced DNA fragmentation was 
significantly suppressed in prion protein expressing cells, suggesting that prion protein 
expression can rescue cells from Mn-induced apoptotic cell death.  Pretreatment with the pan 
caspase inhibitor Z-VAD-FMK significantly blocked Mn-induced DNA fragmentation in 
both PrPC- and PrPKO-cells, suggesting that caspases mediate the apoptotic cell death process.  
Since the pan caspase inhibitor did not completely block cell death, caspase-independent cell 
death events may also contribute to Mn-induced apoptosis.  Our studies with H2O2 suggest 
that cellular prion proteins not only protect against metal-induced apoptotic cell death but 
also protect against oxidative insult.    
 
In conclusion, we demonstrate for the first time that prion protein expression can 
rescue neural cells from Mn-induced apoptotic cell death, possibly by affecting intracellular 
Mn accumulation, in addition to being neuroprotective against oxidative damage.  Finally, 
this study emphasizes the importance of characterizing the effect of metal interactions with 
cellular prion protein and elucidating the possible role of metals in the pathogenesis of Prion 
diseases. 
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 Table 1. Intracellular Mn and copper content in PrPC and PrPKOcells 
 
 
Mn content 
Treatment PrPC-cells Fold difference compared to control PrP
KO-cells 
Fold 
difference 
compared to 
control 
Untreated 2.4 ± 0.6 1 0.25 ± 0.03 *** 1 
30 µM MnCl2 112.9 ± 4.8 47.5 205.7 ± 6.4 *** 839.4 
100 µM MnCl2 428.9 ± 13.2 180.2 537.2 ± 16.7 *** 2192.5 
 
Copper content 
Treatment PrPC-cells Fold difference compared to control PrP
KO-cells 
Fold difference 
compared to 
control 
Untreated 23.9 ± 5.2 1 7.3 ± 3.0 *** 1 
30 µM MnCl2 18.8 ± 8.0 0.8 4.3 ± 1.2 *** 0.6 
100 µM MnCl2 27.0 ± 5.5 1.1 4.5 ± 1.1 *** 0.6 
 
 
Values represent mean of ng/mg protein ± S.E.M. performed in n=4 (***P<0.001 for 
comparison between groups) 
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Table 2. Effect of antioxidant Trolox on manganese content 
 
 
Mn content 
Treatment PrPC-cells PrPKO-cells 
Untreated 3.4 ± 0.2 0.6 ± 0.01 
100 µM MnCl2 447.2 ± 6.8 451.8 ± 6.2 
100 µM MnCl2 + 2 mM Trolox 457.4 ± 7.6 446.6 ± 6.6 
 
 
Values represent mean of ng/mg protein ± S.E.M. performed in n=4. 
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Figure 1. Prion protein expression.   
 
(A) Western blot was performed to verify prion protein expression in the PrPC-cells, and the 
lack of prion protein expression in the PrPKO-cells.  Lane 1 represents PrPC-cells and lane 2 
represents PrPKO-cells.  β-Actin was used to confirm equal loading of proteins.  (B) 
Immunocytochemistry was also performed to verify prion protein expression in the cells.  
Prion protein was stained with anti-3F4 antibody conjugated with Alexa 488 (green stain).  
Nuclear staining was performed with Hoechst 33342. 
115 
 
Figure 2. PrPC-cells are more resistant to manganese toxicity.   
 
(A) Both PrPKO- and PrPC-cells were exposed to manganese (10-10000 µM), and cytotoxicity 
was measured using the Trypan blue exclusion assay.  The EC50 values were 59.9 µM and 
117.6 µM, respectively, for each cell line.  Each of the points represents mean ± S.E.M.  Mn-
induced cytotoxicity in PrPKO-cells and PrPC-cells.  (B) Phase-contrast and Sytox® 
fluorescence staining images of PrPC- and PrPKO-cells with Mn treatment.  Cells were 
exposed to 100 µM Mn for 24 hr and then stained with 1µM Sytox® green nucleic dye, and 
images were captured using a Nikon TE2000 microscope and SPOT digital camera 
(Diagnostic Instruments, Sterling Heights, MI).  
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Figure 3. Manganese treatment does not alter DMT-1 or Transferrin levels in PrPC- 
cells and PrPKO-cells.   
 
(A)  Both PrPC-cells and PrPKO-cells were treated with 100µM Mn for 24 hr and collected for 
analysis by Western blot for DMT-1 levels.  The positive control was mouse liver lysate. β-
Actin was used to confirm equal loading of proteins.  (B) Western blot analysis of transferrin 
levels.  Positive controls were mouse brain lysates and mouse liver lysates.  β-Actin was used 
to confirm equal loading of proteins. 
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Figure 4. Manganese-induced mitochondrial dysfunction in PrPKO- and PrPC-cells.   
 
(A) Time course of mitochondrial activity.  Cells were treated with 100µM Mn and 
mitochondrial activity was measured for 1, 3, 6, 9, 15, 18, and 24 hr using the MTT assay.  
(B) Mitochondrial membrane potential (∆Ψm) was measured using DIOC6.  Cells were 
collected and incubated with 40nM DIOC6 for 15 min, and incubated with 100µM Mn for 6 
hr prior to analysis with flow cytometry.  Data represent the mean ± SEM for two separate 
experiments performed in triplicate.  **P<0.01, ***P<0.001, comparing PrPC- and PrPKO-
cells. 
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Figure 5. Manganese-induced ROS generation in PrPKO- and PrPC-cells.   
 
 (A) Representative flow cytometric histogram of dihydroethidium fluorescence in PrPC-cells 
and PrPKO-cells treated with 100 µM Mn.  Dihydroethidium was added to the cells and 
incubated for 15 min at 37ºC in the dark.  Then Mn was added, and fluorescence intensity 
was measured at 60 min by flow cytometry.  The shift of the curve to the right indicates an 
increase in ROS generation.  The x-axis shows the log scale of fluorescence intensity and the 
y-axis represents the cell count.  For both histograms, the solid curve represents the untreated 
cells, while the outline represents the treated cells.  (B) Quantification of ROS generation 
with Mn treatment.  Data represent the mean ± SEM for two separate experiments done in 
triplicate.  ***P<0.001, comparing treated cells to untreated cells, and treated PrPC-cells to 
treated PrPKO-cells. 
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Figure 6. Visualization of ROS generation in manganese-treated PrPKO-and PrPC-cells 
over time.   
 
Following a 5-min incubation at 37ºC with 1µM dihydroethidium, the cells were treated with 
100 µM Mn, and the fluorescence images were captured.  The fluorescence of the treated 
cells increased over time.  Mn treatment increased the number of fluorescent cells over time, 
whereas images of untreated cells showed relatively low fluorescence at the 60 min time 
point.  
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Figure 7. Manganese-induced depletion of GSH levels in PrPKO- and PrPC-cells.   
 
(A) Baseline GSH levels of PrPC-cells and PrPKO-cells.  (B) Effect of bulthione sulfoximide 
(BSO) on GSH levels in PrPC-cells and PrPKO-cells.  The cells were treated with 100 uM 
BSO for 6 hr and then GSH levels were measured.  (C) Effect of Mn on PrPC-cells and 
PrPKO-cells.  The cells were treated with 100 uM Mn for 24 hr and then GSH levels were 
measured and compared.  (D)  Baseline levels of total SOD and MnSOD activity were 
compared between PrPC-cells and PrPKO-cells.  Data represent the mean ± SEM for two 
experiments performed in triplicate.  *P<0.05, comparing Mn-treated PrPC and PrPKO-cells. 
 
 
121 
 
 
 
 
 
 
Figure 8. Manganese-induced caspase-9 and -3 activation in PrPKO- and PrPC-cells. 
 
Cells were treated with 30 µM or 100 µM Mn for 24 or 30 hr, and caspase-9 and -3 activities 
were measured with a fluorescence plate reader using specific caspase substrates (50 µM Ac-
LEDHD-AFC for caspase-9 activity and 50 µM Ac-DEVD-AFC for caspase-3 activity).  
(A,B) 30 µM Mn treatment induced caspase-9 activation starting at 18 hr; caspase-3 
activation started at about the same time as caspase-9, and peaked at 24 hr, with PrPKO-cells 
having a higher activity at 24 hr (P<0.01).  (C,D) 100 µM Mn treatment induced caspase-9 
activation around 6 hr, peaking around 18 hr, with slight differences between the two cell 
lines (P<0.05).  Caspase-3 activity began around 6 hr, and peaked around 18 hr without any 
difference between the two cell lines.  The value of each treatment group represents the mean 
± S.E.M. from two separate experiments performed in triplicate (*P<0.05;**P<0.01). 
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Figure 9. Phase-contrast and Hoechst 33342 staining of manganese treated PrPKO- and 
PrPC-cells. 
 
After Mn treatment, cells were incubated with Hoechst 33342 (10µg/ml) for 30 min.  
Following incubation with Hoechst 33342, cells were visualized and images were captured 
using a Nikon TE2000 microscope and SPOT digital camera. (A) Phase contrast images of 
untreated and treated cells for both PrPC-cells and PrPKO-cells. (B) Hoechst 33342 stained 
images showing chromatin condensation in cells, as indicated by arrows. 
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Figure 10. DNA fragmentation in PrPKO- and PrPC-cells.   
 
PrPC-cells and PrPKO-cells were treated with different doses of Mn with or without 100 µM 
Z-VAD-FMK (pan caspase inhibitor). (A) 30 µM Mn exposure increased DNA 
fragmentation, with PrPKO-cells showing a higher percentage of DNA fragmentation at 24 hr.  
(B) 100 µM Mn exposure increased DNA fragmentation to a greater extent; again, DNA 
fragmentation increased more significantly in PrPKO-cells than in PrPC-cells.  (C) Inhibitor 
studies with 100 µM Mn co-treated with 100 µM Z-VAD-FMK significantly inhibited Mn-
induced DNA fragmentation.  (D) Treatment with 100µM H2O2 for 24 hr resulted in 
significantly higher amounts of DNA fragmentation in PrPKO-cells as compared to PrPC-
cells.  Data represent mean ± S.E.M. from two separate experiments done in triplicate. 
**P<0.01,***P<0.001 comparing between cell lines and between treatments. 
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Abstract 
Prion disease is the result of an abnormal folding of the normal prion protein (PrPC); 
it has been suggested that metals other than copper may alter the normal processing of PrPC.  
This study examines the processing of PrPC following manganese treatment.  Using PrPC-
overexpressing mouse cell lines with an altered PrPC epitope (3F4), Western blot analysis 
showed an increase of PrPC in both cytosolic and membrane-rich fractions after treatment 
with manganese (100 µM).  This increase in PrPC levels relative to untreated cells was not 
due to increased mRNA transcription, as shown with quantitative RT-PCR.  Measurement of 
proteasomal activity revealed that there was no significant decrease in proteasome activity 
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after manganese treatment.  Interestingly, pulse-chase analysis showed that the PrPC turnover 
rate was significantly altered with manganese treatment.  Limited digestion with proteinase-
K revealed that manganese treatment decreased the proteinase-K sensitivity of PrPC.  
Additionally, cell-free lysate incubation with manganese did not alter the PK sensitivity of 
PrP.  These data together strongly suggest that manganese alters the turnover rate of fully 
processed PrPC through either indirect methods or in a manner requiring co-translational 
loading of manganese to PrPC, thereby resulting in altered PrPC biological half-life and 
protease sensitivity. 
 
Introduction 
Transmissible spongiform encephalopathies (TSEs), otherwise known as prion 
diseases, are fatal neurodegenerative diseases that affect various mammalian species (1-3).  
Unlike conventional infectious diseases, prion diseases are believed to be caused by an 
abnormally folded host encoded protein that accumulates in the central nervous system, and 
lymphoreticular system  (3-6).  Expression of the normal cellular form of the prion protein, 
termed PrPC, is ubiquitous in the host, whereas the abnormal form, often referred to as 
scrapie prion protein (PrPSc), is found to accumulate primarily in the aforementioned sites in 
affected animals (7-9).  These two forms of PrP are identical in amino acid sequence but 
differ in structural conformation.  PrPC is primarily α-helical, while PrPSc is primarily 
composed of β-sheets (10, 11).  The structural differences endow PrPC and PrPSc with 
different biochemical properties. PrPC is sensitive to protease digestion, and does not form 
into aggregates, while PrPSc is associated with increased resistance to proteinase-K digestion, 
ability to aggregate into fibrils, and the propensity to act as a template to further propagate 
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formation of PrPSc from PrPC (12, 13).  The exact mechanism of conversion is unclear, but it 
is clear that the presence of PrPC is crucial in the pathogenesis of prion diseases (14, 15). 
PrPC is a cell surface glycoprotein that is attached to the cell membrane via a 
glycosylphophatidyl-inositol anchor, and has been reported to be degraded through the 
ubiquitin proteasomal pathway (16, 17).  The C-terminal portion of the protein is highly 
structured with a disulfide bridge and two N-linked glycosylations (18, 19).  The N-terminus 
is relatively unstructured with high affinity metal binding sites at five octapeptide repeats 
(PHGGGWGQ) found between amino acid 50 and 91, and two additional sites at amino acid 
96 and 106 with strong affinity to divalent cations (20-25).  Copper in particular has been 
associated with the normal function of PrPC, and it has been suggested that replacement of 
copper with other divalent cations may contribute to the conversion of PrPC to PrPSc (26-31).   
Although there has been no documented case of PrPC spontaneously converting into 
PrPSc through the addition of divalent cations, recent studies suggest that it could facilitate a 
better conversion efficiency when PMCA (protein misfolding cyclic amplification) technique 
was used for in vitro conversion (32-34).  In addition, scrapie-infected brain samples 
exhibited alterations in brain metal content; lowered copper and increased manganese levels 
were observed (30).  In another study, it was shown that replacement of copper with 
manganese within the PrPC molecule resulted in proteinase-K resistant forms of PrP (26).  
Such studies offer the possibility that imbalance of metal ions might play a role in the 
pathogenesis of prion diseases.  In the present study, a mouse neural progenitor cell line 
expressing the mouse prion protein containing an epitope detected by a specific monoclonal 
antibody (3F4) was used to examine the effect of manganese on prion protein expression and 
stability. 
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MATERIALS AND METHODS 
 
Cell culture 
Mouse neural progenitor (MNP) cells expressing prion protein (PrPC), kindly provided by Dr. 
Suzette Priola at Rocky Mountain Laboratory (NIAIDS, Hamilton, MT) were cultured as 
described previously (35).  Cells at confluency were harvested into phosphate buffered saline 
(PBS) and resuspended in either homogenization buffer (20 mM Tris-HCl pH 8.0, 2 mM 
EDTA, 10 mM EGTA, 2 mM DTT, 1 mM PMSF, 25 µg/ml aprotinin, and 10 µg/ml 
leupeptin), or lysis buffer (0.5 % Triton X-100, 0.5 % sodium deoxycholate, 5 mM Tris-HCl, 
150 mM NaCl, 5 mM EDTA in PBS pH 7.4).  For preparation of soluble and insoluble cell 
fractions, low detergent lysis buffer (20 mM Tris/HCl, pH 8.0, 10 mM EGTA, 2 mM EDTA, 
2 mM dithiothreitol, 1 mM phenylmethysulfonyl fluoride, 25 µg/ml aprotinin, and 10 µg/ml 
leupeptin, 0.5 % Triton X-100), and insoluble lysis buffer (20 mM Tris/HCl, pH 8.0, 10 mM 
EGTA, 2 mM EDTA, 2 mM dithiothreitol, 1 mM phenylmethysulfonyl fluoride, 25 µg/ml 
aprotinin, and 10 µg/ml leupeptin, 0.5 % Triton X-100, 0.2 % SDS) were used.  Mouse 
neuroblastoma (N2a) cells were cultured as described previously (36).  N2a cells were treatd 
with varying concentrations of manganese (0, 100, 300, and 500 µM) and collected for 
analysis via Western blot analysis. 
 
Reagents and antibodies 
MnCl2, β-actin, and phenylmethylsulphonylfluoride (PMSF) were purchased from Sigma (St. 
Louis, MO); Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, 
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CA).  DMEM (Dulbecco’s modified eagle medium), fetal bovine serum, L-glutamine, 
penicillin, Trypsin/EDTA, and streptomycin were purchased from Invitrogen (Gaithersburg, 
MD); proteinase-K was purchased from Promega (Madison, WI); monoclonal mouse anti-
PrP (3F4) antibody recognizing sequences 109 through 112 in hamster and human PrP was 
purchased from Signet Labs (Berkeley, CA).  Monoclonal mouse anti-PrP (SAF32) antibody 
recognizing murine PrP was purchased from Cayman Chemicals (Ann Arbor, MI). 
 
SDS-PAGE and immunoblotting 
After harvest, MNP cells were lysed, homogenized, sonicated, and centrifuged as described 
previously (37, 38).  The supernatants were collected from cell lysates, and protein 
concentrations were determined and used for SDS-gel electrophoresis.   Cytoplasmic and 
membrane-rich fractions containing equal amounts of protein were loaded in each lane and 
separated on a 15% SDS-PAGE gel as described previously (37, 38).   
 
For determination of high molecular weight ubiquitinated proteins, low detergent soluble and 
insoluble fractions were separated according to a procedure described previously with slight 
modifications (39).  After exposure to manganese or MG-132 (non-specific proteasomal 
inhibitor) (Sigma, St. Louis, MO), MNP cells were collected and washed once with ice cold 
PBS.  The cell pellets were suspended in low detergent lysis buffer.  Lysates were 
ultracentrifuged at 100000 X g for 40 min., and the detergent soluble fraction was obtained 
by collecting the resulting supernatant.  The detergent insoluble pellets were washed once 
with lysis buffer and resuspended in insoluble lysis buffer, and sonicated for 20 s.  Equal 
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amounts of protein were loaded in 8% SDS-polyacrylamide gel as determined by the 
Bradford protein assay.   
 
Proteins were then transferred to a nitrocellulose membrane, and non-specific binding sites 
were blocked by treating with 5 % non-fat dry milk powder.  Membranes were then treated 
with primary antibody directed against the 3F4-epitope present in the PrPC protein (1:500 
dilution), or SAF-32 (1:1000) for N2a cells which was followed by treatment with secondary 
HRP-conjugated anti-mouse antibody.  For detection of ubiquitinated proteins, the 
membranes were probed with ubiquitin antibody (1:500; DAKO Cytomation, Carpinteria, 
CA) overnight at 4ºC, followed by secondary HRP-conjugated anti-rabbit antibody.  
Secondary antibody-bound proteins were detected using the ECL chemiluminescence kit 
(Amersham, Piscataway, NJ).  To confirm equal protein loading, blots were reprobed with a 
β-actin antibody (Sigma, St. Louis, MO) at a dilution of 1:5000.  Western blot images were 
captured with a Kodak 2000 MM imaging system. 
 
Confocal laser microscopy 
MNP cells were grown on coverslips precoated with poly-L-lysine, and treated with 
cadmium.  Cells were washed once with PBS, and fixed in 4 % paraformaldehyde.  After 
fixation, cells were washed three times with PBS, and incubated with blocking buffer (5 % 
bovine serum albumin, 5 % goat serum in PBS) to block nonspecific sites.  For prion primary 
antibody (3F4) binding, fixed cells were incubated in the same blocking buffer with 0.1 % 
Triton X-100.  Fluor-chrome conjugated secondary antibody incubation was performed in the 
blocking buffer.  Nucleus staining was performed with DRAQ5 (Alexis Biochemicals, San 
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Diego, CA) at 5 µM.  After final nucleus staining, fixed cells were washed with PBS and 
mounted onto a slide with Prolong (Invitrogen, Carlsbad, CA) anti-fade reagent mounting 
medium.  Confocal laser scanning was carried out using a Nikon C1 confocal microscope 
(Melville, NY). 
 
qPCR 
Total RNA was extracted by using Absolutely RNA Miniprep Kit (Stratagene, La Jolla, CA) 
following the manufacturer’s protocol.  First strand cDNA synthesis was performed with 
random hexamers as primers using a High Capacity cDNA Archive Kit (Applied Biosystems, 
University Park, IL) following the manufacturer’s protocol.  Primers used were: target gene - 
mouse PrP forward (FWD) 5’-CACGAGAATGCGAAGGAACA-3’, reverse (REV) 5’-
TTAGGAGAGCCAAGCAGA CT-3’; and internal control gene - mouse 18S rRNA FWD 
5’-TCAAGAACGAAAGTCGGAGGTT-3’, REV 5’-GGACATCTAAGGGCATCACAG-3’.  
QPCR was performed with a Mx3000P real-time PCR thermocycle (Stratagene, La Jolla, 
CA) using FullVelocity SYBR Green QPCR kit according the manufacturer’s protocol.  For 
actinomycin D treatment, cells were treated with actinomycin D (5µg/ml) for 3, 6, and 9 hr, 
and processed as described previously.  Amplification was performed in 40 cycles at 95 ºC 
for 10 s, and 60 ºC for 30 s, following initial denaturation at 95 ºC for 5 min.  The data were 
normalized by using ∆CT method (∆CT=CT target gene-CT internal control).   
 
Proteasomal peptidase activity assay   
The proteasome enzymatic assay was performed as described previously (39).  In brief, after 
manganese or control treatment, cells were collected, washed and lysed in hypotonic lysis 
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buffer (10 mM HEPES, 5 mM MgCl2, 10 mM KCl, 1 % sucrose, and 0.1 % CHAPS).  For 
determination of chymotrypsin-like activity, the lysates were then incubated with the 
fluorogenic substrate Suc-LLVY-AMC (Calbiochem, San Diego, CA) at 75 µM in assay 
buffer (50 mM Tris-HCl, 20 mM KCL, 5 mM magnesium acetate, and 10 mM dithiothreitol, 
pH 7.6) for 30 min at 37 ºC.  The cleaved fluorescent product was measured at an excitation 
wavelenth of 380 nm and emission wavelength of 460 nm using a fluorescent plate reader 
(Gemini XS, Molecular Devices, Sunnyvale, CA).  The enzymatic activity was normalized to 
the protein concentration as determined using a Bradford protein assay. 
 
Metabolic labeling and immunoprecipitation 
Approximately 75% confluent MNP cells were rinsed once with PBS, and deprived for 1 hr. 
in DMEM lacking cysteine and methionine.  Cells were labeled for 1 hr. by adding 300 
µCi/ml of [35S]-methionine (Amersham, Piscataway, NJ) to the medium.  After incubation, 
cells were rinsed twice with ice-cold PBS, and collected with a rubber policeman.  Lysis 
buffer was added to the cell pellet and lysed on ice for 30 min.  Samples were then incubated 
with 3F4 prion antibody overnight on a platform rocker at 4 ºC.  Protein A-Sepharose beads 
were added and placed on the platform rocker for an additional 2 hr. at 4 ºC.  
Immunoadsorbed proteins were washed twice in ice-cold lysis buffer, and analyzed by 15 % 
SDS-PAGE.  Gels were exposed to a Phosphor-film and captured with a Typhoon 8600 
Imager (Amersham, Piscataway, NJ).  Captured images were analyzed with ImageQuant 
software (Amersham, Piscataway, NJ).  The amount of total PrP present at each time point 
following the chase period (1, 3, 6, 12, and 24 hr.) was expressed as percentage of PrP 
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present at 1 hr. post chase time.  Half-life was calculated by fitting to a single exponential 
decay curve. 
 
Limited proteolysis of PrP 
Prion protein resistance to proteinase-K digestion was determined as previously described 
with slight modifications (36).  For in vitro manganese incubation, cells were either treated 
with 100 µM Mn or untreated.  After a 24 hr. incubation period, cells were collected and 
washed once with PBS.  Lysis buffer was added to the pellet and vortexed.  Clarified cell 
lysates were obtained by centrifugation at 16000 X g for 10 min. Proteinase-K was added to 
the cell lysates at a final concentration of 1 µg/ml and incubated at 37 ºC for selected time 
points.  To stop the digestion, PMSF was added to a final concentration of 4 mM, and sample 
loading buffer was added to the digested lysates prior to analysis by Western blot.  For cell-
free studies, cells at confluency were collected and lysed in the lysis buffer.  Following 
protein measurements using Bradford’s method, approximately 5 mg/ml of cell lysates were 
separated into manganese treatment and non-treated control.  For manganese treatment, 100 
µM Mn was added to the cell lysate, and incubated in 37 ºC for 1 hr. prior to limited 
proteolysis. 
 
Data analysis and statistics 
Data were analyzed with Prism 4.0 software (GraphPad Software, San Diego, CA).  
Bonferroni’s post-hoc multiple comparison testing was used to delineate significance 
between manganese-treated groups, and the control (untreated) samples.  Differences with 
P<0.05 were considered to be significant and are indicated with asterisks.  For densitometric 
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analysis of limited proteolysis, band intensity was normalized to control bands at 0 min, and 
one-phase exponential decay was fit to the data.   
 
RESULTS 
 
Manganese treatment upregulates prion protein expression 
Previously, we have shown that the EC50 of manganese was 100 µM in MNP cells (40).  This 
concentration was used for all experiments.  MNP cells treated with manganese showed a 
time-dependent increase in PrPC expression in both cytosolic and membrane fractions within 
12 hrs., decreasing after 24 hrs. post-treatment (Fig 1A).  Non-treated cells did not exhibit an 
increase in PrPC levels up to the 24 hr. time point.  Equivalent loading of proteins in each 
lane were confirmed with the β-actin housekeeping gene.  Immunocytochemical (ICC) 
methods coupled with confocal laser microscopy were utilized to confirm the increased PrPC 
expression after manganese treatment (Fig 1B).  Images captured with confocal laser 
microscopy indicated an altered morphology of the MNP cells following manganese 
treatment, and more PrPC immunoreactivity was present with manganese treatment as 
compared to non-treated control.  With the manganese treatment, the morphology of the cells 
have drastically changed, with a stronger immunoreactivity of PrP to be condensed closely to 
the nucleus as compared to the control. 
 
Increased PrPC level is not due to increased transcriptional rate or impaired ubiquitin 
proteasomal system (UPS) 
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To investigate the mechanism involved in the upregulation of PrPC levels following 
manganese treatment, PrP mRNA expression was evaluated by quantitative reverse 
transcriptase polymerase chain reaction.  No significant difference in the mRNA levels was 
found between manganese treated and non-treated cells (Fig 2A).  To confirm that increased 
PrPC levels were not due to differences in mRNA stability, cells were treated with 
actinomycin D before qRT-PCR was performed, however, we were only able to examine the 
PrP mRNA levels up to 12 hr. with actinomycin treatment since beyond 12 hr. it was too 
toxic to the cells.  Our data up to 12 hr. of actinomycin treatment indicates that no difference 
between manganese treated and non-treated samples existed (Fig 2B).  Since PrPC 
upregulation was not based on transcription levels, impairment of the cellular degradative 
system was examined.  An assay of chymotrypsin-like activity revealed that manganese 
treatment does not impair UPS over the course of 24 hr (Fig 2C).  To further verify that 
manganese does not impair the UPS, formation of high molecular weight ubiquitinated 
proteins was examined (Fig 2D).  As seen with soluble and insoluble fractions obtained at 
various time points, there was no significant formation of high molecular weight 
ubiquitinated proteins with manganese treatment.  MG-132, a non-specific inhibitor of UPS, 
was used as a positive control for assessing proteasome activity.  To further rule out 
possibilities of other cellular degradative systems, lysozyme activity in cell lysates was 
measured as well (Fig 2E); no significant difference between manganese-treated and non-
treated controls was indicated in this assay. 
 
Manganese delays the turnover of PrPC
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Since neither the PrPC transcription rate nor the UPS was altered after manganese treatment, 
its effect on PrPC metabolism was investigated.  The degradation rate of PrPC in the presence 
or absence of manganese was assessed via pulse-chase autoradiography.  A difference was 
observed, with PrPC present at later time points in manganese-treated cells (Fig 3A).  These 
results were also evaluated by densitometric analysis (Fig 3B).  The autoradiogram indicates 
that at the 24 hr. chase period, there was a significant difference in labeled PrPC between 
non-treated and manganese-treated samples.  Analysis indicated that in the absence of 
manganese, the half-life of PrPC was measured to be around 13 hrs., while in presence of 
manganese the half-life was increased to 21 hrs.  The results show that manganese 
significantly decreases the relative turnover rate of PrPC, resulting in higher levels of PrPC in 
the manganese-treated cells when compared to untreated controls. 
 
Manganese treatment in vitro results in decreased proteolytic susceptibility of PrPC  
The mechanism of reduced turnover of PrPC induced by manganese treatment was 
investigated using limited proteolysis of cell lysates by proteinase K (PK).  Proteinase K is a 
non-specific proteinase used regularly in the detection of infectious PrP (19, 20).   We 
utilized PK to examine the proteolytic susceptibility of PrPC in cell lysates that had been 
treated with manganese or left untreated as control (see Methods).  PrPC in cell lysates that 
had been treated with manganese consistently exhibited a lower susceptibility to PK 
digestion than PrPC in the untreated control (Fig 4A).  To confirm that the persistence of 
PrPC in the treated lysate was due to an alteration in PrPC susceptibility and not due to 
reduced activity of PK in the presence of manganese, the same samples were immunoblotted 
with β-actin primary antibody (Fig 4B).  No change in β-actin proteolytic susceptibility was 
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observed in the samples indicating that the intrinsic PK activity was not altered with 
manganese treatment (100 µM).  Data points from normalized densitometric analysis were fit 
to a single-phase exponential decay curve, and a kinetic rate profile was obtained (Table 1; 
Fig 4C).  The apparent half-life of PrPC in manganese treatment is greater than the apparent 
half-life of the untreated control, but the half-life of β-actin was not altered with manganese 
treatment.  This finding suggests that the reduced turnover of PrPC in cells with manganese 
treatment was due to altered susceptibility of the protein to proteolytic digestion. 
 
Cell-free system incubation with manganese does not alter the proteolytic susceptibility 
of PrPC
To examine whether a direct physical interaction with manganese results in decreased 
susceptibility to proteolytic digestion, cell lysates were prepared and incubated with 
manganese for 6hrs. prior to analysis by limited proteolysis.  As seen with Fig 5A, limited 
proteolysis following cell free manganese incubation did not result in decreased 
susceptibility of PrPC to proteolytic digestion as compared to control in our system.  To 
verify that the proteolytic capability of PK was not altered, the same samples were also 
probed with β-actin (Fig 5B).  Data points from normalized densitometric analysis were fit to 
a single-phase exponential decay and a kinetic rate profile was obtained (Table 2; Fig 5C). 
 
Manganese treatment also increases PrPC levels in N2a cells 
One study has suggested that divalent metal induced increase in PrPC content could be due to 
the effect of divalent metal on the vectors used to express PrPC in cell culture (41).  Since our 
cell culture model system utilizes a vector-driven expression of PrPC, we wanted to verify 
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that the effect of manganese on PrPC content was not due to vector-divalent metal interaction.  
N2a cells were treated with manganese at varying concentrations (0 ~ 500µM) for 24 hr. 
prior to analysis.  Interestingly, treatment with manganese resulted in significant increase in 
PrPC content in N2a cells (Fig 6).  This finding further validates our model system, and 
strongly indicates that in our system, the effect of manganese on PrPC content is not due to 
divalent metal interaction with the vector. 
 
CONCLUSION 
Many physiological and cellular changes occur during prion infections such as 
neuronal vacuolization, neuronal loss, gliosis, oxidative impairment, and metal imbalance (30, 
42-45).  Some of the most striking changes at the cellular levels after prion infection are the 
loss of antioxidant function and altered metal content, suggesting a role of metals in the 
pathogenesis of prion diseases (30, 42).   
Here we show that manganese treatment of cells induces an increase in PrPC levels.  It 
can be speculated that increased manganese exposure could lead to increased PrPC levels, 
thereby increasing the chance of interaction between PrPC and PrPSc, and increasing the rate 
of PrPSc conversion.  Studies have shown that multiple copies of the PrP gene can result in 
shortened incubation time from infection to disease onset (46-48).  Additionally, increased 
PrPC expression could also act as a nucleus for spontaneous conversion of PrPC into PrPSc.  It 
is interesting to note that the UPS was not impaired by the manganese treatment indicating 
that proteasomal dysfunction is not responsible for the PrPC upregulation observed in the 
present study.   
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Brown and colleagues have previously shown that primary rat astrocytes treated with 
manganese exhibit reduced proteolytic susceptibility, which they attribute to production of 
protease-resistant forms of PrP (26). Bocharova and colleagues, however, have shown that 
manganese has little if any direct effect on recombinant PrP protease resistance or secondary 
structure (49). Our results indicate that treatment with manganese results in increased 
stability of the protein reducing the proteolytic susceptibility; this in turn results in increased 
levels of PrPC.  This reduction in susceptibility requires manganese treatment of viable cell 
cultures based on the observation that manganese treatment of cell lysates does not alter 
proteolytic susceptibility of PrPC.  Thus, our results are consistent with both Brown and 
Bocharova.  This implicates two possible mechanisms by which metal ions may influence 
PrPC levels, and subsequently influence TSE disease progression and/or susceptibility.  In the 
first possible mechanism, manganese may interact with PrPC directly, but only be loaded on 
to the protein during translation or maturation.  Alternatively, manganese may influence the 
expression of a PrPC ligand, thus indirectly influencing PrPC stability and proteolytic 
susceptibility.   
In the current study, we have shown that MNP cells treated with manganese showed 
increased amounts of PrPC.  This increase in PrPC expression was not due to an increase in 
PrP transcription rate or to impairment of the UPS degradative pathway.  It was determined 
that the PrPC increase was to the result of a decreased protein turnover rate.  This decreased 
protein turnover rate does not arise from altered transcription rate or cellular degradative 
systems, rather from decreased protease susceptibility of PrPC from cells treated with 
manganese.  Furthermore, cell-free system incubation with manganese did not alter the 
proteolytic susceptibility of PrPC in our system.  And our studies with N2a cells further 
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substantiates the increase in PrPC content with manganese treatment Overall, our study 
indicates manganese as a factor that could indirectly interact with PrPC to stabilize the protein, 
resulting in decreased degradative susceptibility, leading to increased PrPC expression in cells 
receiving manganese treatment.  Suggesting that manganese interaction with PrPC could lead 
to insights into the functional role of PrPC, as well as to the possible pathogenesis of prion 
disease. 
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Table 1: Manganese treatment results in decreased proteolytic degradation rate of 
prion proteins in vitro 
 
 
 
 PrP  β-actin 
 Untreated Mn2+-treated  Untreated Mn2+-treated 
kobs 0.43 ± 0.3 0.09 ± 0.02  0.83 ± 0.1 0.78 ± 0.1 
Half-life (min) 1.65 ± 0.7 7.52 ± 1.2  0.84 ± 0.2 0.88 ± 0.2 
 
 
 
 
 
 
 
The data are the parameter of a best fit of a single-phase exponential (± S.D.) to data shown 
in Figure 4. 
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Table 2: Manganese treatment does not alter the proteolytic degradation rate of prion 
protein in cell-free system. 
 
 
 
 PrP  β-actin 
 Untreated Mn2+-treated  Untreated Mn2+- treated 
kobs 0.15 ± 0.09 0.16 ± 0.1  0.43 ± 0.14 0.47 ± 0.16 
Half-life (min) 4.5 ± 2.1 4.1 ± 2.5  1.6 ± 0.7 1.5 ± 0.8 
 
 
 
 
 
 
 
The data are the parameter of a best fit of a single-phase exponential (± S.D.) to data shown 
in Figure 5. 
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Fig 1. Increased PrPC expression in MNP cells following manganese treatment. A) Western 
blot analysis of PrPC at various time points with manganese treatment.  MNP cells 
were treated with manganese (100µM) for 0, 6, 12, 18, and 24 hr., and harvested.  
Cytosolic fraction and membrane-rich fractions were obtained, and analyzed by 
Western blotting.  B)  Immunocytochemical expression of PrP in MNP cells with and 
without manganese treatment.  PrPC staining is in green, and nucleus staining is in 
blue. 
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Fig 2.  Effect of manganese on mRNA levels and ubiquitin proteasomal system.  A) 
Comparison of PrP mRNA levels in manganese-treated and control cells.  MNP cells 
were treated with manganese for 24 h, and PrP mRNA levels were determined by 
quantitative PCR method.  B) Evaluation of PrP mRNA stability with manganese 
treatment.  MNP cells were treated with actinomycin D to inhibit transcription of 
mRNA, and PrP mRNA levels were determined at 3, 6, and 12 hr. timepoints.  C)  
Measurement of proteasomal activity with manganese treatment.  Chymotrypsin-like 
activity following manganese treatment was measured at 24 hr..  D) Evaluation of 
high molecular weight ubiquitinated protein formation with manganese treatment.  
MNP cells were treated with manganese for up to 24 hr.; cells were collected at 0, 6, 
12, 18, and 24 hr. and separated into soluble and insoluble fractions for Western blot 
analysis.  E)  Measurement of lysosomal activity with manganese treatment.  
Lysosomal activity was measured following manganese treatment at 24 hr. 
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Fig 3. Effect of manganese on turnover rate of PrPC.  A) Confluent MNP cells were 
metabolically labeled with 300 µCi/ml [35S]Met for 1 hr. at 37 ºC.  After the pulse, 
cells were incubated in cell culture medium without [35S]Met in the presence or 
absences of manganese at 37 ºC for the indicated chase time periods.  PrPC was 
immunoprecipitated with 3F4 antibody prior to SDS-PAGE and autoradiography.  B) 
Densitometric evaluation of autoradiogram.  PrPC collected 1 hr. after the radioactive 
pulse was set as 100 % PrPC population.  Decrease in protein amounts following the 
chase periods are expressed as a percentage of total protein plotted as a function of 
time.  The data points were fitted to an exponential curve using non-linear regression 
analysis.  Each data point represents the mean ± SEM for 3 replicates.   
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Fig 4. Manganese decreases PrPC susceptibility to proteinase-K digestion.  A)  Limited 
proteolysis of PrPC in presence or absence of manganese with PK.  MNP cells treated 
with manganese and lysates were prepared as described in the methods section.  
Samples were separated into equal fractions and treated with 1 µg/ml PK at 37 ºC.  
PK digestion was inhibited at indicated time periods with addition of 4 mM PMSF, 
and processed for Western blotting with 3F4 antibody.  Next to the Western blot 
analysis is the densitometric analysis of the quantified bands fit to a single-phase 
exponential decay.  B)  The same samples were analyzed with β-actin antibody; each 
data point represents mean ± SEM from experiments performed in triplicate and 
densitometric analysis fit was with single-phase exponential decay. 
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Fig 5.  Cell-free system incubation with manganese does not influence PrPC susceptibility to 
proteinase-K digestion.  A)  Following cell-free system incubation with 100 µM 
manganese for 1 hr. at 37 ºC, cell lysates were subjected to limited proteolysis with 1 
µg/ml PK at 37 ºC.  At the indicated time points, digestion was stopped with addition 
of PMSF (final concentration = 4 mM).  Samples were processed for Western blot 
analysis, band intensities were quantified, and bands were fit to a single-phase 
exponential decay.  B)  The same samples were analyzed with β-actin antibody; each 
data point represents mean ± SEM from experiments performed in triplicate and 
densitometric analysis was fit to a single-phase exponential decay. 
 
 
 
 
 
153 
 
Fig 6. N2a cells treated with manganese shows increase in PrPC content.  Western blot 
analysis of PrPC collected from N2a cells with varying concentration of manganese (0, 
100, 300, and 500 µM).  Equivalent loading was verified by reprobing with β-actin. 
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Abstract 
 Prion protein is a glycosylated copper-binding membrane protein with antioxidant 
capacity and other possible roles.  Using inductively coupled plasma-mass spectrometry 
(ICP-MS), we quantified intracellular levels of copper in PrPC and PrPKO neuronal cells, and 
found that PrPC cells contain higher basal copper content.  Although the cellular viability 
difference between PrPC and PrPKO was not significantly large, PrPC treated with copper 
showed higher amounts of GSH and higher SOD activity.  Determination of PrP levels 
following copper treatment showed slight increases in PrP levels in the cytosol that were not 
evident in surface PrP or PrP that was shed from the cells.  Interestingly, treatment with 
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copper significantly reduced the amount of PrP turnover relative to the untreated control.  
Additionally, treatment with copper decreased the susceptibility of PrP to proteolytic 
digestion with proteinase-K.  Cell-free incubation of cell lysates with copper also resulted in 
decreased susceptibility of PrP to proteolytic digestion.  Taken together, these findings 
support previous observations that PrP has antioxidant capacities and that copper interacts 
with PrP directly to alter the normal metabolism of PrP, most likely by altering the normal 
susceptibility to proteolytic degradation.   
 
Introduction 
 Transmissible spongiform encephalopathies (TSEs), otherwise known as prion 
diseases, are a class of fatal neurodegenerative disorders that afflict various mammals (1-3).  
Steps leading to initiation or progression of the disease remain to be solved, yet it is very 
clear that an endogenous host protein termed prion protein (PrP) is required (4, 5).  PrP is a 
normal endogenous protein expressed in most tissues, and accumulation of the disease-
associated form (PrPSc) is detected in the central nervous system and in the lymphoreticular 
system (6-8).  Recently, PrPSc has been isolated in muscle, but it is not clear if the source 
may be contamination of samples with peripheral nerves (9-12).   
PrP is a glycophosphatidyl-inositol-anchored protein (13, 14), and the normally 
processed mature protein is ~213 amino acids in length with two N-linked glycans (15).  
NMR structures have been determined for PrP from various host species, and these studies 
demonstrate that the C-terminal region is well structured, while the N-terminus is less 
structured (16, 17).  The normal cellular form of the protein (PrPC) has the same amino acid 
sequence as PrPSc, however, their structural and physical characteristics differ significantly 
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(18, 19).  PrPC contains a high proportion of α-helices, is readily digested with proteinase-K 
(PK), and is usually monomeric in nature (20, 21).  However, PrPSc may exist as multimers, 
readily forms fibrils, and contains a higher proportion of β-sheets, which tend to be highly 
resistant to PK digestion (20, 22).  
 Although the function of the protein is still debated, the capacity to bind to divalent 
metal cations in the octapeptide repeat region and two other histidine sites is widely accepted 
(23-26).  More specifically, copper has been described to bind to PrP with a greater affinity 
compared to other divalent cations, with various effects (27).  The copper-PrP interaction has 
been shown to increase antioxidant capacities by increasing the activity of superoxide 
dismutase-like ability of the copper-bound PrP (28-30).  Several reports also indicate that 
copper induces rapid endocytosis of PrP from the surface and increases the amount of PrP 
shed from the cells (31-33).   
Naturally, such causal interrelationship between copper and PrP would indicate the 
potential role of copper in the pathobiology of TSEs.  In our current work we provide further 
evidence that shows the interaction between copper and PrP results in increased antioxidant 
status.  We show that the increased antioxidant status is only found in our PrP-expressing cell 
line.  In addition, copper treatment increased intracellular PrP levels, which is most likely 
due to the stabilization of PrP as evidenced by delayed degradation of PrP and altered 
susceptibility to PK digestion.  These findings could aid in elucidating the importance of and 
the mechanism in the role of divalent cations in the pathogenesis of the prion disease. 
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Methods 
Chemicals and reagents  
CuCl2, monochlorobimane, β-actin, and phenylmethylsulphonylfluoride (PMSF) were 
purchased from Sigma (St. Louis, MO); Bradford protein assay kit was purchased from Bio-
Rad Laboratories (Hercules, CA).  DMEM, fetal bovine serum, L-glutamine, penicillin, 
Trypsin/EDTA, and streptomycin were purchased from Invitrogen (Gaithersburg, MD); 
Proteinase-K was purchased from Promega  (Madison, WI).  Monoclonal mouse anti-PrP 
(3F4) antibody recognizing sequences 109 through 112 in hamster and human PrP was 
purchased from Signet Labs (Berkeley, CA).   
 
Cell culture   
Mouse neuronal cells expressing prion protein and prion protein knock-outs were 
kindly provided by Suzette Priola (Rocky Mountain Laboratories, NIAIDS, Hamilton, MT), 
and cultured as described previously (34).  The cell line expressing PrP is referred to as the 
PrPC cells; cells expressing vector alone are referred to as PrPKO cells.  Both cells were grown 
in DMEM with 5 % fetal bovine serum supplemented with 2 mM L-glutamine, 50 units of 
penicillin, and 50 µg/ml streptomycin in humidified air of 5 % CO2 at 37 ºC. 
 
Cytotoxicity assays   
To examine cell death, cells were grown on 6-well plates at a density of 5 x 105 cm-2 
and treated with CuCl2 in a range of concentrations from 10 µM to 10 mM for 24 hr.  Cell 
death was determined by the trypan blue exclusion method with an Improved Nebauer-type 
Hemacytometer.  The cell viability was normalized as percent of the control. 
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Glutathione assay   
Methods were adapted from the ApoAlert® Glutathione Detection Kit (Clontech, 
Palo Alto, CA) to measure intracellular glutathione (GSH).  After manganese treatment, the 
cell lysates were prepared according to the manufacturer’s protocol included with the kit.  
The cell lysates were centrifuged at 132,000 x g for 10 minutes.  The resulting supernatant 
was collected and incubated with 1 mM monochlorobimane (glutathione-binding dye) for 20 
minutes at 37 ºC.  Formation of the monochlorobimane dye binding with glutathione was 
measured using a fluorescence plate reader (excitation 395 nm, emission 480 nm, Molecular 
Devices Corporation, Gemini XS Plate Reader).  Results were calculated by normalizing the 
fluorescence signals from the samples to the amount of protein.  Protein concentration was 
measured using the Bradford protein assay as described previously (35). 
 
ICP-MS 
Inductively coupled plasma mass spectrometry (ICP-MS) was used to determine 
intracellular copper concentration.  The ICP-MS device was a high-resolution double 
focusing instrument operated in medium resolution (m/∆m = 4,000) in order to resolve 63Cu 
and 65Cu from any potential interferences (36).  Both Cu isotopes were measured to verify 
that there were no significant unresolved interferences, but only the most abundant isotope, 
63Cu, was used to calculate the concentration of Cu in each sample.  The cells were prepared 
by trypsinization, and after washing twice with phosphate buffered solution (PBS), the 
number of cells was counted.  Samples containing an equal number of cells were 
resuspended in 1 % nitric acid and spiked with gallium.  69Ga+ was chosen as an internal 
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standard because its m/z ratio is similar to that of the elements of interest, and it has no major 
spectroscopic interferences.    A 10 µl aliquot of a 10 ppm Ga standard was added to each of 
the samples.  A multi-element standard was prepared using 10 µl aliquots of 10 ppm standard 
solutions of Cu and Ga in 1 ml 1 % nitric acid.  All solutions were prepared with Milli-Q 
18.2 MΩ water. The nitric acid blank, the multi-element standard, and each of the samples 
were introduced into the ICP-MS via a 100 µl/min self-aspirating PFA nebulizer (Elemental 
Scientific, Inc., Omaha, NE).  Between samples the nitric acid blank was used to rinse the 
nebulizer.   The results for each sample are calculated using the integrated average 
background-subtracted peak intensities from 20 consecutive scans.  In order to correct for 
elemental sensitivity in the ICP, the multi-element standard was used to derive a 
normalization factor for Cu.  Protein concentration was used to normalize the concentration 
of Cu calculated for each sample. 
 
Superoxide dismutase assay  
SOD activity was measured using Superoxide Dismutase Kit (Cayman Chemicals, 
Ann Arbor, MI).  Briefly, the cells were treated with copper, and samples were prepared 
according to instructions.  Samples were then incubated with tetrazolium salt, xanthine 
oxidase, and hypoxanthine.  Standards provided with the kit were used to calculate the SOD 
activity in the samples.  Reaction rates of the samples were calculated as per instructions and 
normalized to protein concentrations derived from the Bradford protein assay. 
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qtPCR 
Total RNA was extracted by using Absolutely RNA Miniprep Kit (Stratagene, La 
Jolla, CA) following the manufacturer’s protocol.  First strand cDNA synthesis was 
performed with random hexamers as primers using High Capacity cDNA Archive Kit 
(Applied Biosystems, University Park, Il) following the manufacturer’s protocol.  Primers 
used were: target gene – PrP forward (FWD) 5’-CACGAGAATGCGAAGGAACA-3’, 
reverse (REV) 5’-TTAGGAGAGCCAAGCAGA CT-3’; and internal control gene - mouse 
18S rRNA FWD 5’-TCAAGAACGAAAGTCGGAGGTT-3’, REV 5’-
GGACATCTAAGGGCATCACAG-3’.  QPCR was performed with Mx3000P real-time 
PCR thermocycler (Stratagene, La Jolla, CA) using FullVeloctiy SYBR Green QPCR kit, 
according the manufacturer’s protocol.  For actinomycin-D treatment, cells were treated with  
5 µg/ml actinomycin-D for 3, 6, and 9 hr., and processed as described previously.  
Amplification following initial denaturation at 95 ºC for 5min was performed in 40 cycles, at 
95 ºC for 10 s, and  60 ºC for 30 s.  The data were normalized by using ∆CT method 
( ∆CT=CT target gene-CT internal control).   
 
Proteasomal peptidase activity assay   
The proteasome enzymatic assay was performed as described previously (37).  In 
brief, after copper or control treatment, cells were collected, washed and lysed in hypotonic 
buffer (10 mM HEPES, 5 mM MgCl2, 10 mM KCl, 1 % sucrose, and 0.1 % CHAPS).  For 
determination of chymotrypsin-like activity, the lysates were then incubated with 75 µM of 
the fluorogenic substrate (Suc-LLVY-AMC; Calbiochem, San Diego, CA) in assay buffer 
(50 mM Tris-HCl, 20 mM KCL, 5 mM magnesium acetate, and 10 mM dithiothreitol, pH 
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7.6) at 37 ºC for 30 min.  The cleaved fluorescent product was measured at an excitation 
wavelenth of 380 nm and emission wavelength of 460 nm using a fluorescent plate reader 
(Gemini XS, Molecular Devices, Sunnyvale, CA).  The enzymatic activity was normalized to 
the protein concentration as determined using a Bradford protein assay. 
 
Sample preparation for SDS-PAGE and immunoblotting 
After harvesting the cells with a rubber policeman, cells were lysed, and centrifuged 
as described previously (35, 38).  The supernatants were collected as cell lysates, and protein 
concentrations were determined and used for Western blotting.  Extracellular media were 
collected at the indicated time points and concentrated using a Millipore Amicon 
Ultracentrifuge concentrator (Billerica, MA).  Surface isolation of PrP was performed using 
Pinpoint™ Cell Surface Protein Isolation Kit from Pierce (Rockford, IL).   Cytoplasmic 
fractions containing equal amounts of protein were loaded in each lane and separated on a 
15 % SDS-PAGE gel as described previously (35, 38).  Proteins were then transferred to 
nitrocellulose membranes, and non-specific binding sites were blocked by treating with 5 % 
non-fat dry milk powder.  The membranes were then treated with primary antibody directed 
against the 3F4-epitope present in the PrPC protein (1:500 dilution) and subsequently treated 
with secondary HRP-conjugated anti-rabbit antibody.  Secondary antibody-bound proteins 
were detected using Amersham’s ECL chemiluminescence kit (Piscataway, NJ)  To confirm 
equal protein loading, blots were reprobed with a β-actin antibody (1:5000 dilution).  
Western blot images were captured with Kodak 2000 MM imaging system (New Haven, CT).  
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Metabolic labeling and immunoprecipitation 
Approximately 75 % confluent PrPC cells were rinsed once with PBS and starved in 
DMEM lacking cysteine and methionine.  Cells were labeled for 1hr. by adding 300 µCi/ml 
of [35S] Methionine (Amersham, Piscataway, NJ) to the medium.  Cells were then treated 
with copper and chased for 1, 6, 12, 24, 48, and 72 hr.  After incubation, cells were rinsed 
twice with ice-cold PBS and collected.  Lysis buffer was added to each cell pellet, and lysed 
on ice for 30 min.  Samples were then incubated with 3F4 prion antibody overnight on a 
platform rocker at 4 ºC.  Protein A-Sepharose beads were added to the samples, which were 
placed on the platform rocker for an additional 2 hr. at 4ºC.  Immunoadsorbed proteins were 
washed twice in ice-cold lysis buffer and analyzed by 15% SDS-PAGE.  Gels were exposed 
to a phosphor film and imaged with Typhoon 8600 (Amersham, Piscataway, NJ).  Captured 
images were analyzed with ImageQuant (Amersham, Piscataway, NJ).  The amount of total 
PrP present at each time point following the chase period was expressed as percentage of PrP 
present at 1hr post-chase time.  Half-life was derived from a best-fit single-phase exponential 
decay curve. 
 
Limited proteolysis of PrP 
Prion protein resistance to proteinase-K digestion was determined as previously 
described with slight modifications (39).  Briefly, cells were collected and washed once with 
PBS.  Lysis buffer (15 0mM NaCl, 50 mM Tris HCl, 5 mM EDTA, 1 % Triton X-100, 1 % 
sodium deoxycholate) was added to the pellet and vortexed.  Clarified cell lysates were 
obtained by centrifugation at 16,000 X g for 10 min.  To the clarified cell lysates, 1 µg of 
proteinase-K was added, and incubated for the indicated time points at 37 ºC.  To stop the 
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digestion, PMSF was added to a final concentration of 2 mM, and equal volumes of 2X 
sample loading buffer was added to the samples.  Samples were boiled for 5 min prior to 
analysis with Western blot.  For cell-free limited proteolysis with copper, cells were grown to 
confluency, and harvested using a rubber policeman.  Cells were lysed with EDTA-free lysis 
buffer (150 mM NaCl, 50 mM Tris HCl, 1 % Triton X-100, 1 % sodium deoxycholate), and 
total amount of protein was measured using the Bradford protein assay.  Equal amount of 
protein was separated into control and copper treatment.  For treatment, 100 µM copper was 
added, and both samples were incubated at 37 ºC for 1 hr.  Following incubation, both lysates 
were subjected to proteoytic digestion as described earlier in this section.   
 
Data and statistical analysis 
Data were analyzed with Prism 4.0 software (GraphPad Software, San Diego, CA).  
Student’s T-test was used to delineate significance between the copper-treated group and the 
control (untreated) sample.  Any differences with P<0.05 were considered to be significant.  
For determination of half-life values, a single-phase exponential decay curve was fit onto the 
values. 
 
 
Results 
PrPC expression protects against copper-induced cell death. 
PrPKO and PrPC expressing cells were exposed to various copper concentrations 
ranging from 0 to 10,000 µM for 24 hr., and the extent of cell death was determined by the 
trypan blue exclusion method.  Figure 1A shows a dose-dependent increase in cytotoxic cell 
death with increasing copper concentration.  The cell viability curve shows that PrPKO cells 
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were more sensitive to copper toxicity as compared to PrPC cells, with EC50s of 186 µM and 
245 µM respectively.  Also, to further characterize the difference between PrPC and PrPKO 
cells, basal copper content in the two cell lines was assessed.  Measurement of basal 
intracellular levels showed that PrPC cells contained higher amounts of intracellular copper 
than PrPKO cells, 23.9 ± 5.2 versus 7.3 ± 2.9 ng/mg protein, respectively (Table 1).  This is 
consistent with other research that has shown that expression of PrP results in higher amounts 
of basal copper levels in both cells and in animal brains.   
To examine the antioxidant status in these cell lines, intracellular glutathione levels 
were examined following exposure to copper at various concentrations ranging from 0 to 
1,000 µM for 24 hr. (Fig 1B).  Interestingly, treatment with a low concentration of copper 
(30µM) induced an increase in intracellular glutathione levels for PrPC cells, followed by 
lower intracellular glutathione levels with higher concentrations of copper.  However, this 
increase in intracellular glutathione levels was not observed in PrPKO cells.  Instead, the 
PrPKO cells exhibited a dose-dependent decrease in glutathione levels.  Next, the activity of 
superoxide dismutase (SOD) was measured in both PrPC and PrPKO cells with and without 
copper treatment (Fig 1C).  Measurement of SOD activity revealed that only PrPC cells 
benefited from the presence of copper and exhibited a significant increase in SOD activity as 
compared to PrPKO cells; PrPKO cells did not show a significant change following copper 
treatment.  These results support previous findings by other researchers that PrPC bound to 
copper exhibits antioxidant-like activity.  Correspondingly, an increase in SOD activity 
following copper treatment of PrPC cells would explain the observed increase in intracellular 
glutathione levels. 
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Effect of copper on PrP expression in PrPC cells 
 Others have reported that treatment with copper can influence the expression level 
and cause shedding of PrP from the cell surface in cell culture models.  To examine this 
phenomenon, cells were treated with copper over a period of 24 hr., and expression of PrP 
levels was examined.  In the cytosolic fraction, there was a visible increase in PrP levels 
following 12 and 24 hr. of treatment (Fig 2A).  Equal loading of protein was verified by 
reprobing with β-actin.  The extracellular media was collected and concentrated at the 
indicated time points and probed for PrP.  Interestingly, the blot did not show any difference 
in the amount of PrP that was shed from PrPC cells following copper treatment compared to 
control cells (Fig 2B).  We obtained similar results when examining the effect of copper 
treatment on surface expression of PrP levels (Fig 2C).  Copper treatment did not increase the 
overall surface expression level of PrP compared to control cells without copper treatment. 
 
Copper treatment does not result in transcriptional increase or decrease in proteasomal 
activity 
To investigate the mechanism involved in the upregulation of PrP levels following 
copper  treatment, PrP mRNA expression was evaluated by quantitative reverse transcriptase 
polymerase chain reaction.  Our results indicated no significant difference in the mRNA 
levels between copper-treated and non-treated cells (Fig 3A).  Since PrP upregulation was 
not based on transcription levels, the effect of impairment of the cellular degradative system 
was examined.  An assay of chymotrypsin-like activity revealed that copper treatment does 
not impair UPS over the course of 24 hr (Fig 3B).   
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Mechanism of copper effects on PrP half-life in vitro 
The mechanism of the copper effect on PrP half-life in copper-treated cells was 
investigated using pulse-chase and limited proteolysis.  Degradation of PrP was examined by 
monitoring metabolically labeled PrP in the presence and absence of copper.  As seen with 
Fig 4, copper treatment altered the degradation of PrP compared to control.  In control cells, 
degradation of PrP was observed starting at 24hr., and traces of radio-labeled PrP are barely 
seen after 48hr.  However, in the copper-treated samples, traces of radio-labeled PrP could be 
seen even at 72hr.  These findings strongly suggest that copper reduces the degradation of 
PrP.   
Next, we examined the susceptibility of PrP to digestion with lysate by proteinase-K 
(PK) in the presence and absence of copper.  We utilized PK to examine the proteolytic 
susceptibility of PrP in cell lysates that had been treated with copper or left untreated as a 
control as previously described (see Methods).  PrP in cell lysates that had been treated with 
copper persisted longer than PrP in the untreated control (Fig 5A & 5C).  To verify that the 
PK activity was not altered due to presence of copper, the same samples were probed with β-
actin (Fig 5B & 5C).  Data points from normalized densitometric analysis were fit to a 
single-phase exponential decay curve and a kinetic rate profile was obtained (Table 2 & Fig 
5C).  The half-life of PrP was significantly increased in in vitro Cu incubation, but the half-
life of β-actin was not altered with Cu incubation.  This finding may suggest that the reduced 
turnover of PrP in cells with Cu incubation was due to altered susceptibility of the protein to 
proteolytic digestion. 
 To further verify that copper binding to PrP alters the proteolytic susceptibility, cell 
lysates were prepared, and incubated with copper for 1 hr.  Following cell-free incubation, 
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lysates were subjected to proteolytic digestion with PK as described previously.  Surprisingly, 
even cell-free incubation with copper resulted in altered proteolytic susceptibility of PrP (Fig 
6A & 6C).  PrP persisted longer with copper treatment, as compared to untreated lysates.  
The same samples were immunoblotted with β-actin to verify that the PK activity was not 
altered (Fig 6B & 6C).  As seen in Fig 6C, PK activity was not altered with cell-free lysate 
incubation with copper.  Data points from normalized densitometric analysis were fit to a 
single-phase exponential decay curve and a kinetic rate profile was obtained (Table 3 & Fig 
6C).  This strongly suggests that cell-free lysate incubation with copper results in copper 
binding with PrP to stabilize the protein, thereby resulting in decreased susceptibility of PrP 
to PK digestion. 
 
Discussion 
There is a strong body of evidence that PrPC interacts with copper by functioning as a 
modulatory protein or as a transport protein (30, 40-43).  Studies have implicated PrPC as an 
antioxidant protein, having SOD-like activity in neuronal cells (24, 28).  The increased 
oxidative stress found in both neuronal cells and in brains of PrP knock-out mice further 
support the role of PrP as an antioxidant (29, 44).  Others have also associated the increased 
copper content in both cells and brain with PrP expression (40, 45-48).  In the context of 
these results, we show that expression of PrPC results in increased basal copper levels, as 
well as an increase in anti-oxidant status of cells following copper treatment.  However, 
closer examination of copper’s effect on PrP expression yields more interesting insight into 
the role of copper in PrP metabolism and structural changes. 
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Studies have shown that treatment with copper causes a rapid endocytosis of PrP 
from the surface into early endosomes (32, 49, 50).  In our present work, we did not observe 
any significant difference in the amount of surface PrP following copper treatment, nor did 
we observe any significant amount of PrP that was shed from the cells with the treatment.  
However, we demonstrate that copper treatment causes an increase in cytosolic PrP levels, 
most likely due to a significant reduction in the turnover rate of PrPC.   
This phenomenon could be explained through the limited digestion studies with PK; 
more specifically, copper-treated PrPc was less susceptible to PK digestion.  This relative 
increase in protease resistance does not necessarily imply a major conformational change 
associated with the conversion of PrPC to PrPSc.  Rather, binding of copper to the octapeptide 
repeat region, as is believed to occur, would likely result in a stabilization of the relatively 
dynamic structure seen in that region (51).  Additionally, the preferential binding of copper to 
the native state would simply result in an increase in the global stability of the protein.  Our 
data with ex vivo incubation with copper supports the increased global stability of the protein 
upon physical binding.  These findings are in line with Bacharova and colleagues, who 
demonstrated that copper-bound recombinant PrP resulted in the stabilization of PrP (52).  It 
is worth noting that the structuring of the N-terminus or increased global stability may not be 
specific to copper, since studies have shown that other divalent cations may bind to PrP as 
well (53-56).  Other work has suggested that the presence of copper could inhibit the activity 
of PK, thereby leading researchers to false conclusions (57).  In light of this information, our 
experiment clearly used a substantially lower concentration of copper, and we also verified 
the relative PK activity between copper and untreated samples by examining the proteolytic 
susceptibility of β-actin. 
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Changes in the structure and the digestion rate of the PrP following binding with 
copper may have some implications in the pathogenesis of the prion disease.  Studies have 
shown that removal of copper from PrPSc enabled rapid digestion of PrPSc with PK, and 
addition of copper reinstated the normal PK resistance (58).  Such modulatory properties of 
copper on PrP strongly suggest an important role of copper in both the physiology and the 
pathogenesis of prion disease.  Another study using yeast PrP has shown that PrP in the 
presence of copper and manganese becomes PK-resistant, a hallmark of PrPSc formation (59).  
However, their conclusion appears to be hastily made; rather than the protein susceptibility 
being greatly altered, our results indicate that the susceptibility of these proteins were only 
slightly altered, thereby resulting in PrP that requires more time to be fully digested. 
In summary, our work confirms previous findings that expression of PrP is associated 
with increased antioxidant status.  Unlike other studies, we did not observe a significant 
decrease in surface PrP or increased shedding of the protein.  However, we did observe 
copper modulation of the metabolism of PrP and the susceptibility of PrP to PK digestion, 
most likely via physical binding of copper to PrP.  Taken together, these results indicate that 
copper-bound PrP shows altered susceptibility to PK digestion, which strengthens the 
hypothesis of the intrinsic interaction of copper with PrP. 
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Table 1.  Comparison of intracellular concentration of copper in PrPC and PrPKo cells.   
 
Basal intracellular copper levels (ng/mg 
protein) 
PrPC cells PrPKO cells 
23.9 ± 5.2 7.3 ± 2.9 
 
Basal levels of copper were normalized to the protein concentration for each of the samples 
(n=4).
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Table 2.  Copper treatment results in decreased proteolytic digestion rate of prion 
protein in vitro 
 
 Untreated control Copper treatment 
 PrP 
kobs 0.39 ± 0.11 0.13 ± 0.03 
Apparent 
Half-life 1.75 min 5.43 min 
 
 β-actin 
kobs 0.16 ± 0.06 0.15 ± 0.04 
Apparent 
Half-life 4.3 min 4.6 min 
 
The data are the parameter of a best fit of a single-phase exponential curve fit (± S.D.) to data 
shown in Figure 4.
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Table 3. Cell-free lysates incubated with copper show altered proteolytic digestion rate 
of prion protein.   
 
 Untreated control Copper treatment 
 PrP 
kobs 0.04 ± 0.01 0.02 ± 0.02 
Apparent 
Half-life 16.7 min 31.5  min 
 
 β-actin 
kobs 0.09 ± 0.03 0.09 ± 0.03 
Apparent 
Half-life 7.9 min 7.7 min 
 
The data are the parameter of a best fit of a single-phase exponential curve fit (± S.D.) to data 
shown in Figure 5. 
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Figure 1.  Effect of copper on PrPC and PrPKO cells.  (A)  Dose-dependent copper-induced 
cell death.  Cells were treated with 0-10 mM CuCl2 for 24hr. and cell viability was 
calculated using the Trypan blue exclusion method.  (B)  Intracellular glutathione 
levels of PrPC and PrPKO cells were measured following 0-1 mM CuCl2 treatment for 
24hr.  (C)  Superoxide dismutase activity in PrPC and PrPKO cells was compared 
following 30 µM of CuCl2 treatment.   All experiments were performed twice in 
triplicate.  ***p<0.001, **p<0.01. 
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Figure 2.  Western blot analysis of PrP expression.  (A)  PrPC cells were treated with 100 µM 
CuCl2 for 0, 6, 12, and 24 hr. and analyzed for levels of cytosolic PrP.  (B)   Media 
was collected at indicated time points from CuCl2-treated PrPC cells and untreated 
PrPC cells to examine levels of PrP that was shed from the cells.  (C)  Surface levels 
of PrP were examined between untreated PrPC cells and PrPC cells treated with 100 
µM CuCl2. Not significant (ns) 
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Fig 3.  Effect of copper on mRNA levels, and ubiquitin proteasomal system.  A) Comparison 
of PrP mRNA levels between copper-treated and control cells.  Cells were treated 
with copper for 24 h, and PrP mRNA levels were determined by quantitative PCR 
method.  B)  Determination of proteasomal activity with manganese treatment.  
Chymotrypsin-like activity following copper treatment was measured at 24 hr.  
Observed differences are within the error of the measurement  
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Figure 4.  Effect of copper on turnover rate of PrP.  (A) Pulse-chase autoradiograph of PrP 
immunoprecipitated from confluent PrP cells metabolically labeled and treated as 
described in the methods.  (B)  Densitometric evaluation of autoradiogram.  PrP 
collected 1 hr. after the radioactive pulse was set as 100 % PrP population.  Decrease 
in protein amounts following the chase periods are expressed as percentage of total 
protein plotted as a function of time.  The data points were fit to an exponential curve 
using non-linear regression analysis.  Each data point represent the mean ± S.E.M. for 
experiments performed in 3 replicates.  
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Figure 5. In vitro copper treatment reduced PrP susceptibility to proteinase-K digestion.  (A)  
Western blot analysis of limited proteolysis of PrP in presence or absence of 100µM 
copper. (B)  Limited proteolysis of β-actin analyzed by western blot in the presence 
or absence of 100 µM copper.  (C) Kinetic rate profiles of the limited proteolysis of 
PrP and β-actin.  Each data point represents the mean ± S.E.M. of the normalized 
band intensity determined by densitometric analysis performed in triplicate.  The 
curve through the data points represents the best-fit to a single exponential decay. 
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Figure 6. Cell-free system incubation with copper influences PrP susceptibility to proteinase-
K digestion.  (A)  Western blot analysis of limited proteolysis of PrP in presence or 
absence of 100µM copper. (B)  Limited proteolysis of β-actin analyzed by western 
blot in the presence and absence of 100 µM copper.  (C) Kinetic rate profiles of the 
limited proteolysis of PrP and β-actin.  Each data point represents the mean ± S.E.M. 
of the normalized band intensity determined by densitometric analysis performed in 
triplicate.  The curve through the data points represents the best-fit to a single 
exponential decay. 
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Abstract 
The role of normal cellular prion protein remains to be fully elucidated; however, it is 
certain that the protein is crucial in the infection and progression of prion disease.  Recently, 
speculations concerning the role of manganese in the formation of abnormal forms of the 
prion protein have been raised.  In our present study, proteasomal activity of manganese and 
another divalent cation, cadmium, was compared in mouse neuronal cells expressing prion 
protein with altered epitope (3F4).  Interestingly, manganese did not show any inhibition of 
proteasomal activity.  Corresponding to the lack of proteasomal inhibition, formation of high 
molecular weight ubiquitinated proteins was not observed with manganese treatment.  
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However, treatment with cadmium significantly inhibited proteasomal activity, which 
resulted in greatly increased formation of high molecular weight ubiquitinated proteins.  
Immunohistochemical analysis also revealed a dramatic increase in the formation of 
oligomers after cadmium treatment, which leads to ubiquitinated PrP, but did not lead to 
formation of PK-resistant PrP.  The results show that proteasomal inhibition occurs with 
cadmium, which subsequently ubiquitinates prion proteins.  The findings suggest a possible 
mechanism in which proteasomal inhibition in neuronal cells could lead to increased amounts 
of ubiquitinated PrP, thereby increasing the chance of non-infectious PrP to interact with 
infectious PrP. 
 
 
Introduction 
 Transmissible spongiform encephalopathies (TSE) of humans, as well as other 
animals are caused by a conformational change of normal prion protein (PrPC) into abnormal 
prion protein (PrPSc) (Prusiner 1982b; Bolton et al. 1984; Prusiner 1984).  PrPSc has a 
tendency to aggregate into fibrils, is highly resistant to digestion by proteinase-K (PK), and 
carries an infectious element (Prusiner 1982a, b; Prusiner et al. 1982; McKinley et al. 1983; 
Roberts et al. 1988; Somerville and Ritchie 1990).  The exact mechanism of conformational 
change remains to be determined, but theoretical models of template-assisted change and 
seed-based changes have been proposed (Zhang et al. 1995; Cohen and Prusiner 1998; 
Brown 2002).  The normal form of PrPC is expressed ubiquitously in the central nervous 
system, the peripheral nervous system, and to a certain extent in the immune system as well 
(Brown et al. 1999; Jeffrey et al. 2000; Prinz et al. 2003; Mohan et al. 2004).  Although the 
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exact function of these proteins remains elusive, they are required in the infection and 
propagation of TSEs (Prusiner et al. 1993; Raeber et al. 1997).  Studies have shown altered 
metal content in the brain of animals infected with TSE, which supports the hypothesis that 
the cause of TSEs could be due to metal imbalances in the brain (Wong et al. 2001c; 
Thackray et al. 2002; Choi et al. 2006). 
 The normal form of the protein is predominantly α-helical in structure and is attached 
to the surface of the cells via a glycosyl phosphatidyl inositol (GPI) anchor (Prusiner 1988; 
Carlson et al. 1989; Haraguchi et al. 1989; Stahl et al. 1992).  The C-terminal regions are 
highly structured, with two N-linked glycosylations (Stahl et al. 1993; Donne et al. 1997; Gill 
et al. 2000).  The N-terminal is rather unstructured, with four octapeptide repeat regions 
(PHGGGWGQ), and His 96 and 106 that have high binding affinity to divalent cations 
(Hornshaw et al. 1995a; Donne et al. 1997; Jackson et al. 2001).  In particular, copper has 
been found to directly interact with these sites, and cause a rapid turnover of PrPC, strongly 
pointing to the role of PrPC in copper metabolism (Miura et al. 1996; Brown et al. 1997; 
Prince and Gunson 1998; Stockel et al. 1998; Brown 2004; Haigh et al. 2005).  Other 
divalent cations have been associated with the same sites as well, but found to have weaker 
affinity (Stockel et al. 1998; Jackson et al. 2001; Gaggelli et al. 2005; Choi et al. 2006).  
Manganese has been suggested to replace copper in the octapeptide repeat region of the PrPC 
and alter the structure of the protein (Brown et al. 2000; Wong et al. 2001b).   
 One possible mechanism of PrPSc propagation could be due to the impairment of the 
proteasomal degradation system (Tenzer et al. 2004).  PrPC is normally degraded by the 
proteasomal system, and when this system is inhibited, abnormal forms could accumulate in 
the cells (Yedidia et al. 2001).  Alternatively, replacement of copper by different divalent 
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cations could alter protein stability, thereby causing accumulation in the cytosol (Di Natale et 
al. 2005; Stanczak et al. 2005).  In either case, we were interested in whether PrPC cells 
treated with manganese could potentially inhibit proteasomal activity, leading to 
accumulation of undegraded PrPC.  Interestingly, manganese did not impair proteasomal 
activity, nor caused accumulation of PrPC in our study.  However, cadmium induced 
impairment in proteasomal activity, increased formation of ubiquitinated PrP and oligomers, 
but inhibition of proteasomal activity did not lead to formation of PK-resistant forms of PrPC. 
 
Materials and Methods 
 
Chemicals and reagents 
CdCl2, β-actin, and phenylmethylsulphonylfluoride (PMSF) were purchased from 
Sigma (St. Louis, MO); Bradford protein assay kit was purchased from Bio-Rad Laboratories 
(Hercules, CA).  DMEM (Dulbecco’s modified eagle medium), fetal bovine serum, L-
glutamine, penicillin, Trypsin/EDTA, and streptomycin were purchased from Invitrogen 
(Gaithersburg, MD); proteinase-K was purchased from Promega  (Madison, WI).  
Monoclonal mouse anti-PrP (3F4) antibody recognizing sequences 109 through 112 in 
hamster and human PrP was purchased from Signet Labs (Berkeley, CA).   
 
In vitro cell culture model 
Mouse neural progenitor cells expressing prion protein (PrPC) were cultured and 
transfected as described previously (Chesebro et al. 1993; Takemura et al. 2006).  Cells at 
confluency were harvested into phosphate buffered saline (PBS) and resuspended in either 
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homogenization buffer (20 mM Tris-HCl pH 8.0, 2 mM EDTA, 10 mM EGTA, 2 mM DTT, 
1 mM PMSF, 25 µg/ml aprotinin, and 10 µg/ml leupeptin) and sonicated, or lysed in lysis 
buffer (0.5 % Triton X-100, 0.5 % sodium deoxycholate, 5 mM Tris-HCl, 150 mM NaCl, 5 
mM EDTA in PBS pH 7.4).  For preparation of soluble and insoluble cell fractions, low 
detergent lysis buffer (20 mM Tris/HCl, pH 8.0, 10 mM EGTA, 2 mM EDTA, 2 mM 
dithiothreitol, 1 mM phenylmethysulfonyl fluoride, 25 µg/ml aprotinin, and 10 µg/ml 
leupeptin, 0.5% Triton X-100) was used to collect the soluble fraction by centrifugation, and 
insoluble lysis buffer (20 mM Tris/HCl, pH 8.0, 10 mM EGTA, 2 mM EDTA, 2 mM 
dithiothreitol, 1 mM phenylmethysulfonyl fluoride, 25 µg/ml aprotinin, and 10 µg/ml 
leupeptin, 0.5% Triton X-100, 2% SDS) was used to resuspend the pellet to obtain the 
insoluble fraction. 
 
Measurement of cell viability 
Cell death was determined using the Trypan Blue exclusion method.  The cells were 
grown in 6-well plates, and then treated with 0 to 100µM cadmium for 24 h.  For time-
dependent cell death, cells were treated with cadmium for 24 and 48 h.  Afterwards, the cells 
were removed using Trypsin/EDTA, and rinsed once with PBS before resuspending samples 
in PBS.  These cells were counted using a hemocytometer.  The calculation of live cells was 
as follows: number of live cells divided by total number of live cells in untreated control.   
 
Proteasomal peptidase activity assay   
The proteasome enzymatic assay was performed as described previously (Sun et al. 
2005).  In brief, after treatment, cells were collected, washed and lysed in hypotonic buffer 
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(10 mM HEPES, 5 mM MgCl2, 10 mM KCl, 1 % sucrose, and 0.1 % CHAPS).  The lysates 
were then incubated in assay buffer (50 mM Tris-HCl, 20 mM KCL, 5 mM magnesium 
acetate, and 10 mM dithiothreitol, pH 7.6) at 37ºC for 30 min with fluorogenic substrates for 
Chymotrypsin-like activity (75 µM Suc-LLVY-AMC, Calbiochem, San Diego CA), and 
Peptidyl-Glutamyl-Peptidase Hydroxylase (PGPH)-like activity (75 µM Z-LLE-AMC, 
Calbiochem, San Diego, CA).  The cleaved fluorescent product was measured at excitation 
wavelength of 380 nm and emission wavelength of 460 nm using a fluorescent plate reader 
(Gemini XS, Molecular Devices, Sunnyvale, CA).  The enzymatic activity was normalized to 
the protein concentrations determined using Bradford protein assay. 
 
Western blot analysis  
Low detergent soluble and insoluble fractions were separated according to procedures 
described previously with slight modifications (Sun et al. 2005).  After exposure to cadmium, 
manganese, or MG-132, cells were collected and washed once with ice cold PBS.  The cell 
pellets were suspended in low detergent lysis buffer.  The lysates were ultracentrifuged at 105 
x g for 40 min.  The detergent soluble fraction was obtained by collecting the resulting 
supernatant.  The detergent insoluble pellets were washed once with lysis buffer, resuspended 
in insoluble lysis buffer, and sonicated for 20 s.  Equal amounts of protein were loaded in 
8 % SDS-polyacrylamide gel as determined by Bradford protein assay.  Proteins were 
transferred to nitrocellulose membranes and blocked with 5 % nonfat dry milk in Tris 
buffered solution with 1% Tween-20 (TBST).  The membranes were probed with ubiquitin 
antibody (1:500; DAKO Cytomation, Carpenteria, CA) overnight at 4 ºC.  Next, samples 
were incubated with horseradish peroxidase (HRP)-conjugated secondary anti-rabbit or anti-
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mouse IgG (1:2000 dilution; Amersham, Piscataway, NJ) for 1 h prior to detection using 
ECL kit (Amersham, Pscataway, NJ).  Images were captured with Kodak 2000 MM imaging 
system (New Haven, CT).  The same membrane was reprobed with anti-mouse β-actin 
(1:5000 dilution).   
 
Immunofluorescence staining 
Immunofluorescence staining was performed as described previously (Kaul et al. 
2005).  Mouse neuronal cells were grown on coverslips pre-coated with poly-L-lysine, and 
treated with cadmium.  Cells were washed once with PBS, and fixed in 4 % 
paraformaldehyde.  After fixation, slides were washed three times with PBS, and incubated 
with blocking buffer (5 % bovine serum albumin, 5 % goat serum in PBS) to block 
nonspecific sites.  For oligomer (A11, Biosource International, Camarillo, CA) and prion 
(3F4, Signet Laboratories, Dedham, MA) primary antibody binding, fixed cells were 
incubated in the same blocking buffer with 0.1 % Triton X-100.  Following primary antibody 
incubation, slides were washed thoroughly with PBS and fluorochrome-conjugated 
secondary antibody incubation was performed in the blocking buffer.  Nucleic stain was 
applied with Hoechst 33342 at a concentration of 10µg/ml.  After final nucleic staining, the 
fixed cells were washed with PBS and mounted onto a slide with ProLong® antifade reagent 
mounting medium (Invitrogen, Carlsbad, CA).  The images were captured by fluorescent 
microscopy (Nikon TE2000) using SPOT digital camera. 
 
Limited proteolysis of PrP 
196 
Prion protein resistance to proteinase-K digestion was determined as previously 
described with slight modifications (Priola et al. 1994).  For in vitro incubation, cells were 
either treated with 10 µM cadmium or untreated.  After a 48 h incubation period, cells were 
collected and washed once with PBS.  Lysis buffer was added to the pellet and vortexed.  
Clarified cell lysates were obtained by centrifugation at 16,000 x g for 10 min. Proteinase-K 
was added to the cell lysates at a final concentration of 1 µg/ml and incubated at 37 ºC for 
selected time points.  To stop the digestion, PMSF was added to a final concentration of 4 
mM, and sample loading buffer was added to the digested lysates prior to analysis by 
Western blot. 
 
Dot blot analysis 
Formation of protein oligomers was determined by dot-blot measurements using anti-
rabbit A11 antibody, which recognizes oligomers of proteins independent of amino acid 
sequences.  Dot-blot analysis using this antibody has been used for identification of protein 
oligomers in various models of neurodegenerative disorders (Sun et al. 2005).  The procedure 
for the dot-blot assay was followed as described by the manufacturer.  Briefly, cadmium-
treated cells were collected after 24 and 48 h, and suspended in homogenization buffer.  
After protein concentrations were determined with the Bradford assay, 10 µg of cell lysates 
were spotted on the nitrocellulose membrane and allowed to air dry for at least 30 min.  
Membranes were then blocked with 5 % nonfat dry milk in TBST for 1 h, followed by 3 
washing steps (15 min each).  Then, the membranes were incubated with A11 anti-oligomer 
antibody (dilution 1:2000) for 1 h at RT, and washed 3 times (15 min each).  Afterwards, the 
membrane was treated with HRP-conjugated secondary anti-rabbit IgG for 1 h.  Antibody-
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bound proteins were detected with an ECL detection kit, and densitometric analysis of the 
dots representing the oligomeric protein aggregates was performed with Kodak’s one-
dimensional image analysis software (New Haven, CT).  For detection of oligomer formation 
in nuclear and cytoplasmic fractions, a NE-PER Nuclear and Cytoplasmic Extraction 
Reagents Kit (Pierce, Rockford, Il) was used for sample preparation prior to dot blot analysis. 
 
Immunoprecipitation assay 
An immunoprecipitation study was conducted to examine the association between 
PrP and ubiquitin protein as previously described, with some modifications (Kaul et al. 2005).  
Briefly, cytosolic protein (400 µg) was immunoprecipitated overnight at 4ºC using 10 µg of 
anti-ubiquitin antibody.  The immunoprecipitates were then incubated with protein A 
Sepharose (Sigma, St. Louis, MO) for 1 h at 4º C.  The protein A-bound antigen-antibody 
complex was then washed three times with homogenization buffer, and resuspended in 2X 
loading buffer.  Samples were boiled for 5 min, and then centrifuged prior to analysis by 
Western blot. 
 
Data analysis and statistics 
Data were analyzed with Prism 4.0 software (GraphPad Software, San Diego, CA).  
Bonferroni’s post-hoc multiple comparison testing was used to delineate significance 
between cadmium-treated groups, the control (untreated), and the manganese-treated samples.  
For densitometric analysis of limited proteolysis, band intensity was normalized to control 
bands at 0 min, and a single-phase exponential decay curve was fit to the data.  Differences 
greater than P<0.05 were considered to be significant and are indicated with asterisks. 
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Results 
 
Cadmium is neurotoxic in mouse neuronal cells 
Although cadmium is not normally considered to be a neurotoxicant, the divalent 
cation was used to examine cellular changes in mouse neuronal cells in the present study. 
Cadmium caused both dose- and time-dependent cell death in mouse neuronal cells, as 
measured by Trypan blue exclusion method (Fig 1 A&B).  Effective concentration was 
determined by treating cells with 0-100 µM CdCl2 for 24 h.  The effective concentration 
(EC50 11.99 µM) was then used for time-dependent studies.  Treatment with 10 µM CdCl2 
resulted in a significant decrease (p<0.01) in cell viability for both 24 and 48 h treatments.  
Phase-contrast images clearly show altered cellular morphologies after cadmium treatment 
(Fig 1 C).  Longer treatment with cadmium (48 h) resulted in very low cell viability.  To 
verify the clumps of cells as apoptotic cells, live cell staining with Sytox® green nucleic dye 
showed higher number of Sytox-positive cells with treatment, indicating prolonged treatment 
with cadmium resulted in high amount of cellular apoptosis. 
 
Cadmium impairs proteasomal activity in mouse neuronal cells 
Since PrP has been shown to have affinity to divalent cations, enzymatic activity of 
the 20S/26S proteasome was examined following manganese and cadmium treatment after 
24 and 48 h (Fig 2A).  Fluorogenic substrates for peptidyl glutamyl peptide hydrolase-like 
activity (PGPH), and chymotrypsin-like activity were used to evaluate the proteasome 
activity.  With cadmium treatment, a significant decrease (p<0.001) was observed with both 
PGPH- and chymotrypsin-like activity at 24 and 48 h.  Interestingly, treatment with 30µM 
199 
MnCl2 did not result in inhibition of proteasome activity in any of the substrates (Fig 2B).  As 
a positive control for the substrates, MG-132 (non-specific proteasome inhibitor) was used 
(Fig 2C).  Treatment with 5 µM MG-132 for 2 h resulted in significant decrease (p<0.001) in 
both substrates.  This shows that cadmium is effective in inhibiting proteasomal activity in 
mouse neuronal cells; however manganese was not as effective as cadmium in inhibiting 
proteasome activity.   
 
Impaired proteasomal activity by cadmium results in accumulation of high molecular 
weight ubiquitinated proteins  
Most proteins are tagged with ubiquitin prior to degradation by proteasomes, and 
impaired proteasomal activity can lead to accumulation of high molecular weight 
ubiquitinated proteins.  This is due to the reduced clearance of ubiquitinated proteins by the 
proteasome.  Impairment of proteasome activity resulted in the accumulation of high 
molecular weight ubiquitinated proteins in both soluble and insoluble fractions after 
cadmium treatment (Fig 3).  As compared to the control (no treatment), both 24 and 48 h 
treatment with cadmium resulted in a significant increase in ubiqutinated proteins (second 
and third lanes, respectively) in both soluble and insoluble fractions.  Although a visible 
difference in the insoluble fractions between 24 and 48 h cadmium treatment was not 
observed, increase in ubiquitinated proteins for the 48 h cadmium treatment was clearly seen 
as compared to the 24 h cadmium treatment in the soluble fraction.  Treatment with MG-132 
treatment also resulted in a slight increase in ubiquitinated proteins in both soluble and 
insoluble fractions (fourth lane).  Equal protein loading was confirmed with β-actin.   
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Cadmium induces formation of oligomers, but not proteinase-K-resistant prion proteins 
Many neurodegenerative disorders are associated with accumulation of misfolded 
proteins.  The recent development of A11 anti-oligomer antibody, which recognizes amino 
acid sequence-independent oligomers of proteins, has enabled for the determination of 
protein oligomers in neurodegenerative models.  To further verify protein aggregation 
induced by cadmium, cells were treated with cadmium for 24 and 48 h, and stained (Fig 4).  
Without treatment, oligomers were not detected; however with cadmium treatment, increased 
fluorescence for oligomers was observed.  From the data the greater amount of oligomers 
seems to correspond to the duration of treatment.  For quantitative analysis, the amount of 
oligomer formation was detected using a dot blot technique (Fig 5A).  The dot intensity 
shows that with cadmium treatment, increased intensity was seen at both 24 and 48 h, 10 % 
and 50 % increases in oligomer formation were observed, respectively.  Representative dot 
blot images of control, cadmium treatment for 24 h, and 48 h are included in the figure.  To 
verify the cellular location of oligomer formation, nuclear and cytoplasmic fractions were 
obtained from the samples for analysis by dot blot (Fig 5B & Fig 5C).  As seen with the 
quantification of dot blot intensity, there was no observable difference in the nuclear fraction 
of control or cadmium-treated samples.  However, analysis of cytoplasmic fraction indicates 
a clear significant difference in the amount of oligomers that are detected in the cytoplasm 
with cadmium treatment.   
To examine whether the altered expressional levels resulted in prion protein with 
altered susceptibility to proteinase-K, cell lysates were subjected to limited proteolysis (Fig 
6).  Cadmium treatment did not result in formation of prion proteins that were resistant to 
proteinase-K digestion.  As shown in Fig 6A, limited proteolysis following cadmium 
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treatment did not result in altered susceptibility of PrPC to proteolytic digestion compared to 
control.  To verify that the proteolytic capability of PK was not altered, the same samples 
were also probed with β-actin (Fig 6B).  Data points from normalized densitometric analysis 
were fit to a single-phase exponential decay curve and a kinetic rate profile was obtained 
(Table 1).  Together, these data show that cadmium treatment results in increased formation 
of oligomers, but formation prion proteins that are resistant to PK digestion was not observed. 
 
Cadmium increases formation of ubiquitinated prion proteins 
Studies have shown that the prion protein is degraded via the ubiquitin degradation 
pathway (Ma and Lindquist 2001).  It is logical that impairment of the proteasome would 
lead to accumulation of ubiquitinated proteins, which could also include prion proteins.  To 
verify that the prion protein was ubiquitinated in cadmium treatment, cell lysates were 
immunoprecipated with ubiquitin antibody, and analyzed by Western blot (Fig 7A).  
Immunoprecipitated prion protein was detected using prion protein antibody (3F4).  As 
shown in the Western blot analysis, the amount of ubiquitinated prion protein was 
significantly increased following cadmium treatment for 48 h with all three glycosylated 
forms of prion protein (Fig 7B).  Cadmium treatment for 24 h treatment did not significantly 
alter the amount of ubiquitinated prion protein for any of the glycosylated forms.   
 
Discussion 
 Significant evidence points to role of ubiquitinated proteins in many neurological 
diseases, and prion disease is no exception (Ciechanover and Brundin 2003; Mayer 2003; 
Kang et al. 2004; Ross and Poirier 2004).  PrPC has been shown to be degraded by the 
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ubiquitin-mediated proteasome pathway (Yedidia et al. 2001; Tenzer et al. 2004), and 
protease-resistant PrP, or PrPSc, has also been shown to be ubiquitinated to be degraded 
through the proteasome pathway (Kang et al. 2004).  In brains of infected animals, increased 
ubiquitin immunoreactivity has been observed (Kang et al. 2004; Kristiansen et al. 2005).  
Since endogenous prion protein is degraded via cellular degradative processes, it is possible 
that impairment to the proteosomal system could contribute to the initiation and/or 
progression of the disease (Cohen and Taraboulos 2003).   
PrP has been implicated to have metal binding sites that have an affinity for divalent 
cations in normal cellular function (Hornshaw et al. 1995b; Wong et al. 2001a; Choi et al. 
2006).  There has been speculation that replacement of copper by other divalent cations could 
potentially alter the structure of the PrP, thereby contributing to the formation of PrPSc 
(Quaglio et al. 2001; Nishina et al. 2004; Wong et al. 2004).  To date, there has been only 
one study that demonstrated rat astrocytes incubated with manganese for prolonged periods 
caused formation of PK-resistant forms of PrP in mammalian cell system (Brown et al. 2000).  
Other folding studies have suggested that PrP could adopt a secondary structure more closely 
resembling PrPSc in the presence of manganese, pointing to the possible role of other metals 
replacing copper (Tsenkova et al. 2004; Treiber et al. 2006; Tsiroulnikov et al. 2006).  Based 
on these findings, we wanted to examine whether inhibition of the ubiquitin proteasomal 
system by divalent cations could lead to increased accumulation of abnormal PrP.   
In our in vitro cell culture model, we observed that manganese did not impair the 
proteasomal activity.  Cadmium, however, significantly impaired proteasomal activity.  The 
cadmium-induced impairment in proteasomal function led to increased formation of 
insoluble and soluble ubiquitinated proteins.  Increased formation of oligomers was also 
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observed; however, increase in formation of PK-resistant PrP did not occur with cadmium 
treatment.  These results suggest several possibilities.  One possibility is that replacement of 
copper with a different divalent cation could alter the conformation of PrP, targeting it for 
degradation; increased rate of targeted proteins could impair the proteasome function, 
thereby increasing the possibility of excessive abnormal PrP to exist in the cytosol.  Another 
possibility is that PrPSc may naturally exist in homeostasis with PrPC, and lack of PrPSc found 
in normal organisms could be due to the high degradation rate associated with PrPSc.  It is 
possible if the degradative system was impaired by inhibition of proteasomal activity, 
accumulation of abnormal PrP could lead to an infectious state.   
Speculations have risen as to whether proteasome inhibition could lead to prion 
disease (Ma and Lindquist 2001; Mishra et al. 2003; Kristiansen et al. 2005; Hetz et al. 2007).  
Treatment with a non-specific proteasome inhibitor (MG-132) has shown to induce 
formation of insoluble PrP in N2a cells (Fioriti et al. 2005), however these formations were 
not toxic to the cells.  Although accumulation of PrP in the cytosol was observed, the authors 
argued that perturbations of the PrP metabolism through the proteasome pathway are not 
likely to be the source of pathogenic PrPSc.  However, it is possible that chronic impairment 
of the proteasome function and accumulation of insoluble PrP could potentially lead to 
development of the pathogenic form.  We have observed that treatment with cadmium 
resulted in accumulation of high molecular weight ubiquitinated proteins in both soluble and 
insoluble fractions.  Although both 24 and 48 h treatment with cadmium resulted in increased 
formation of high molecular weight ubiquitinated proteins, immunoprecipitation studies 
revealed that PrP was significantly ubiquitinated only after 48 h treatment.   
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Together, our results suggest that certain metals could impair the proteasomal 
function in neural cells, leading to increased ubiquitination of proteins and cell death.  
Although it is not clear whether this impairment was directly due to cadmium binding with 
PrP or impairment of other cellular processes, the accumulation of ubiquitinated PrP was 
clearly present in longer incubation periods (48 h). These findings suggest the possibility of 
altered metal homeostasis in the brain leading to various neurological disorders through the 
proteasome system. 
 
 
Acknowledgements 
The project described was supported by Grant Number W81XWH-05-1-0239 from National 
Institute of Health, United States Department of Defense, United State Army Medical 
Research and Materiel Command through Vanderbilt University, and its contents are solely 
the responsibility of the authors and do not necessarily represent the official views of the 
National Institutes of Health, United States Department of Defense, United State Army 
Medical Research and Materiel Command and Vanderbilt University.  This work was also in 
part supported by the NIH grant ES38644.  Mouse prion neural cell line was kindly provided 
by Sue Prioloa, NIH-Rocky Mountain Lab.  We would also like to thank Mr. Mostafa 
Zamanian for his assistance with proteasomal assay and cell culture work, and Ms. Keri 
Henderson for her assistance in the preparation of this manuscript.   W. Eugene and Linda 
Lloyd Endowed Professorship to AGK is also acknowledged. 
205 
References 
Bolton D. C., McKinley M. P. and Prusiner S. B. (1984) Molecular characteristics of the 
major scrapie prion protein. Biochemistry 23, 5898-5906. 
Brown D. R. (2002) Mayhem of the multiple mechanisms: modelling neurodegeneration in 
prion disease. J Neurochem 82, 209-215. 
Brown D. R. (2004) Role of the prion protein in copper turnover in astrocytes. Neurobiol Dis 
15, 534-543. 
Brown D. R., Hafiz F., Glasssmith L. L., Wong B. S., Jones I. M., Clive C. and Haswell S. J. 
(2000) Consequences of manganese replacement of copper for prion protein function and 
proteinase resistance. Embo J 19, 1180-1186. 
Brown D. R., Qin K., Herms J. W., Madlung A., Manson J., Strome R., Fraser P. E., Kruck 
T., von Bohlen A., Schulz-Schaeffer W., Giese A., Westaway D. and Kretzschmar H. (1997) 
The cellular prion protein binds copper in vivo. Nature 390, 684-687. 
Brown K. L., Stewart K., Ritchie D. L., Mabbott N. A., Williams A., Fraser H., Morrison W. 
I. and Bruce M. E. (1999) Scrapie replication in lymphoid tissues depends on prion protein-
expressing follicular dendritic cells. Nat Med 5, 1308-1312. 
Carlson G. A., Westaway D., DeArmond S. J., Peterson-Torchia M. and Prusiner S. B. 
(1989) Primary structure of prion protein may modify scrapie isolate properties. Proc Natl 
Acad Sci U S A 86, 7475-7479. 
Chesebro B., Wehrly K., Caughey B., Nishio J., Ernst D. and Race R. (1993) Foreign PrP 
expression and scrapie infection in tissue culture cell lines. Dev Biol Stand 80, 131-140. 
206 
Choi C. J., Kanthasamy A., Anantharam V. and Kanthasamy A. G. (2006) Interaction of 
metals with prion protein: possible role of divalent cations in the pathogenesis of prion 
diseases. Neurotoxicology 27, 777-787. 
Ciechanover A. and Brundin P. (2003) The ubiquitin proteasome system in 
neurodegenerative diseases: sometimes the chicken, sometimes the egg. Neuron 40, 427-446. 
Cohen E. and Taraboulos A. (2003) Scrapie-like prion protein accumulates in aggresomes of 
cyclosporin A-treated cells. Embo J 22, 404-417. 
Cohen F. E. and Prusiner S. B. (1998) Pathologic conformations of prion proteins. Annu Rev 
Biochem 67, 793-819. 
Di Natale G., Grasso G., Impellizzeri G., La Mendola D., Micera G., Mihala N., Nagy Z., 
Osz K., Pappalardo G., Rigo V., Rizzarelli E., Sanna D. and Sovago I. (2005) Copper(II) 
interaction with unstructured prion domain outside the octarepeat region: speciation, stability, 
and binding details of copper(II) complexes with PrP106-126 peptides. Inorg Chem 44, 
7214-7225. 
Donne D. G., Viles J. H., Groth D., Mehlhorn I., James T. L., Cohen F. E., Prusiner S. B., 
Wright P. E. and Dyson H. J. (1997) Structure of the recombinant full-length hamster prion 
protein PrP(29-231): the N terminus is highly flexible. Proc Natl Acad Sci U S A 94, 13452-
13457. 
Fioriti L., Dossena S., Stewart L. R., Stewart R. S., Harris D. A., Forloni G. and Chiesa R. 
(2005) Cytosolic prion protein (PrP) is not toxic in N2a cells and primary neurons expressing 
pathogenic PrP mutations. J Biol Chem 280, 11320-11328. 
Gaggelli E., Bernardi F., Molteni E., Pogni R., Valensin D., Valensin G., Remelli M., 
Luczkowski M. and Kozlowski H. (2005) Interaction of the human prion PrP(106-126) 
207 
sequence with copper(II), manganese(II), and zinc(II): NMR and EPR studies. J Am Chem 
Soc 127, 996-1006. 
Gill A. C., Ritchie M. A., Hunt L. G., Steane S. E., Davies K. G., Bocking S. P., Rhie A. G., 
Bennett A. D. and Hope J. (2000) Post-translational hydroxylation at the N-terminus of the 
prion protein reveals presence of PPII structure in vivo. Embo J 19, 5324-5331. 
Haigh C. L., Edwards K. and Brown D. R. (2005) Copper binding is the governing 
determinant of prion protein turnover. Mol Cell Neurosci 30, 186-196. 
Haraguchi T., Fisher S., Olofsson S., Endo T., Groth D., Tarentino A., Borchelt D. R., 
Teplow D., Hood L., Burlingame A. and et al. (1989) Asparagine-linked glycosylation of the 
scrapie and cellular prion proteins. Arch Biochem Biophys 274, 1-13. 
Hetz C., Castilla J. and Soto C. (2007) Perturbation of endoplasmic reticulum homeostasis 
facilitates prion replication. J Biol Chem. 
Hornshaw M. P., McDermott J. R. and Candy J. M. (1995a) Copper binding to the N-
terminal tandem repeat regions of mammalian and avian prion protein. Biochem Biophys Res 
Commun 207, 621-629. 
Hornshaw M. P., McDermott J. R., Candy J. M. and Lakey J. H. (1995b) Copper binding to 
the N-terminal tandem repeat region of mammalian and avian prion protein: structural studies 
using synthetic peptides. Biochem Biophys Res Commun 214, 993-999. 
Jackson G. S., Murray I., Hosszu L. L., Gibbs N., Waltho J. P., Clarke A. R. and Collinge J. 
(2001) Location and properties of metal-binding sites on the human prion protein. Proc Natl 
Acad Sci U S A 98, 8531-8535. 
208 
Jeffrey M., McGovern G., Martin S., Goodsir C. M. and Brown K. L. (2000) Cellular and 
sub-cellular localisation of PrP in the lymphoreticular system of mice and sheep. Arch Virol 
Suppl, 23-38. 
Kang S. C., Brown D. R., Whiteman M., Li R., Pan T., Perry G., Wisniewski T., Sy M. S. 
and Wong B. S. (2004) Prion protein is ubiquitinated after developing protease resistance in 
the brains of scrapie-infected mice. J Pathol 203, 603-608. 
Kaul S., Anantharam V., Kanthasamy A. and Kanthasamy A. G. (2005) Wild-type alpha-
synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic 
neuronal cells against MPP+-induced apoptotic cell death. Brain Res Mol Brain Res 139, 
137-152. 
Kristiansen M., Messenger M. J., Klohn P. C., Brandner S., Wadsworth J. D., Collinge J. and 
Tabrizi S. J. (2005) Disease-related prion protein forms aggresomes in neuronal cells leading 
to caspase activation and apoptosis. J Biol Chem 280, 38851-38861. 
Ma J. and Lindquist S. (2001) Wild-type PrP and a mutant associated with prion disease are 
subject to retrograde transport and proteasome degradation. Proc Natl Acad Sci U S A 98, 
14955-14960. 
Mayer R. J. (2003) From neurodegeneration to neurohomeostasis: the role of ubiquitin. Drug 
News Perspect 16, 103-108. 
McKinley M. P., Bolton D. C. and Prusiner S. B. (1983) A protease-resistant protein is a 
structural component of the scrapie prion. Cell 35, 57-62. 
Mishra R. S., Bose S., Gu Y., Li R. and Singh N. (2003) Aggresome formation by mutant 
prion proteins: the unfolding role of proteasomes in familial prion disorders. J Alzheimers 
Dis 5, 15-23. 
209 
Miura T., Hori-i A. and Takeuchi H. (1996) Metal-dependent alpha-helix formation 
promoted by the glycine-rich octapeptide region of prion protein. FEBS Lett 396, 248-252. 
Mohan J., Brown K. L., Farquhar C. F., Bruce M. E. and Mabbott N. A. (2004) Scrapie 
transmission following exposure through the skin is dependent on follicular dendritic cells in 
lymphoid tissues. J Dermatol Sci 35, 101-111. 
Nishina K., Jenks S. and Supattapone S. (2004) Ionic strength and transition metals control 
PrPSc protease resistance and conversion-inducing activity. J Biol Chem 279, 40788-40794. 
Prince R. C. and Gunson D. E. (1998) Prions are copper-binding proteins. Trends Biochem 
Sci 23, 197-198. 
Prinz M., Heikenwalder M., Junt T., Schwarz P., Glatzel M., Heppner F. L., Fu Y. X., Lipp 
M. and Aguzzi A. (2003) Positioning of follicular dendritic cells within the spleen controls 
prion neuroinvasion. Nature 425, 957-962. 
Priola S. A., Caughey B., Raymond G. J. and Chesebro B. (1994) Prion protein and the 
scrapie agent: in vitro studies in infected neuroblastoma cells. Infect Agents Dis 3, 54-58. 
Prusiner S. B. (1982a) Research on scrapie. Lancet 2, 494-495. 
Prusiner S. B. (1982b) Novel proteinaceous infectious particles cause scrapie. Science 216, 
136-144. 
Prusiner S. B. (1984) Prions: novel infectious pathogens. Adv Virus Res 29, 1-56. 
Prusiner S. B. (1988) Molecular structure, biology, and genetics of prions. Adv Virus Res 35, 
83-136. 
Prusiner S. B., Bolton D. C., Groth D. F., Bowman K. A., Cochran S. P. and McKinley M. P. 
(1982) Further purification and characterization of scrapie prions. Biochemistry 21, 6942-
6950. 
210 
Prusiner S. B., Groth D., Serban A., Koehler R., Foster D., Torchia M., Burton D., Yang S. L. 
and DeArmond S. J. (1993) Ablation of the prion protein (PrP) gene in mice prevents scrapie 
and facilitates production of anti-PrP antibodies. Proc Natl Acad Sci U S A 90, 10608-10612. 
Quaglio E., Chiesa R. and Harris D. A. (2001) Copper converts the cellular prion protein into 
a protease-resistant species that is distinct from the scrapie isoform. J Biol Chem 276, 11432-
11438. 
Raeber A. J., Race R. E., Brandner S., Priola S. A., Sailer A., Bessen R. A., Mucke L., 
Manson J., Aguzzi A., Oldstone M. B., Weissmann C. and Chesebro B. (1997) Astrocyte-
specific expression of hamster prion protein (PrP) renders PrP knockout mice susceptible to 
hamster scrapie. Embo J 16, 6057-6065. 
Roberts G. W., Lofthouse R., Allsop D., Landon M., Kidd M., Prusiner S. B. and Crow T. J. 
(1988) CNS amyloid proteins in neurodegenerative diseases. Neurology 38, 1534-1540. 
Ross C. A. and Poirier M. A. (2004) Protein aggregation and neurodegenerative disease. Nat 
Med 10 Suppl, S10-17. 
Somerville R. A. and Ritchie L. A. (1990) Differential glycosylation of the protein (PrP) 
forming scrapie-associated fibrils. J Gen Virol 71 ( Pt 4), 833-839. 
Stahl N., Baldwin M. A., Hecker R., Pan K. M., Burlingame A. L. and Prusiner S. B. (1992) 
Glycosylinositol phospholipid anchors of the scrapie and cellular prion proteins contain sialic 
acid. Biochemistry 31, 5043-5053. 
Stahl N., Baldwin M. A., Teplow D. B., Hood L., Gibson B. W., Burlingame A. L. and 
Prusiner S. B. (1993) Structural studies of the scrapie prion protein using mass spectrometry 
and amino acid sequencing. Biochemistry 32, 1991-2002. 
211 
Stanczak P., Valensin D., Juszczyk P., Grzonka Z., Migliorini C., Molteni E., Valensin G., 
Gaggelli E. and Kozlowski H. (2005) Structure and Stability of the Cu(II) Complexes with 
Tandem Repeats of the Chicken Prion. Biochemistry 44, 12940-12954. 
Stockel J., Safar J., Wallace A. C., Cohen F. E. and Prusiner S. B. (1998) Prion protein 
selectively binds copper(II) ions. Biochemistry 37, 7185-7193. 
Sun F., Anantharam V., Latchoumycandane C., Kanthasamy A. and Kanthasamy A. G. 
(2005) Dieldrin induces ubiquitin-proteasome dysfunction in alpha-synuclein overexpressing 
dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death. J Pharmacol 
Exp Ther 315, 69-79. 
Takemura K., Wang P., Vorberg I., Surewicz W., Priola S. A., Kanthasamy A., Pottathil R., 
Chen S. G. and Sreevatsan S. (2006) DNA aptamers that bind to PrP(C) and not PrP(Sc) 
show sequence and structure specificity. Exp Biol Med (Maywood) 231, 204-214. 
Tenzer S., Stoltze L., Schonfisch B., Dengjel J., Muller M., Stevanovic S., Rammensee H. G. 
and Schild H. (2004) Quantitative analysis of prion-protein degradation by constitutive and 
immuno-20S proteasomes indicates differences correlated with disease susceptibility. J 
Immunol 172, 1083-1091. 
Thackray A. M., Knight R., Haswell S. J., Bujdoso R. and Brown D. R. (2002) Metal 
imbalance and compromised antioxidant function are early changes in prion disease. 
Biochem J 362, 253-258. 
Treiber C., Simons A. and Multhaup G. (2006) Effect of copper and manganese on the de 
novo generation of protease-resistant prion protein in yeast cells. Biochemistry 45, 6674-
6680. 
212 
Tsenkova R. N., Iordanova I. K., Toyoda K. and Brown D. R. (2004) Prion protein fate 
governed by metal binding. Biochem Biophys Res Commun 325, 1005-1012. 
Tsiroulnikov K., Rezaei H., Dalgalarrondo M., Chobert J. M., Grosclaude J. and Haertle T. 
(2006) Cu(II) induces small-size aggregates with amyloid characteristics in two alleles of 
recombinant ovine prion proteins. Biochim Biophys Acta. 
Wong B. S., Brown D. R. and Sy M. S. (2001a) A Yin-Yang role for metals in prion disease. 
Panminerva Med 43, 283-287. 
Wong B. S., Chen S. G., Colucci M., Xie Z., Pan T., Liu T., Li R., Gambetti P., Sy M. S. and 
Brown D. R. (2001b) Aberrant metal binding by prion protein in human prion disease. J 
Neurochem 78, 1400-1408. 
Wong B. S., Brown D. R., Pan T., Whiteman M., Liu T., Bu X., Li R., Gambetti P., Olesik J., 
Rubenstein R. and Sy M. S. (2001c) Oxidative impairment in scrapie-infected mice is 
associated with brain metals perturbations and altered antioxidant activities. J Neurochem 79, 
689-698. 
Wong E., Thackray A. M. and Bujdoso R. (2004) Copper induces increased beta-sheet 
content in the scrapie-susceptible ovine prion protein PrPVRQ compared with the resistant 
allelic variant PrPARR. Biochem J 380, 273-282. 
Yedidia Y., Horonchik L., Tzaban S., Yanai A. and Taraboulos A. (2001) Proteasomes and 
ubiquitin are involved in the turnover of the wild-type prion protein. Embo J 20, 5383-5391. 
Zhang H., Kaneko K., Nguyen J. T., Livshits T. L., Baldwin M. A., Cohen F. E., James T. L. 
and Prusiner S. B. (1995) Conformational transitions in peptides containing two putative 
alpha-helices of the prion protein. J Mol Biol 250, 514-526. 
213 
 
 
 
 
Table 1: Cadmium treatment does not alter the proteolytic degradation rate of prion 
protein in in vitro cell culture system 
 
 
 PrP β-actin 
 Untreated Cd
2+-
treated Untreated Cd
2+-treated 
kobs 0.38 ± 0.16 0.35 ± 0.13 0.32 ± 0.13 0.31 ± 0.1 
Half-life (min) 1.8 ± 1.2 2.0 ± 1.0 2.2 ± 1.5 2.2 ± 1 
 
 
 
 
 
 
 
 
 
The data were obtained by fitting a single-phase exponential curve to experiments performed 
in triplicates, and are represented as mean ± SEM. 
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Figure 1. Cell viability.  (A) Dose-dependent cadmium-induced cell death.  Cells were 
treated with 0-100 µM CdCl2 for 24 h, and cell viability was calculated using the Trypan blue 
exclusion method. EC50 values were calculated with a non-linear regression model.  (B) 
Time-dependent cell death induced by cadmium.  Cells were treated for 24 and 48 h with 10 
µM CdCl2 and cell viability was calculated as described previously.  (C) Images of time 
dependent cell death induced by cadmium.  Phase-contrast images were used to observe cell 
morphologies, while impermeable nucleic dye Sytox® green was used to observe cells with 
compromised membranes.  All the data were replicated twice in triplicates, **p<0.01. 
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Figure 2. Measurement of proteasome activity.  (A) Cells were treated with cadmium for 24 
and 48 h, and activity of two different proteasomal substrates were examined.  Peptidyl 
Glutamyl Peptidase Hydrolase (PGPH)-like activity, and Chymotrypsin-like activity. Black 
bars represent control without treatment, red bars indicate treatment for 24 h, and blue bars 
represent treatment for 48 h (B) Proteasomal activity following manganese treatment for 24 
and 48 h. (C) For positive control, cells were treated with MG-132 for 2 h (green bars). 
***p<0.001, n=6 
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Figure 3.  Detection of high molecular weight ubiquitinated proteins.  Soluble and insoluble 
fractions of cadmium-treated cells at 24 and 48 h were analyzed.  For a positive control, cells 
were treated with 5 µM of MG-132 (non-specific proteasomal inhibitor) for 2 h.  Equal 
protein loading was confirmed with β-actin. 
 
217 
 
 
 
 
 
Figure 4.  Detection of oligomer formation following cadmium treatment.  Nucleus staining 
was performed with Hoechst 33342 (blue), prion was detected with 3F4 antibody conjugated 
to Alexa 488 secondary anti-mouse (green), and oligomer formation was detected with A11 
antibody conjugated to Cy3 secondary anti-rabbit (red).  Combined images are shown on the 
far right. 
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Figure 5. The amount of oligomer formation was quantified by Dot blot assay.  Below the 
graph is a representative image of various treatments: control, cadmium 24 h, and cadmium 
48 h treatment, respectively from left to right.  (A) Dot blot quantification of total lysates 
from cadmium-treated cells.  (B) Dot blot quantification of nuclear fraction in cadmium-
treated cells.  (C) Dot blot quantification of cytoplasmic fraction in cadmium-treated cells.  
**p<0.01, ***p<0.01, n=3 
 
219 
 
 
 
Figure 6. In vitro cadmium treatment does not alter PrPC susceptibility to proteinase-K 
digestion.  (A) Western blot analysis of limited proteolysis of PrPC in presence or absence of 
10µM cadmium.  (B) Limited proteolysis of β-actin analyzed by Western blot in the presence 
and absence of cadmium.  Kinetic rate profiles of the limited proteolysis of PrPC and β-actin 
are next to the Western blot images.  Each data point represents the mean ± SEM of the 
normalized band intensity determined by densitometric analysis performed in triplicate.  The 
curve through the data points represents the best fit to a single-exponential decay. 
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Figure 7. Immunoprecipitation of prion protein with ubiquitin.  (A)  Treated and non-treated 
cell lysates were immunoprecipitated with ubiquitin and detected with prion protein antibody 
(3F4).  (B)  Three glycosylated forms of prion protein were quantified using Kodak analysis 
program.  ***p<0.001, n=3 
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Abstract 
 Prion disease is an enigmatic neurodegenerative disorder that has been shown to be 
caused by accumulation of abnormal endogenous prion protein.  Exact causes of the disease 
are still unknown, but the ‘protein only’ hypothesis has paved the way to a newly established 
concept of endogenous protein propagating into a disease-causing state.  The prion protein is 
an ubiquitiously expressed protein found in high levels in the central nervous system, 
immune system, and to a certain extent in muscles and internal organs.  The function of this 
protein remains to be elucidated, but studies have suggested it to be a metalloprotein with 
binding affinity for divalent cations.  Our previous experiments with mouse neural cell lines 
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indicated that interaction of prion protein with manganese results in increased prion protein 
levels through decreased protein turnover rate.  To extend our research closer to in vivo 
system, we examined the effect of manganese on prion protein in mouse brain slice cultures.  
Interestingly, incubation of mouse brain slice cultures with manganese (300µM) resulted in 
increased prion protein levels, and increased manganese content.  To examine whether the 
increase in prion protein levels affects the rate of conversion into infectious prion protein, 
protein misfolding cyclic amplification (PMCA) was performed on the samples.  Our results 
indicate that there were no significant differences in the conversion rate.  Together, these data 
strongly suggest that although manganese treatment results in increased prion protein levels 
in mouse brain slice cultures, this does not translate into the samples being better substrates 
for prion conversion via PMCA. 
 
 
Introduction 
 Prion diseases are fatal neurodegenerative disorders that can affect both humans and 
animals [13, 40, 42, 45].  Prion diseases are widely believed to be initiated by infection, 
ingestion, or natural formation of abnormally folded endogenous prion protein (PrPC), 
resulting in a pathogenic form (PrPSc) [9, 35, 37, 43].  The abnormal folding into PrPSc results 
in predominant β-sheet formation in the secondary structure, unlike PrPC which consist 
mostly of α-helices [17, 18, 25, 39].  The transformation into PrPSc is also accompanied by 
distinct properties in which they become infectious, highly resistant to digestion with 
proteases, and in some cases aggregate into fibrils [19, 47-49].  Endogenous PrPC is 
expressed in most tissues and highest expressions are found in the central nervous system and 
223 
the lymphoid tissues [12, 41, 42, 44].  PrPC is a surface protein with unclear physiological 
functions, but  some have speculated on the functions of PrPC to be involved in cellular 
survival, metal sequestration, superoxide dismutase-like activity, and cellular development [7, 
12, 14, 21, 26, 31, 34, 58].  Within the structure of the protein, there are putative metal 
binding sites at the N-terminus called the octapeptide repeat region, and two additional 
histidine sites that has shown to have strong metal binding capacities [6, 12, 24, 26].  These, 
metal binding sites found in PrPC may shed some light in pathogenesis, or function of the 
protein.   
 From studies with prion-knockout mice, it is clear that the expression of prion protein 
is necessary in order for infection and propagation of the disease [5, 36, 46, 51].  Although 
the mechanism of disease initiation and progression remains ambiguous, the amount of PrPC 
present, and the processing of the protein may lead to elucidating the mystery surrounding 
prion disease.  Interestingly, Telling and colleagues have shown that transgenic mice 
overexpressing the prion protein exhibited significantly shorter than normal disease onset in 
experimental settings [30, 54].  They concluded that the level of PrP expression could have a 
large impact on the progression of the disease.  More recently, de Soto’s group has shown 
that cell lines that have been treated with ER-stressors produced PrP forms that were 
considered to be better substrates for PrPSc conversion by the protein misfolding cyclic 
amplification (PMCA) method [8, 23, 50].  These two studies suggest the possibility that 
increased PrP levels, and or altered protein processing could be a potential influencing factor 
in PrPC to PrPSc conversion. 
Our previous findings have shown that incubation of mouse PrPC expressing neural 
cells with manganese resulted in a significant increase in PrP expression (in preparation).  
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Results have suggested that there was no alteration to mRNA levels, or cellular degradative 
systems.  Strong evidence has pointed to the possibility that divalent cations have a 
stabilizing effect on the proteins, thereby reducing the turnover rate, resulting in increased 
intracellular PrP levels.  In line with the finding that was reported with mouse neural cells, 
our current experiment examined the PrP expression level in mouse brain cultures following 
manganese treatment.  Surprisingly, upon examination of PrP levels in mouse brain slice 
cultures, we have observed significant increase in protein levels following manganese 
treatment.  To verify that the mouse brain slice cultures treated with manganese contained 
higher content of manganese, inductively coupled plasma mass spectrometry (ICP-MS) was 
utilized to measure internalized manganese levels in mouse brain slice cultures.  Our results 
indicated that with manganese treatment, a significant amount of manganese content was 
found in the mouse brain slices, however, levels of other trace elements copper, iron, or zinc 
contents were not altered.  We also examined the conversion effectiveness of manganese-
treated brain slices utilizing with the PMCA method, and showed that increased PrP levels in 
mouse brain slice cultures treated with manganese were not more efficient in the conversion 
of PrPC to PrPSc. 
 
Methods 
 
Chemicals.  Manganese chloride (MnCl2) was purchased from Sigma (St. Louis, MO); 
Bradford protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA).  
DMEM, fetal bovine serum, L-glutamine, penicillin, and streptomycin were purchased from 
Invitrogen (Gaithersburg, MD).   
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Mouse brain slice preparation 
Mouse brain slices were obtained from 30-60-day old C57BL/6 mice.  All 
experimental procedures were approved by the Animals Care and Use Committee at Iowa 
State University, and were in accordance with the NIH Guide for the Care and Use of 
Laboratory Animals.  Animals were anesthetized with isofluorane, and brain was removed 
and placed in  ice cold artificial cerebralspinal fluid (aCSF: 125 mM NaCl, 2.5 mM KCl, 26 
mM NaHCO3, 1.25 mM NaH2PO4, 1.2 mM MgSO4, 2 mM CaCl2, and 15 mM dextrose).   
Coronal slices (400 µm) were generated and placed in ice cold aCSF.  After preparation, the 
slices were transferred to sterile porous membrane units (Millicell® 12 mm CM PTFE 0.4 
µm, Millipore, Billerica, MA) and preincubated in incubation media containing 25 % Hank’s 
Balanced Salt Solution (HBSS), 25 % heat-inactivated horse serum, 50 % Modified Eagle 
Medium (MEM), 5 mM L-glutamine, 6.5 mg D-glucose l-1, 20 mM HEPES, and 
streptomycin/penicillin (5 g ml-1 and 5000 units ml-1 respectively) for two hours prior to 
initiation of manganese treatments.  Slices were cultured for 1, 3, and 7 days at 37 ºC in 5 % 
CO2 with or without manganese (300 µM).  The culture medium was changed every 2 days 
until the last day of treatment. 
 
Quantification of brain-derived PrP 
Brain homogenates were prepared (10 % w/v) in lysis buffer containing 150 mM 
NaCl, 10 mM Tris HCl, 10 mM EGTA, 2 mM EDTA, 1 mM PMSF protease inhibitor 
cocktail (Roche Diagnostics, Indianapolis, IN).  Protein concentration was measured using 
the Bradford method with bovine serum albumin as a standard, as previously described [11, 
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27, 28].  An equal concentration of protein was loaded for each sample, and separated 
proteins were transferred onto nitrocellulose membrane and probed with SAF32 monoclonal 
antibody.  Following primary antibody incubation, blots were washed thoroughly, and 
incubated with horseradish peroxidase-conjugated secondary antibody and visualized with 
enhanced chemiluminescence (GE Healthcare, Piscataway, NJ).  For verification of equal 
loading of proteins, the blots were stripped and reprobed with β-actin.  All images were 
captured with Kodak 2000MM imaging system.  PrP levels were normalized to β-actin, and 
plotted as percentage of PrP level of untreated sample at 1 day. 
 
Internalized manganese concentration in mouse brain slices 
Brain slices were collected at 1, 3, and 7 days following treatment and weighed prior 
to analysis with inductively coupled plasma mass spectrometry (ICP-MS) to determine the 
concentrations of Mn, Fe, Cu, and Zn in each sample.  The ICP-MS device was a high-
resolution double-focusing instrument operated at medium resolution (m/∆m = 4,000) in 
order to resolve the isotopes of interest from any interferences [1, 11, 33].  The signals from 
the two most abundant isotopes of Fe, Cu, or Zn were measured, and the average 
concentration calculated from both isotopes is reported.  Manganese is monoisotopic, so its 
concentration was calculated from the signal from one isotope.  Each sample was placed in 
an acid-washed 5 ml Teflon vial and digested in 150 µl high purity nitric acid (Ultrex II, J.T. 
Baker).  Following digestion, the samples were diluted to 5 ml with Milli-Q 18.2 MΩ 
deionized water, giving a final acid concentration of approximately 2 % nitric acid.  There 
was some minor precipitation upon dilution.  The supernatant was analyzed with ICP-MS.  
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An internal standard method was used for quantification.  Gallium was chosen as the 
internal standard because its m/z ratio is similar to that of the elements of interest, and it has 
no major spectroscopic interferences.   A small spike of Ga standard solution was added to 
each sample such that the final concentration of Ga was 10 ppb.  A 10 ppb multi-element 
standard (Mn, Fe, Cu, Zn, Ga) was also prepared.  The nitric acid blank, the multi-element 
standard, and each of the samples were introduced into the ICP-MS via a 100 µl/min self-
aspirating PFA nebulizer (Elemental Scientific, Inc.).  Between samples, the nitric acid blank 
was used to rinse the nebulizer.   The results for each sample are calculated using the 
integrated average background-subtracted peak intensities from 20 consecutive scans.  In 
order to correct for differences in isotopic abundance and elemental sensitivity in the ICP, the 
multi-element standard was used to derive normalization factors for Mn, Fe, Cu, and 
Zn.  The concentration of each element was then calculated for each sample. 
Protein misfolding cyclic amplification 
Brain samples of both control and manganese treatments were collected 7 days post-
treatment and prepared as homogenates (10 % w/v) as described by Weber et al [59].  Brain 
homogenates (10 % w/v) from C57/Bl mice were used as positive control for the PMCA 
technique.  Serial dilution of scrapie brain homogenates were made directly into the mouse 
brain homogenates.  The samples were aliquoted into frozen treatment (control, no PMCA), 
and sonication treatment (with PMCA technique).  PMCA reaction was performed by 
incubating the homogenates with the diluted scrapie brain homogenate at 37 º C with 
agitation.  Every 30 min, samples were subjected to 20 seconds of sonication using an 
ultrasonic microtip probe at 8.0 power setting (MiSonix S-3000 MPX), followed by 
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incubation at 37 º C.  For control of PMCA samples, both untreated and Mn-treated mouse 
brain slice homogenates were incubated with 1:10 dilution of 10% RML infected brain 
homogenate.  Total of 48 cycles of PMCA were performed, and all samples were digested 
with 60 µg/ml PK for 30 min at 37 º C prior to analysis with Western blot using 6H4 
antibody (1:10,000 dilution).  PrP was visualized using enhanced chemiluminescence 
reaction (GE Healthcare, Psicataway, NJ), and images were captured using Kodak 4000MM 
imaging system. 
 
Data and statistical methods 
Data were analyzed with Prism 4.0 software (GraphPad Software, San Diego, CA).  
Bonferroni’s post-hoc multiple comparison testing was used to delineate significance 
between the control (untreated) and the manganese-treated samples.  Differences greater than 
P<0.05 were considered to be significant and are indicated with asterisks. 
 
Results 
 
PrP expression in mouse brain slice cultures treated with manganese 
Our previous finding suggests treatment with manganese results in increased PrP 
expression in in vitro cell culture models.  To examine whether this phenomenon could be 
observed in a different model system, mouse brain slices were prepared and cultured for 1, 3, 
and 7 days in presence or absence of manganese (300 µM), and total amount of PrP was 
detected using immunoblotting (Fig. 1).  After 7 days of manganese treatment, we observed a 
significant increase in PrP expression, as compared to the untreated control.  Equal loading of 
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protein was verified with β-actin.  The band intensity of PrP was quantified and normalized 
to respective control at Day 1, and plotted.  A modest increase in PrP expression was 
observed in manganese-treated mouse brain slices at 3 days of treatment; the increase in PrP 
levels at 7 days post-incubation was significantly higher.   
 
Internalized manganese concentrations 
To verify manganese uptake into the mouse brain slice cultures, slices were collected 
following treatment and weighed before digestion with nitric acid.  Since manganese is 
known to compete with other divalent cations for binding, concentration of copper, iron, 
manganese, and zinc were analyzed in mice brain slice samples.  As seen with Fig 2, 
significant increase in manganese content was observed with samples treated with 
manganese starting at Day 1.  However, levels of other divalent cations were not significantly 
altered with manganese treatment, and remained constant through 7 days of manganese 
treatment.  The ICP-MS data suggest that the divalent cation concentrations of other metals 
were not significantly influenced with the addition of manganese treatment. 
 
Protein misfolding cyclic amplification 
In order to test the effectiveness of PrPSc conversion in brain homogenates from 
C57/Bl mice, PMCA was performed with RML-infected mouse brain homogenates (10% 
w/v) as seed for conversion, and diluted to 1:10, 1:20, 1:40, and 1:100 (Fig. 3).  Our results 
indicate that PrPSc conversion by PMCA was successful up to dilution of 1:40.  Studies have 
suggested that increased PrP levels could influence the relative infection rate in transgenic 
mice.  Our results from Figure 1 suggest that the 7-day Mn treatment corresponded to 
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significant increases in PrP levels, therefore mouse brain slices from 7 day treatments (and 
control) were collected and homogenized (10 % w/v) prior to PMCA method (Fig. 4).  To 
verify that none of the initial PMCA substrates contained PK-resistant PrP, samples without 
RML-infected brain homogenates were also digested with PK.  The results from the Western 
blot analysis revealed that there does not seem to be a noticeable difference in the efficacy of 
PrPSc conversion in mouse brain slice culture with or without manganese in the 1:10 dilution.  
The results also clearly show that PMCA increased the amount of PK-resistant PrP that could 
be detected, as compared to the respective frozen and 37 ºC incubated samples without 
PMCA.   
 
 Discussion 
Although the function of PrPC remains to be elucidated, the octapeptide repeat region 
of the protein structure suggests a metal-binding role of PrPC [10, 12, 24, 52, 61].  Numerous 
studies have shown that PrPC has strong binding affinities to various divalent cations (copper, 
nickel, manganese, zinc) [3, 6, 12, 26, 38, 53, 56, 61].  One of the most significant 
differences seen with the absence of PrPC in both mice brain and cell culture is the reduced 
basal content of crucial divalent cations such as copper and manganese, strongly suggesting 
that PrPC modulate metal homeostasis [11, 22, 55].  Other studies have also highlighted the 
role of metals in formation of PrP aggregates and alteration of protein structure [4, 20, 26, 32, 
57].   Interestingly, Brown et al. have shown that rat astrocyte primary cultures treated 
chronically with manganese induced formation of PK-resistant PrP [4].  A different study 
with yeast prion proteins also showed that yeast cells treated with manganese-supplemented 
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media generated PK-resistant forms of PrP [57].  Together, these results point to the possible 
role of manganese in generation of PK-resistant PrP. 
Our previous experiments yielded interesting results showing that a mouse neuronal 
cell line treated with manganese resulted in increased PrPC expression that was not dependent 
on increased transcription rate or decreased cellular degradation, rather it was due to 
decreased protein susceptibility to proteolytic digestion most likely through stabilization of 
PrPC (in preparation).  Continuing from our previous findings, we attempted to examine 
whether a similar phenomenon could be observed in mouse brain slice cultures, and to 
examine whether this phenomenon resulted in better substrates for PMCA reaction.  
Similarly to our results with cell culture studies, mouse brain slice cultures treated with 
manganese showed increased PrPC levels as well.  Metal content analysis revealed no 
discerning alterations to other divalent metals (i.e. copper, zinc or iron); however, manganese 
content was significantly increased with treatment.  These two findings may be crucial since 
there are number of factors that could potentially have an impact on the rate of conversion of 
PrPC to PrPSc.  Fischer et al. showed decreased incubation time for infection to the terminal 
diseased state in transgenic mice overexpressing PrP, suggesting that increased PrP content 
could have a role in shortening disease progression [2, 16, 60]; this implies that the amount 
of substrate (PrPC) available could be a crucial factor in conversion of PrPC to PrPSc.  Kim et 
al. have shown that divalent metals could be considered as a factor in the conversion step, by 
showing that PMCA reaction performed with high concentrations of metals resulted in 
formation of PK-resistant PrP, supporting the possible role of metals in the conversion 
process [29].  In attempts to tie the two experiments together, our study examined whether 
increased PrP content from manganese exposure could be a better substrate for conversion.   
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Although our results indicate that increased PrPC could be seen in mouse brain slice 
cultures treated with higher concentrations of manganese content, these samples did not 
prove to be better substrates for PMCA reaction.  One possible explanation for the reduced 
efficacy of PMCA reaction in conversion of PrPC to PrPSc could be due to the differences in 
ratio of fats, carbohydrates, and/or protein content in the mouse brain slice culture as opposed 
to whole brain homogenates.  Since our samples consisted of slices comprised mostly of 
basal ganglia, it is certainly possible that the ratio of various components could be different.  
Deleault et al. have shown that other factors aside from native PrPC, such as copurified lipids 
and a synthetic polyanion could be necessary in proper PMCA reactions [15]. 
In summary, our data confirm that the increase in PrPC levels following manganese 
treatment can be observed in mouse brain slice cultures, but the cultures were not found to be 
a better substrate for PrPSc conversion utilizing the PMCA reaction.  Thus, increases in both 
manganese concentration and PrPC content may not be absolute factors contributing to the 
PrPSc conversion with the PMCA reaction. 
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Fig. 1. Manganese treatment results in increased PrP levels in mouse brain slices. 
Representative western blot analysis of total PrP levels in mice brain treated with manganese 
and untreated are shown at top.  Below the representative Western blot image is the 
quantification of band intensity of PrP normalized with β-actin levels.  Each data point 
represents experiments performed in triplicate *P<0.05. 
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Fig. 2.  Examination of divalent cation levels in mice brain slices treated with 
manganese. 
Analysis of divalent cation levels in mice brain slices untreated and treated with manganese 
are shown in four separate panels indicated by the cation examined.  Each data point 
represents experiments normalized to wet weight of mice brain slices performed in triplicate 
***p<0.001, **p<0.01. 
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Fig. 3.  Detection of PrPres in mouse brain homogenates with PMCA reaction. 
Western blot image of PK-digested PrP following PMCA reaction.  Samples were either 
frozen or put under PMCA condition for 24 hr.  Following the termination of the PMCA 
reaction, samples were digested with PK, and analyzed by Western blot. 
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Fig 4.  Detection of PrPres in manganese-treated mouse brain slice cultures following 
PMCA amplification. 
Western blot image of PK-digested PrP following PMCA reaction.  For control of PMCA, 
samples for both untreated and manganese-treated mouse brain slice cultures were frozen or 
incubated at 37 ºC for 24 hr.  Following termination of the PMCA reaction, samples were 
digested with PK, and analyzed by Western blot. 
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CHAPTER VII: GENERAL CONCLUSIONS 
 
 The major findings of the author’s research described in this dissertation have been 
discussed in detail in the Discussion sections of each chapter.  The overall conclusions 
derived from these studies, and proposed interaction of manganese and prion protein will be 
discussed here, followed by findings from preliminary studies and future directions. 
 
Neuroprotection of prion protein  
 Prion protein (PrP) is a ubiquitously expressed protein in mammals with functions 
that remain to be elucidated (Martins et al. 2001).  Studies with prion protein knockout mice 
and cells have shed some light into the role of prion protein (Colling et al. 1996; Raeber et al. 
1998).  Mice lacking prion protein expression have shown increased susceptibility to 
oxidative stress, and altered brain metal content; similar results have been found in cell lines 
lacking prion protein expression (Brown et al. 2002; Choi et al. 2007; Miele et al. 2002; 
Wechselberger et al. 2002; Wong et al. 2001b).  Such findings strongly suggest the role of 
prion protein in modulating metal homeostasis, as well antioxidant levels.   
In the studies described in this dissertation, we demonstrated that the mouse neuronal 
cell lines expressing prion protein were more protected against manganese induced 
neurotoxicity compared to mouse neuronal cell lines lacking prion protein expression.  Both 
basal and internalized manganese levels revealed that lacking prion protein expression 
resulted in significantly lower basal manganese levels, and upon treatment, the increase in 
internalized manganese was highly significant.  Examination of reactive oxygen species 
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(ROS) formation, caspase activation, and cell death all revealed increased susceptibility of 
 
 
Figure 12. Proposed model of PrPC neuroprotection against manganese neurotoxicity 
Manganese ions enter the cells and are usually sequestered to the mitochondria, and 
accumulation of excessive manganese in the mitochondria leads to generation of reactive 
oxygen species and mitochondrial dysfunction.  This results in activation of the cellular 
apoptotic cascade of initiator caspase (9), followed by effector caspase (3).  This then leads 
to cellular apoptosis.  We propose that PrPC functions either at the cellular surface or 
intracellularly to prevent excessive manganese from disrupting cellular homeostasis, thereby 
protecting neuronal cells against manganese-induced cell death. 
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the mouse neuronal cell line lacking prion protein expression to manganese neurotoxicity; 
this increased susceptibility is likely a result of the homeostatic balance of manganese, as 
evidence by the significantly lower amount of basal manganese levels in these cells, and also 
the fold increase in manganese concentration following treatment.  It is likely that the prion 
protein functions to protect these cells from manganese by acting as both a metal 
sequestering protein, and an anti-oxidant (Figure 12).  Studies with hydrogen peroxide also 
revealed similar findings and showed increased susceptibility of mouse neuronal cell line 
lacking prion protein expression (manuscript in preparation).  This may explain why the 
mouse neuronal cell line lacking prion protein was more susceptible to manganese-induced 
neurotoxicity.  One possible function of normal PrP is to provide protection against oxidative 
damage induced by cellular stress and metal toxicity. 
 
Interaction of prion protein and divalent cations 
 The physical interaction between manganese and prion protein has been proposed to 
occur at the octapeptide repeat region of the prion protein, and could modulate the protein’s 
structure (Bocharova et al. 2005; Brown et al. 2000a; Choi et al. 2006; Levin et al. 2005; 
Treiber et al. 2006).  Our initial study demonstrated that mouse neuronal cell lines expressing 
prion protein were more protected against manganese-induced neurotoxicity as compared to 
mouse neuronal cell line lacking prion protein expression.  However, questions remain as to 
the fateof the prion protein in cells treated with manganese.  We addressed this question by 
examining protein content levels in a manganese-treated PrP expressing mouse neuronal cell 
line.  Our results indicated that with manganese treatment, prion protein expression levels 
were significantly increased over time.  A previous study has shown that increase d prion 
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protein expression in a particular cell line treated with copper, but the increase was due to the 
effect of copper on elevating the activity of the reporter vector with Prnp (Varela-Nallar et al. 
2005).  To verify that this was not the case in our system, mouse neuroblastoma (N2a) cell 
line expressing endogenous prion protein without a vector was treated with manganese.  In 
our N2a cell line treated with manganese, a dose-dependent increase in expression of prion 
protein was observed (Chapter 3).   
Based on these results, we then hypothesized that the increase in protein expression 
could be contributed to increased transcription or inhibition of the ubiquitin proteasomal 
system (UPS).  Surprisingly, our data demonstrated that treatment of manganese did not alter 
the transcriptional levels of prion protein.  Neither indicating that manganese nor copper 
changed transcription or UPS of these cells.  While examining whether manganese inhibited 
the UPS, cadmium was initially used as a negative control to examine the effect of a different 
divalent cation not shown to interact with prion protein on cellular protein metabolism.  
Interestingly, manganese did not have any effect on UPS; alternatively, cadmium was shown 
to be significantly effective in inhibiting UPS.  Inhibition of UPS by cadmium had highly 
neurotoxic effects, and lead to the ubiquitination of prion protein.  Qualitative examination of 
cadmium-treated mouse neuronal cells showed protein aggregation in the cytoplasm.  This 
strongly points to a possible mechanism of neurotoxicity of cadmium through the inhibition 
of the cellular degradative system, thus leading to formation of protein aggregates in the cells 
(Figure 13).  Although cadmium has not been described to have a binding affinity to PrP, we 
can not rule out the possibility that cadmium could bind to PrP, leading to ubiquitination of 
the protein.  Experiments with detection of proteinase-K resistant PrP showed no alteration of 
protein stability in PrP with cadmium treatment.   
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Figure 13. Schematic of proteasome inhibition by cadmium and fate of ubiquitinated 
prion proteins 
Our studies indicate that the cadmium inhibts the proteasome, leading to ubiquitination and 
possible aggregation of prion protein.  These ubiquitinated prion proteins could become seed 
for increased chance of spontaneous conversion into PrPres or PrPSc forms.  Or, the 
accumulation of ubiquitinated prion proteins could increase the chance of contact with PrPSc, 
thereby increasing direct interaction for conversion. 
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Examination of the protein turnover indicated a significantly delayed protein turnover with 
manganese treatment, which is evidence of altered prion protein metabolism.  There are 
numerous possible mechanisms by which protein turnover could be altered to produce such 
an effect.  One possibility is the increased stability of a protein, so that it would be more 
resistant to the normal cellular degradative systems.  This has been shown previously, by 
Brown et al., in a manganese prion protein interaction study which showed proteinase-K 
(PK) resistant forms of prion protein in rat astrocytes after prolonged treatment with 
manganese (Brown et al. 2000a).  If the prion protein in these cell lines treated with 
manganese was indeed becoming PK-resistant, this could explain why the protein turnover 
rate was significantly delayed.  Utilizing limited proteolysis, by digesting prion protein with 
PK over time, showed that with manganese treatment, prion protein exhibited decreased 
susceptibility to PK digestion.  This is not to say that these manganese-treated prion proteins 
were PK-resistant like the infectious prion protein, rather these manganese-treated prion 
proteins showed altered susceptibility to PK most likely due to increased protein stability.  
However, studies performed with cell-free lysates confirmed that the decreased susceptibility 
of PrP to PK digestion required intact cells.  Combined with results of limited proteolysis 
from intact cells treated with manganese, at least in our system, manganese may not interact 
with PrP directly, and may require a possible PrP ligand to increase the global stability of the 
protein (Figure 14). 
Copper, which has been highly noted for their strongest affinity to PrP, also interacts 
with PrP to increase stability.  Similar to the findings with manganese, copper did not alter 
the transcriptional rate or the cellular degradative system (UPS); however, treatment with 
copper significantly reduced the protein turnover rate.  Limited proteolysis revealed  
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Figure 14. Proposed schematic of altered prion protein susceptibilituy to protease 
digestion with manganese treatment 
In normal protein homeostasis, PrP is proposed to be in homeostatic balance between the 
folded and the partially unfolded form.  It is in the partially unfoled form that the protease is 
able to digest away at the unfolded regions.  In manganese treatment, it is proposed that a PrP 
ligand which is affected by manganese treatment works to stabilize the global structure of 
PrP, shifting the homeostasis between the folded form and the partially unfolded form, 
leading to lower amounts of partially unfolded forms being digested by proteases. 
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decreased susceptibility of PrP to PK digestion, and incubation of cell free lysates with 
copper also resulted in similar findings.  This demonstrates that copper has the propensity to 
directly bind to PrP, increasing the protein stability as suggested by studies by other 
researchers (Figure 15).   
Together these studies suggest that inhibition of UPS may not be a causative factor in 
formation of PK resistant PrP in metal treated mouse neuronal cells, but alteration to the 
stability of PrP induced by interaction with copper and manganese may have effect on 
formation of PK resistant PrP.  Studies have shown that the N-terminus of PrP is flexible and 
is readily digested away in detection of PK resistant PrP (Jones et al. 2005a; Leclerc et al. 
2006; Weissmann et al. 1996).  Decreased susceptibility to proteolytic digestion would 
suggest that the PrP with metals are more stable than untreated PrP.  From this, it is possible 
to deduce that interaction of PrP with copper and manganese could increase the stability of 
the protein by interaction at the N-terminus, thereby increasing the global stability of the 
protein.  However, it is interesting to note that copper and manganese exerted different 
effects when cell free lysates system was utilized to examine the relative PrP susceptibility to 
PK digestion.  It is possible that certain divalent cations may have the capacity to directly 
bind to PrP and increase the global protein stability, while other divalent cations may require 
secondary ligand or the metals needs to be loaded on to PrP cotranslationally.  In either case, 
the schematic depicts the increased propensity for PrP to fold into a structure with higher 
stability with manganese or copper, thus reducing the available substrates for digestion.  This 
demonstrates that the interaction between divalent cations and PrP is a complex interaction, 
and requires further examination into the mechanism of interaction between PrP and divalent 
cations. 
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Figure 15.  Proposed schematic of altered prion protein susceptibility to protease 
digestion with copper treatment 
In normal protein homeostasis, PrP is proposed to be in homeostatic balance between the 
folded and the partially unfolded form.  It is in the partially unfoled form that the protease is 
able to digest away at the unfolded regions.  With copper treatment, it is most likely that the 
copper is directly interacting with PrP at the N-terminal region, folding the region to increase 
the global stability of PrP.  This increased global stability of PrP shifts the homeostatic 
balance between the folded form and the partially unfolded form to favor the folded form, 
decreasing the amount of PrP that can be digested with proteases, thereby increasing PrP 
content in intact cells treated with copper 
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Manganese treatment increases PrP levels in mouse brain slice cultures, but does not 
influence formation of PK resistant PrP by PMCA reaction 
 Studies with transgenic PrP mouse models have shown that increased expression of 
PrP could shorten the time of infection to clinical diseased state (Fischer et al. 1996; 
Westaway et al. 1994b).  The studies with PrP overexpressing transgenic mouse would 
suggest that the amount of substrate (PrPC) available is a key factor in determination of 
disease incubation time.  Since our in vitro cell culture model have shown increase in PrP 
expression with manganese treatment, we attempted to examine this phenomenon in ex vivo 
models using mouse brain slice cultures.  Our findings revealed that similar to cell culture 
models, mouse brain slice cultures acutely treated with manganese also showed increase in 
PrP expression.  To examine whether manganese induced increase in PrP expression in 
mouse brain slice cultures proved to be better substrates for PrPSc conversion, we utilized 
PMCA method to stimulate PrPSc propagation.  The PMCA method is based on the 
mechanism of seeded aggregation, where large PrPSc aggregates are broken up into smaller 
aggregate units, which provide seeds for further PrPSc aggregation with addition of substrates 
(Piening et al. 2005; Soto et al. 2002; Supattapone 2004).  The premise of our experiments 
was that the increased PrP expression found with manganese treatment would provide more 
substrates for the PMCA reaction.  However, the results from our data show that the 
increased amount of PrP with manganese treatment was not a better substrate for PMCA 
reaction.  Both untreated and manganese treated samples did not show differences in amount 
of amplified PrPSc.  One possible speculation for the lack of difference in detectable amounts 
of PrPSc with PMCA reaction could be due to the protein stabilizing effect of manganese on 
PrPC.  As aforementioned, the increase in PrP expression in manganese treatment could be 
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contributed to increased global protein stability.  It could be the increase in stability that 
could inhibit PMCA reaction from converting PrPC to PrPSc with increased efficiency.  
Further studies are needed to confirm the effect of manganese on prion proteins in mouse 
brain slice cultures.  
 In summary, we characterized the neuroprotective function of PrPC in response to 
manganese induced neurotoxicity and found that the expression of PrPC significantly 
protected mouse neuronal cell lines against manganese neurotoxicity.  We also examined the 
interaction of PrPC with divalent cations.  Both manganese and copper increased PrPC levels 
through increasing global protein stability, and was not dependent on increased 
transcriptional levels or decreased cellular degradative system.  Cadmium on the other hand 
inhibited UPS and this lead to formation of protein aggregates and ubiquitinated PrPC that 
was not resistant to PK digestion.  Ex vivo studies with mouse brain slice cultures also 
revealed that manganese treatment increased PrP expression, but might not be able to 
increase the efficacy of PrPSc conversion using the PMCA method.  Altogether, the studies 
presented here in this dissertation outlines the beginning steps in understanding the complex 
interaction of divalent cations and PrP, which may shed light on possible role of divalent 
cation in the pathogenesis of prion disease. 
 
Future Directions 
 In order to better understand the complex interaction between divalent cations and 
PrP, further studies are required to refine the findings discussed above.   
One future direction is to examine the role of octapeptide regions in modulation of 
manganese neurotoxicity.  Prion knockout models have revealed an important insight into the 
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role of PrPC in metal homeostasis (Brown 2003).  Various PrPC mutants such as octapeptide 
repeat region deletion and PrPC mutants with increased number of octapeptide regions, and 
their susceptibility to manganese induced neurotoxicity and internalized manganese could 
prove valuable information regarding to the role of the octapeptide repeat regions in 
managing manganese neurotoxicity.   
Another future direction could be to characterize the role of manganese in PrPSc 
infection.  Although our preliminary results with PMCA technique using manganese treated 
mouse brain slice cultures did not yield any significant findings, the duration of manganese 
treatment could be a crucial factor.  Infectivity studies using cell culture models chronically 
treated with manganese could have similar effect as acute treatment, but question remain as 
to whether chronic treatment may alter manganese treated PrPC to PrPSc infection. 
And lastly, in order to better understand the PrP-divalent cation interaction, it is 
necessary to utilize purified recombinant PrP to examine the interaction without other 
cellular factors.  One such study would be the characterization of the binding location of 
divalent cations, and examine whether there are differences in the binding capacity by 
performing competition binding with electro-spray ionization mass spectrometry.  Another 
study to examine the divalent metal induced global protein stability could be characterized 
utilizing the recombinant PrP. 
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